

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Combined prognostic value of 12 novel cardiological biomarkers. A 10-year follow-up of placebo receiving patients with stable coronary disease sampled at random times during their disease course

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-033720
Article Type:	Original research
Date Submitted by the Author:	28-Aug-2019
Complete List of Authors:	<p>Winkel, Per; Copenhagen University Hospital Rigshospitalet, The Copenhagen Trial Unit, Centre for Clinical Intervention Research Jakobsen, Janus; Copenhagen Trial Unit, 7812 Hilden , Jørgen; Section of Biostatistics, Department of Public Health Research, University of Copenhagen, Copenhagen, Denmark. Jensen , Gorm; Department of Cardiology, Hvidovre Hospital, Copenhagen University Hospital, Copenhagen, Denmark Kjøller, Erik; Herlev and Gentofte Hospital, Cardiology Sajadieh, Ahmad; Department of Cardiology, Bispebjerg Hospital, University Hospital, Copenhagen, Denmark Kastrup, Jens; Rigshospitale, University of Copenhagen Kolmos, Hans; Department of Clinical Microbiology, Odense University Hospital, Odense, Denmark. Iversen, Kasper; Herlev Hospital, Cardiology Bjerre, Mette; The Medical Research Laboratory, Department of Clinical Medicine, Aarhus University, Denmark Larsson, Anders; Department of Medical Sciences, Uppsala University, Uppsala, Sweden Ärnlöv, Johan; Karolinska Universitetssjukhuset, Family Medicine and Primary Care Gluud, Christian; Copenhagen University Hospital Rigshospitalet, The Copenhagen Trial Unit, Centre for Clinical Intervention Research</p>
Keywords:	biomarker, Cardiology < INTERNAL MEDICINE, Coronary heart disease < CARDIOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1

2
3
4 **Combined prognostic value of 12 novel cardiological biomarkers. A 10-year follow-up**
5 **of placebo receiving patients with stable coronary disease sampled at random times**
6 **during their disease course**
7
8
9

10
11
12
13 Per Winkel,¹ Janus Christian Jakobsen,^{1,2,3} Jørgen Hilden,⁴ Gorm Boje Jensen,⁵ Erik
14 Kjøller,^{1,6} Ahmad Sajadieh,⁷ Jens Kastrup,⁸ Hans Jørn Kolmos,⁹ Kasper K Iversen⁶, Mette
15 Bjerre¹⁰, Anders Larsson,¹¹ Johan Ärnlöv,^{12,13} Christian Glud¹
16
17
18
19
20
21
22
23
24
25
26

27 Corresponding author: Per Winkel

28
29 Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet,
30 Copenhagen University Hospital, Copenhagen, Denmark
31
32
33
34
35
36
37

38 Correspondence

39
40
41 E-Mail per.winkel@ctu.dk
42
43

44 Telephone number +45 35457166
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

2

ABSTRACT

Objective

We investigated whether 12 novel circulating biomarkers were capable, when added to 'standard predictors' available in general practice, of improving the 10-year prediction of cardiovascular events and mortality in 2199 patients with stable coronary heart disease (CLARICOR trial placebo group). The patients participated as placebo receiving patients in the randomised CLARICOR trial at a random time in their disease trajectory.

Methods

The predictors were based on demographic information from hospital files, interviews, and blood samples collected at entry into the trial. We studied the prognosis for all-cause death and for the composite outcome of either all-cause death, myocardial infarction, unstable angina, or cerebro-vascular disease. We estimated each participant's survival probability at specified time points and report the correct prediction rate, 0.5 being taken as cut point for the estimated survival probability, with Cox regression analysis.

Results

When only 'standard predictors' were included, 83.4% of all-cause death predictions and 68.4% of composite outcome predictions were correct. Log(calprotectin) and log(cathepsin S) were not associated ($P \geq 0.01$) with the outcomes, not even as single predictors. Adding the remaining ten biomarkers (high-sensitive assay cardiac troponin T; neutrophil gelatinase-associated lipocalin; osteoprotegerin; N-terminal pro-B-type natriuretic peptide;

3

tumor necrosis factor receptor 1 and 2; PAPP-A; endostatin; YKL40; cathepsin-B), which were all individually significantly associated with the prediction of the two outcomes, increased the figures to 84.7% and 69.7%.

Conclusion

When 'standard predictors' routinely available in general practices are used for risk assessment in consecutively sampled patients with stable coronary heart disease, the addition of 10 novel biomarkers to the prediction model improved the correct prediction of all-cause death and the composite outcome by less than 1.5%.

Trial registration: ClinicalTrials.gov, NCT00121550. Date of registration 13 July 2005

Date of enrolment of first participant 12 October 1999

Keywords: CLARICOR, cardiovascular disease, cardiovascular risk prediction, ischaemic heart disease, predictors, mortality.

INTRODUCTION

In a previous paper¹ and in accordance with our published and peer-reviewed statistical analysis plan,² we assessed the prognostic value of quantities, readily available during clinical routine work, when a patient with stable coronary heart disease is seen by the practicing physician or at an outpatient clinic without renewed cardiac complaints.

We examined predictors for all-cause death alone and a composite outcome (all-cause death, acute myocardial infarction (AMI), unstable angina pectoris (UAP), and cerebrovascular disease (CeVD)). We used an operational definition of the term 'stable coronary disease' adapted from the 'clarithromycin for patients with stable coronary heart disease' (CLARICOR) trial^{3,4} which covers a common and important class of patients, used the data from the placebo patients to develop the prognostic model, and tested how well it predicted the actual outcomes during the 10-year period following randomisation.

The frequency of correct status predictions increased by 3.5% for all-cause death and by 5.2% for the composite outcome when the routinely available predictors shown in table 1 were used. One might speculate that this rather modest result could be improved by combining the routinely available predictors with some of those biomarkers which from a pathophysiological point of view seem promising.

5

1
2
3
4 Within the last years many such biomarkers e.g.^{5,6} have appeared, all claimed to add some
5
6 prognostic information in patients with stable coronary artery heart disease. In most cases
7
8 the information has been evaluated in addition to that of routinely available clinical and
9
10 laboratory information. We and others have tested the individual importance of many of
11
12 these biomarkers and in many studies statistical inference supports the view that biomarkers
13
14 may improve the prediction⁷⁻¹².
15
16
17

18
19 Our objectives were to clarify: (1) which of these newer biomarkers maintain their prognostic
20
21 importance if all of them were simultaneously available and were combined with the routinely
22
23 available clinical and laboratory information, and (2) what would then be their relative
24
25 practical contribution if they were added to the 'standard predictors' such as age etc.
26
27
28
29
30
31

32 **MATERIAL**

33 34 35 **The patients**

36
37
38 The study population is the placebo patients from the CLARICOR-study.^{3,4} Patients aged 18
39
40 to 85 years, from the Copenhagen area, who had a discharge diagnosis of myocardial
41
42 infarction or angina pectoris during 1993-1999 and were alive in August 1999 were invited
43
44 by letter for an interview and a 14-days trial of clarithromycin versus placebo.^{3,4} Out of the
45
46 4372 who were randomised during October 1999 through April 2000, 2199 were in the
47
48 placebo group.
49
50
51

52
53
54 The main results of the trial were that clarithromycin increased the risk of cardiovascular as
55
56 well as all-cause death.¹³⁻¹⁵ Therefore, we here focus on the placebo group.
57
58
59
60

6

1
2
3
4 To secure that only patients were in a stable state of their coronary heart disease, patients
5 were excluded if they fulfilled one or more of the following conditions: (1) had suffered from
6 acute myocardial infarction or unstable angina pectoris within the previous 3 months; (2)
7 had had intra-coronary interventions within the previous 6 months; (3) had impaired renal
8 function; (4) had hepatic dysfunction; (5) had congestive heart failure (New York Heart
9 Association (NYHA) IV classification of heart failure); (6) had active malignancy; (7) were
10 without capacity to manage own affairs; (8) were breast feeding; and (9) were possibly
11 pregnant.
12
13
14
15
16
17
18
19
20
21
22

23 All patients were followed up until death or end of the CLARICOR trial on DEC 31, 2009
24 using public Danish registries. Only two of the 2199 participants were lost track of, due to
25 emigration.
26
27
28
29
30
31
32
33

34 **The predictors**

35
36
37 Information on smoking status, current medication, known hypertension, diabetes, sex, age,
38 and myocardial infarction at index hospitalisation or unstable angina pectoris was obtained
39 from the local hospital files and patient interviews.
40
41
42
43
44

45 *Biochemical measurements on serum collected at enrolment visit*

46
47
48 Biochemical data were obtained from analysis of serum specimens sampled at inclusion of
49 the patients and stored at – 80 degrees C. The quantities measured include lipoproteins,¹⁶
50 high-sensitivity-C-reactive-protein/mg/L (hs-CRP/mg/L),⁷ and glomerular filtration
51 /rate/mL/min (GFR/mL/min) using creatinine.¹⁷ Along with variables already mentioned,
52
53
54
55
56
57
58
59
60

7

these quantities are those collectively referred to as 'standard predictors' and specified in Table 1.

Biomarkers included as newer biomarkers were YKL40/ $\mu\text{g/L}$;⁸ high-sensitive assay cardiac troponin T/ ng/L (hs-cTnT/ ng/L);⁹ binary pregnancy associated plasma protein-A (binary-PAPP-A); which is coded as 1 if PAPP-A was ≥ 4 mIU/L or 0 otherwise;¹⁰ N-terminal pro-B-type natriuretic peptide/ ng/L (proBNP/ ng/L);⁹ cathepsin-B/ $\mu\text{g/L}$;^{6,18} endostatin/ ng/mL ;¹⁹ cathepsin-S/ $\mu\text{g/L}$;^{6,20} soluble TNF receptor 1/ pg/mL ; and soluble TNF receptor 2/ pg/mL ; (sTNFR1/ pg/mL and sTNFR2/ pg/mL);^{5,21} neutrophil gelatinase-associated lipocalin/ ng/L (NGAL/ ng/L);²² calprotectin/ mg/L ;¹¹ and osteoprotegerin/ ng/L ; (OPG/ ng/L).¹² Due to storage problems some marker data are missing on some patients, as listed in Table 1.

The outcomes

Initial follow-up of the patients lasted for approximately 2.6 years, during which outcomes were collected through hospital and death registries and assessed by an adjudication committee.⁴ Corresponding register data later produced similar results.^{23,24} The adjudicated outcomes were therefore replaced and augmented by register outcomes to cover up to 10 years +/- 3 months of follow-up. Last register follow-up was December 31, 2009. The public registers have an almost 100% coverage and the quality of these are described elsewhere.^{25,26} The algorithm used to get from the International Statistical Classification of Diseases used in the national registries to the events of the composite outcome is described in detail previously.¹³

8

We assessed (1) the time from randomisation to all-cause death and (2) the time from randomisation until the first occurrence of one of the following outcomes: acute myocardial infarction (AMI), unstable angina pectoris (UAP), cerebrovascular disease (CeVD), or all-cause death.

METHODS

Statistical analysis

The statistical principles and techniques used have previously been published.^{1,2} We used Cox regressions (SAS 9.4) where all analyses that included covariates were stratified by centre. We also analysed data using a parametric, accelerated failure-time model using the generalized gamma model of error (see Figure 1).²⁷ A significance level of 0.01 was used to pinpoint empirical trends worthy of note. The logarithms of the present text are natural logarithms, and all Cox hazard ratios refer a unit increase, i.e. a factor $e = 2.72$ concentration increase whenever the predictor is a log (serum level/unit).

Biomarkers with a hazard rate with P value ≥ 0.01 when used alone as covariate as well as when used in combination with the 'standard predictors' were excluded from further analyses. The remaining biomarkers were considered prognostic.

Assessment of the practical impact of using the set of newer biomarkers was obtained by comparing the percent correct predictions obtained when the standard predictors were used alone with the percentage obtained when they were combined with the novel biomarkers using the method described earlier.¹

RESULTS

Table 1 presents an overview of the covariates expected to be available from stable cardiovascular disease patients during clinical routine work ('standard predictors') plus the 12 newer biochemical quantities under investigation. The mean observation time was 8.323 year. The total number of patient observation years was 16630 year. 738 (63.1%) patients died during the observation period. 1204 (60.3%) experienced a composite outcome.

Out of 2199 placebo patients, 1998 had complete biochemical data. As Little's test²⁸ had $P = 0.49$, suggesting that the values were missing completely at random, we used complete case analyses in the following. The data revealed that at 3 years, 2073 (94.3%) were still alive and 1826 (83.0%) had not yet suffered a composite outcome. At 6 years, 1758 (79.9%) were still alive and 1261 (57.3%) had not yet suffered a composite outcome. At 9 years, the numbers were 1487 (67.6%) and 969 (44.9%).

Inferential impact of the newer biomarkers

As the proportional hazard's assumption was violated for age²⁹ and age interacted significantly with time since randomisation, we included an interaction between age at entry and time (since randomisation) in the inference analyses.

Table 2 shows the results of a Cox regression of all-cause death on each of the 12 biomarkers when the biomarker was used alone as a covariate (columns 2 through 4), and when it was used in combination with the 'standard predictors' (columns 5 through 7).

10

1
2
3
4 Columns 8 through 10 in Table 2 shows the result of a regression of the outcome on the
5
6
7 'standard predictors' and the 10 best biochemical predictors. Now only log (proBNP /ng/L)
8
9 and log(hs-cTnT/ng/L) have a HR significantly ($P < 0.01$) different from 1.
10
11 Log(calprotectin/mg/L) and log(cathepsin-S/ μ g/L) did not have an inferential impact ($P <$
12
13 0.01 not attained), not even when used alone.
14
15
16

17 Table 3 corresponds to Table 2 except that the outcome is the composite outcome. It is
18
19 noted that a time-dependent covariate is now included because log (OPG/ng/L) violated the
20
21 proportional hazard assumption. This was remedied by including the covariate log
22
23 (OPG/ng/L) ·time/year. It is seen that when all the biomarkers were included in the Cox
24
25 analysis log(OPG/ng/L)·time/year, log(proBNP/ng/L), and log(hs-cTnT/ng/L) were the only
26
27 ones which had a P value below the threshold of 0.01. Again log(calprotectin/mg/L) and
28
29 log(cathepsin-S/ μ g/L) could be excluded from the final analysis, the result of which is shown
30
31 in columns 8 through 10.
32
33
34
35
36
37
38
39

40 **Practical impact of the novel biomarkers**

41
42 The results of the predictions of survival status made at 3 years, at 6 years, and at 9 years
43
44 following randomisation in the 2199 placebo patients are summarised in Table 4.
45
46
47

48 When the 'standard predictors' were included as covariates (column 5) for all-cause
49
50 mortality, 83.3% of the predictions were correct. Adding the 10 newer biochemical
51
52 predictors (column 6) the percentage was increased by 1.4% to 84.7%. It is noted that the
53
54 results obtained with the parametric model (column 7) are not dramatically different when
55
56 this theoretically equally valid model is used. When only the two significant predictors (log
57
58
59
60

11

(proBNP/ng/L) and log (hs-cTnT/ng/L)) were used in the Cox model in place of all 10 (column 8), the results were practically unaffected (compare columns 8 and 6).

Table 5 shows the results corresponding to Table 4 obtained when the composite outcome was used. Including the 'standard predictors' in the model increases the percent correct predictions from 63.2 (see column 4, Table 5) to 68.4 (see column 5, Table 5), i.e. an increase of 5.2%. Adding the 10 newer biomarkers to the model increases the number of correct predictions by 1.3%. Using the parametric model does not change the results appreciably and neither does a reduction of the biomarkers to include only the three significant ones.

DISCUSSION

In this study we assessed the combined value of 12 newer biomarkers not routinely used in clinical work to predict all-cause death and a composite outcome (AMI, UAP, CeVD, or all-cause death). We used a cut value of $P=0.5$ to separate correct predictions of the observed patient status from incorrect ones. When we combined the biomarkers with the 'standard predictors' routinely available for a general practitioner when he/she meets a patient with stable coronary heart disease, 84.7 % of the survival status were correctly predicted. In case of the composite outcome the number was 68.4%. In both cases, the combined contribution of the newer biomarkers amounted to less than 2%.

12

1
2
3
4 Most of the studies we have identified in the literature only include small study samples, ^{e.g.20}
5
6 were developed in patients with acute coronary syndromes, ^{e.g.21} or had a short follow-up. ^{e.g.}
7
8

22

9
10
11
12 Our patients resemble those of The Prospective Observational Longitudinal Registry of
13
14 Patients with Stable Coronary Heart Disease (CLARIFY) study³⁰ which enrolled 20.291
15
16 patients. The CLARIFY patients had been observed with a median of 24.1 months. However,
17
18 enrollment took place 10 years later than in the CLARICOR trial and the incidence of
19
20 cardiovascular deaths or myocardial infarctions in these patients was considerably lower,³⁰
21
22 probably reflecting improved quality of treatment and more frequent statin treatment in the
23
24 CLARIFY patients (84% compared to only 41% in the CLARICOR material).
25
26
27

28
29 In our present study, we are using our data to develop a prediction model. Then we use the
30
31 same data that we used to develop the model. Clearly this is bound to produce overly
32
33 optimistic results compared to testing our model using independent data. But we argue that
34
35 the aim of this study was not to present a prediction model but to assess the newer
36
37 biomarkers' contribution to model performance when added on top of routinely available
38
39 clinical and laboratory data. Therefore, if tested on independent data, the contribution of the
40
41 newer biomarkers to prognosis of patients with stable coronary heart disease are likely going
42
43 to be worse than observed here.
44
45
46
47
48
49
50

51 **Methodology**

52
53
54 Regarding our methodology, the performance statistics reported here are minimal, but they
55
56 suffice to show that the results are meagre. Prediction at 3, 6, and 9 years covers the follow-
57
58 up as well as would a sophisticated integral over continuous time.
59
60

Strengths

The strengths of the CLARICOR trial are the size of the patient population, the long duration of follow-up, few losses to follow-up (0.1%), the ethnic homogeneity of the patient population (most being Caucasians), rarity of missing values, with focus on an operationally defined, homogeneous and relevant patient category. The design implies that the patients are sampled at random, presumably uneventful, time points during their stable state (as defined by the CLARICOR trial).

Limitations

Among those 7586 patients who declined our invitation to visit a cardiology centre, many must have been eligible for the CLARICOR trial, and we do not know how they looked and fared. With a response rate about 50%, the cohort could represent a prognostic elite if responders were mostly mobile and health-conscious patients. So, selection bias cannot be excluded.

Furthermore, users of these data should remain aware of one feature: patients if any who became eligible for the CLARICOR trial during the period 1993 to 1999 and then died before August 1999 are absent. Thus, our data do not represent patients as they enter a stable disease state (as delimited by CLARICOR exclusion criteria); instead, they may be regarded as community patients (subject to some self-selection) seen by their physician or at an outpatient clinic on a random date during their stable state.

14

1
2
3
4 The patients recruited for the CLARICOR trial were diagnosed with coronary heart disease
5 about 20 years ago. Because of the developments in treatment and rehabilitation, there has
6 been a very significant and gradual improvement in the prognosis of such patients as shown
7 in national data.³¹ Given these uncertainties, prognostic findings in the CLARICOR cohort
8 may not be directly applied to present-day patients. However, the overall, somewhat
9 disappointing, picture presented by the predictive performance of standard¹ and newer
10 biochemical predictors studied 10-20 years ago would hardly be much different if studied
11 today.
12
13
14
15
16
17
18
19
20
21
22

23 Potential weaknesses of the present cohort within the context of prognostication of stable
24 coronary heart disease patients as here defined include the fact that only questionnaire data
25 were collected at randomisation. No data are available concerning left ventricle function,
26 body mass index, blood pressure, and general health. These shortcomings are mitigated by
27 the fact that, by design, the present study sees the patient in a situation where (s)he visits a
28 physician for reasons unrelated to the coronary disease, as already stressed. In such
29 situations, counselling and decisions must typically be made without access to
30 echocardiography or other special investigations. Furthermore, if this information had been
31 available, the prognostic gain we study would probably have been still poorer. Moreover, we
32 included age, sex, hypertension, prior myocardial infarction, information about current
33 medication which has previously been shown to be a fair replacement for prognostication
34 instead of left ventricular ejection fraction.³²
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51 It is noted that the patients studied by us were all in a stable state of their disease, without
52 cardiac complaints. Therefore, one should not conclude from this study that the biomarkers
53 studied here may not be useful in many other clinical contexts, although biomarkers have
54
55
56
57
58
59
60

15

1
2
3
4 been shown to of modest help in evaluating cardiovascular risk assessment in asymptomatic
5
6 people not suffering from CAD.³³
7
8
9
10

11
12 **Conclusions** In the present clinical context the contribution of the 12 biomarkers not yet
13
14 used in clinical routine work proved to be minimal. Furthermore, 9 of the 10 novel biomarkers
15
16 could all except for osteoprotegerin be replaced by hs-cTnT and proBNP.
17
18
19

20 21 **Strengths and limitations of this study**

- 22 • 9 years duration of follow-up
 - 23 • Patients sampled at random times during their stable state
 - 24 • Only 0.1% losses to follow-up
 - 25 • Patients recruited about 20 years ago
 - 26 • Only questionnaire information data were collected at randomisation
- 27
28
29
30
31
32
33
34
35

36 37 **Patient and public involvement**

38
39
40
41
42 There was no direct patient involvement in the design of the trial, but the majority of the
43
44 investigators had daily contact with patients comparable to those included in the trial and
45
46 therefore knew their needs and preferences well. Moreover, there were patient
47
48 representatives as part of the regional ethics committee approving the trial. The public
49
50 involvement was trough the approvals given by the regional ethics committee (KF 01-076/99
51
52 and journal no. H-12012125), the Danish Medicines Agency (2612-975), and the Danish
53
54 Data Protection Agency (1999-1200-174).
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

17

What is already known about this subject?

Patients with stable coronary artery disease are at an increased risk of death or non-fatal cardiovascular incidents.

What does this study add?

New knowledge regarding the long-term impact of 12 newer biochemical factors not used in clinical routine for the prediction of all-cause death or of non-fatal cardiovascular incidents or all-cause mortality in patients with stable coronary heart disease ascertained at baseline review not prompted by renewed cardiac complaints.

Ten of the 12 biochemical factors did show a highly significant expected association with long-term course, but the practical prognostic impact is weak with a combined improvement of the number of correctly predicted patient status of less than 1.5%. For useable prognostic differentiation, stronger clinical markers are needed.

Author affiliations

18

1
2
3
4 1 Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet.

5
6 Copenhagen University hospital, Blegdamsvej 9, Copenhagen, Denmark.

7
8
9 2 Department of Cardiology, Holbæk Hospital, Holbæk, Denmark.

10
11
12 3 Department of Regional Health Research, The Faculty of Health Sciences, University of
13
14 Southern Denmark

15
16
17 4 Section of Biostatistics, Department of Public

18
19
20 Health Research, University of Copenhagen, Copenhagen, Denmark.

21
22
23 5 Department of Cardiology, Hvidovre Hospital, Copenhagen University Hospital,
24
25 Copenhagen, Denmark.

26
27
28 6 Department of Cardiology S, Herlev Hospital,

29
30
31 Copenhagen University Hospital, Copenhagen, Denmark.

32
33
34 7 Department of Cardiology,

35
36
37 Bispebjerg Hospital, University Hospital, Copenhagen, Denmark.

38
39
40 8 Department of Cardiology B, The Heart Centre, Rigshospitalet, Copenhagen

41
42
43 University Hospital, Copenhagen, Denmark.

44
45
46 9 Department of Clinical

47
48
49 Microbiology, Odense University Hospital, Odense, Denmark.

50
51
52 10 The Medical Research Laboratory, Department of Clinical Medicine, Aarhus University,
53
54
55 Denmark.

19

1
2
3
4 11 Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
5
6

7 12 Division of Family Medicine and Primary Care, Department of Neurobiology, Care
8 Sciences and Society, Karolinska Institutet, Huddinge, Sweden
9

10
11
12 13 Division of Family Medicine and Primary Care, Department of Neurobiology, Care
13 Science and Society, Karolinska Institutet, Huddinge, Sweden.
14
15
16

21 **Abbreviations**

22
23 AMI: acute myocardial infarct; Apo A1: apoprotein A1; Apo B: apoprotein B; CeVD: cerebro-
24 vascular disease; Chol-HDL: cholesterol high density lipoprotein; Chol-LDL: cholesterol low
25 density lipoprotein; CLARICOR: Clarithromycin for patients with stable coronary heart
26 disease; CRP: c-reactive protein; GFR: Glomerular filtration rate; hs-cTnT: High-sensitive
27 assay cardiac troponin T; NGAL: neutrophil gelatinase-associated lipocalin; NYHA: New
28 York Heart Association; OPG: osteoprotegerin; PREMACE: Predictors for major
29 cardiovascular outcomes in stable ischaemic heart disease; proBNP: N-terminal pro-B-type
30 natriuretic peptide;
31
32 TNFR1: tumor necrosis factor receptor 1; TNFR2: tumor necrosis factor receptor 2; UAP:
33 unstable angina pectoris.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48

49 **Acknowledgements**

50
51 We thank the CLARICOR trial participants. We thank the investigators and
52 other staff involved during the first phases of the CLARICOR trial (for full list of
53 names, please see references 6, 11, and 13). We also thank our original funders of the
54
55
56
57
58
59
60

20

1
2
3
4 CLARICOR trial (see references 6, 11, and 13). The Copenhagen Trial Unit, Centre for
5
6 Clinical Intervention Research, is thanked for providing monetary support for part of the
7
8 biochemical analyses for the PREMAC study as well as wages for Per Winkel, Janus C.
9
10 Jacobsen, and Christian Gluud.
11
12

13 14 **Funding**

15
16 This study was funded by the Copenhagen Trial Unit, Centre for Clinical
17
18 Intervention Research; original funders of the CLARICOR trial; and The
19
20 Swedish Research Council, Swedish Heart-Lung foundation; Thur us
21
22 Foundation; Marianne and Marcus Wallenberg Foundation, Dalarna
23
24 University; and Uppsala University.
25
26
27
28
29

30 31 **Availability of data and materials**

32
33 All pertinent anonymised data will be uploaded at ZENODO (<http://zenodo.org/>)
34
35 when the individual manuscripts have been published.
36
37
38
39

40 41 **Authors' contributions**

42
43 PW, JH, JCJ, and CG contributed substantially to the concept and design and
44
45 drafted the manuscript. PW and JH conducted the statistical analyses. AL and J  conducted
46
47 the analysis of lipids and creatinine. All authors revised the manuscript critically for important
48
49 intellectual content, gave final approval of version to be published, and
50
51 agreed to be accountable for all aspects of the work in assuring that questions related to
52
53 the accuracy or integrity of any part of the work are appropriately investigated and
54
55 resolved.
56
57
58
59
60

21

Competing interests

The authors declare that they have no competing interests.

Ethics approval and consent to participate was given by

VEKKF01-076/99; Danish Medicines Agency 2612-975; Danish Data Protection

Agency 1999-1200-174; VEK H-B-2009-015.

For peer review only

REFERENCES

1. Winkel P, Jakobsen JC, Hilden J, et al. Prognostic value of routinely available data in patients with stable coronary heart disease. A 10-year follow-up of patients sampled at random times during their disease course. *Open Heart* 2018:e000808. Doi:10.1136/openhrt-2018-000808

22

- 1
2
3
4 2. Winkel P, Jakobsen JC, Hilden J, Lange T, Jensen GB, Kjølner E, et al:
5
6 Predictors for major cardiovascular outcomes in stable ischaemic heart disease (PREMAC):
7
8 statistical analysis plan for data originating from the CLARICOR (clarithromycin for patients
9
10 with stable coronary heart disease) trial: Diagnostic and Prognostic Research (2017) 1:10
11
12 DOI 10.1186/s41512-017-0009-y.
13
14
- 15
16 3. Jespersen CM, Als-Nielsen B, Damgaard M, Hansen JF, Hansen S, Helø OH,
17
18 et al: Randomised placebo controlled multicentre trial to assess short term clarithromycin
19
20 for patients with stable coronary heart disease: CLARICOR trial. *BMJ*. 2006; 332:22–7.
21
22
- 23
24 4. Hansen S, Als-Nielsen B, Damgaard M, Helø OH, Petersen L, Jespersen CM,
25
26 et al: Intervention with clarithromycin in patients with stable coronary heart disease: the
27
28 CLARICOR trial design. *Heart Drug*. 2001; 1:14–9.
29
30
- 31
32 5. Carlsson AC, Ruge T, Kjølner E, Hilden J, Kolmos HJ, Sajadieh A o. a. 10-year
33
34 associations between tumor necrosis factor receptors 1 and 2 and cardiovascular events in
35
36 patients with stable coronary heart disease: a CLARICOR (effect of clarithromycin on
37
38 mortality and morbidity in patients with coronary heart disease) trial substudy. *Journal of the*
39
40 *American Heart Association* 2018 apr 23;7(9): e 008299 Doi:10. 116/JAHA 127.008299
41
42
- 43
44 6. Wuopio J, Hilden J, Bring C, Kastrup J, Sajadieh A, Jensen GB o.a. Cathepsin
45
46 B and S as markers for cardiovascular risk and all-cause mortality in patients with stable
47
48 coronary heart disease during 10 years: a CLARICOR trial substudy. *Atherosclerosis*. 2018
49
50 nov 1:278: 97 to 102. Tilgængelig fra, DOI: 10. 1016/j atherosclerosis. 2018.09.006
51
52
- 53
54 7. Harutyunyan MJ, Mathiasen AB, Winkel P, Gøtze JP, Hansen JF, Hildebrandt
55
56 P, et al: High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in
57
58
59
60

1
2
3
4 patients with stable coronary heart disease: a prognostic study within the CLARICOR trial.
5
6 Scand J Clin Lab Invest. 2011; 71:52–62.
7
8

9
10 8. Kastrup J, Johansen JS, Winkel P, Hansen JF, Hildebrandt P, Jensen GB, et
11 al. High serum YKL40 concentration is associated with cardiovascular and all-cause
12 mortality in patients with stable coronary artery disease. Eur. Heart J. 2009; 30:1066-72.
13
14
15

16
17 9. Lyngbaek S, Winkel P, Gotze JP, Kastrup J, Gluud C, Kolmos HJ, et al. Risk
18 stratification in stable coronary artery disease is possible at cardiac troponin levels below
19 conventional detection and is improved by use of N-terminal pro-B-type natriuretic peptide.
20 European Journal of Preventive Cardiology 2014; 21:1275-1284.
21
22
23
24

25
26
27 10. Iversen KK, Teisner B, Winkel P, Gluud C, Kjoller E, Kolmos HJ, et al.
28 Pregnancy associated plasma protein-A as a marker for myocardial infarction and death in
29 patients with stable coronary artery disease: a prognostic study within the CLARICOR Trial.
30 Atherosclerosis 2011; 214:203-208.
31
32
33
34

35
36
37 11. Larsen SB, Grove EL, Pareek M, Kristensen SD, Hvas AM. Calprotectin and
38 platelet aggregation in patients with stable coronary artery disease. PloS ONE 2015;
39 10(5):e0125992.
40
41
42
43

44
45 12. Bjerre M, Hilden J, Kastrup J, Skoog M, Hansen JF, Kolmos HJ, et al.
46 Osteoprotegerin independently predicts mortality in patients with stable coronary artery
47 disease: the CLARICOR trial. Scandinavian Journal of Clinical and Laboratory Investigation
48 2014; 74:657-664.
49
50
51
52
53
54
55
56
57
58
59
60

24

- 1
2
3
4 13. Winkel P, Hilden J, Hansen JF, Kastrup J, Kolmos HJ, Kjoller E, et al.
5
6 Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular
7
8 mortality and cerebrovascular morbidity over 10years in the CLARICOR randomised,
9
10 blinded clinical trial. *International Journal of Cardiology* 2015, 182:459-465.
11
12
13
14 14. Winkel P, Hilden J, Fischer Hansen J, Hildebrandt P, Kastrup J, Kolmos HJ, et
15
16 al: Excess sudden cardiac deaths after short-term clarithromycin administration in the
17
18 CLARICOR trial: why is this so, and why are statins protective? *Cardiology*. 2011; 118:63–
19
20 67.
21
22
23
24 15. Glud C, Als-Nielsen B, Damgaard M, Fischer Hansen J, Hansen S, Helø OH,
25
26 et al: Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the
27
28 CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart
29
30 disease. *Cardiology*. 2008; 111:280
31
32
33
34 16. Helmersson-Karlqvist J, Ridefelt P, Lind L, Larsson A. Reference values for 34
35
36 frequently used laboratory tests in 80-year-old men and women. *Maturitas*. 2016; 92: 97-
37
38 101.
39
40
41
42 17. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al:
43
44 Estimating glomerular filtration rate from serum creatinine and cystatin C. *N Engl J Med*.
45
46 2012;367:20–9.
47
48
49
50 18. Wang N, Bai X, Jin B, Han W, Sun X, Chen X. The association of serum
51
52 cathepsin-B concentration with age-related cardiovascular-renal subclinical state in a
53
54 healthy Chinese population. *Arch Gerontol Geriatr*. 2016; 65:146-55.
55
56
57
58
59
60

25

- 1
2
3
4 19. Arnlov J, Ruge T, Ingelsson E, Sundstrom J, Lind L. Serum endostatin and risk
5 of mortality in the elderly: findings from 2 community-based cohorts. *Arterioscler Thromb*
6 *Vasc Biol.*2013, 33: 2689-95.
7
8
9
10
11 20. Jobs E, Ingelsson E, Risérus U, Nerpin E, Jobs M, Sundström J, et al.
12 Association between serum cathepsin S and mortality in older adults. *JAMA.* 2011;
13 306:1113-21.
14
15
16
17
18 21. Carlsson AC, Larsson TE, Helmersson-Karlqvist J, Larsson A, Lind L, Årnlöv J.
19 Soluble TNF receptors and kidney dysfunction in the elderly. *J Am Soc Nephrol.*
20 2014;25:1313-20.
21
22
23
24
25
26
27 22. Helmersson-Karlqvist J, Larsson A, Carlsson AC, Venge P, Sundstrom J,
28 Ingelsson E, et al. Urinary neutrophil gelatinase-associated lipocalin (NGAL) is associated
29 with mortality in a community-based cohort of older Swedish men. *Atherosclerosis* 2013;
30 227:408-13.
31
32
33
34
35
36
37 23. Kjøller E, Hilden J, Winkel P, Frandsen NJ, Galatius S, Jensen G, et al: Good
38 interobserver agreement was attainable on outcome adjudication in patients with stable
39 coronary heart disease. *J Clin Epidemiol.* 2012; 65:444–53.
40
41
42
43
44
45 24. Kjøller E, Hilden J, Winkel P, Galatius S, Frandsen NJ, Jensen GB, et al:
46 Agreement between public register and adjudication committee outcome in a cardiovascular
47 randomized clinical trial. *Am Heart J.* 2014; 168:197–204.ok
48
49
50
51
52
53 25. Helweg-Larsen K: The Danish register of causes of death. *Scand J Public*
54 *Health.* 2011;39(7 30. Suppl):26-9.
55
56
57
58
59
60

26

- 1
2
3
4 26. Lynge E, Sandegaard JL, Rebolj M: The Danish National Patient Register.
5
6 Scand J Public Health. 2011;39(7 suppl):30–3.
7
8
- 9 27. Allison PD: Survival Analysis Using SAS: A Practical Guide, second edition
10
11 2010 SAS institute Inc. Cary, NC, USA.
12
13
- 14 28. Little R: A test of missing completely at random for multivariate data with missing
15
16 values. J Am Stat Assoc. 1988; 83:1198–1202.
17
18
- 19 29. Lin DY, Wei LJ, Ying Z: Checking the Cox model with cumulative sums of
20
21 martingale-based residuals. Biometrika. 1993; 80:557–72.
22
23
- 24 30. Steg PG, Greenlaw N, Tendera M, et al. Prevalence of anginal symptoms and
25
26 myocardial ischemia and their effect on clinical outcomes in outpatients with stable coronary
27
28 artery disease. Data from the International Observational CLARIFY Registry. JAMA Intern
29
30 Med. 2014;174(10):1651-1659. doi:10.1001/jamainternmed.2014.3773
31
32
- 33 31. Schmidt M, Jacobsen JB, Lash TL, Bøtker HE, Sørensen HT: 25-year trends in
34
35 first time hospitalisation for acute myocardial infarction, subsequent short and long-term
36
37 mortality, and the prognostic impact of sex and comorbidity: a Danish nationwide cohort
38
39 study. BMJ. 2012;344: e356.
40
41
42
- 43 32. Solomon SD, Claggett B, Desai AS, et al. Influence of ejection fraction on
44
45 outcomes and efficacy of sacubitril/valsartan (lcz696) in heart failure with reduced ejection
46
47 fraction. Circulation 2016;9:e00274.
48
49
50
- 51 33. Scott IA. Evaluating cardiovascular risk assessment in asymptomatic
52
53 people. BMJ 2009;a2844doi:10.1136/bmj.a2844
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1 A




Figure 1 B


**Legend to figure 1**

Figure 1 A Distribution of years to death using the accelerated failure model where the error term is modelled using the general gamma distribution.

Figure 1 B shows similar plot for the distribution of years to composite outcome.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Quantity	Distribution
Demographics and previous history	
Sex (male) N (%)	1518 (69.0%)
Age/year mean (SD)	65.2 (10.4) 2199
Smoking status N (%)	Smokers 753 (34.2%) Ex-smokers 1011 (46.0%) Never smoked 435 (19.8%)
Hypertension N (%)	883 (40.2%)
Diabetes N (%)	337 (15.3%)
Previous AMI N (%)	1494 (67.9%)
Current medication	
Aspirin N (%)	1937 (88.1%)
Beta-blocker N (%)	681 (31.0%)
Calcium-antagonist N (%)	772 (35.1%)
ACE-inhibitor N (%)	577 (26.3%)
Long-lasting nitrate N (%)	457 (20.8%)
Diuretics N (%)	773 (35.2%)
Digoxin N (%)	126 (5.7%)
Statins N (%)	904 (41.1%)
Anti-arrhythmic drugs N (%)	51 (2.3%)
Standard biochemical predictors	
log (CRP/mg/L) mean (SD) N ^a	1.03 (1.12) 2159
ApoA1/mg/dL mean (SD) N	1.70 (0.34) 2076
log (ApoB/mg/dL) mean (SD) N	0.16 (0.27) 2075
Chol-HDL/mmol/L mean (SD) N	1.02 (0.32) 2074
Chol-LDL/mmol/L mean (SD) N	2.56 (0.72) 2079
log (Cholesterol/mmol/L) mean (SD) N	1.73 (0.20) 2075
log (Tri-glyceride/mmol/L) mean (SD) N	0.73 (0.53) 2078
Glomerular filtration rate (GFR/mL/min) mean (SD) N	71.8 (19.2) 2079
Newer biochemical predictors	
log (proBNP/ng/L) mean (SD) N	5.26 (1.37) 2149
log (hs-cTnT/ng/L) mean (SD) N	2.01 (0.78) 2111
log (endostatin/ng/mL) mean (SD) N	10.3 (0.34) 2121
log (OPG)/ng/L) mean (SD) N	7.49 (0.40) 2108
log (TNFR1/pg/mL) mean (SD) N	7.40 (0.40) 2120
log (TNFR2/pg/mL) mean (SD) N	8.54 (0.33) 2120
PAPP-A ≥ 4mIU/L count (%) N	288 (13.1%) 2140
log (YKL40/μg/L) mean (SD) N	4.75 (0.66) 2163
log (NGAL/ng/L) mean (SD) N	11.6 (0.46) 2121
log (Cathepsin B/μg/L) mean (SD) N	10.6 (0.45) 2120
log (Cathepsin S/μg/L) mean (SD) N	9.48 (0.27) 2121
log (Calprotectin/mg/L) mean (SD) N	0.77 (0.59) 2086

Legend to table 1

Table 1 Distributions of demographics, previous history, current medication, standard biochemical predictors, and newer biochemical predictors in 2199 placebo receiving patients from the CLARICOR trial.³

Abbreviations as in section on abbreviations in the main paper.

FOOTNOTES

- a) The value of N varies because the laboratory tests have missing values (mostly due to storage problems). log: natural logarithm.

Newer biochemical candidate predictor	When candidate predictor is the only predictor included in the model (stratified by centre)			When 'standard predictors' is added to the model (stratified by centre)			When in addition the 10 selected predictors are added to the model (stratified by centre)		
	HR ^b	95% CI	P	HR	95% CI	P	HR	95% CI	P
log (endostatin/ng/mL)	3.49	2.81 to 4.33	<0.0001	1.75	1.34 to 2.27	<0.0001	1.23	0.92 to 1.63	0.16
log (OPG/ng/L)	3.37	2.88 to 3.94	<0.0001	1.68	1.35 to 2.09	<0.0001	1.21	0.97 to 1.63	0.092
log (sTNFR1/pg/mL)	3.80	3.19 to 4.54	<0.0001	1.84	1.46 to 2.33	<0.0001	1.10	0.81 to 1.48	0.55
og (sTNFR2/pg/mL)	5.45	4.40 to 6.76	<0.0001	2.39	1.80 to 3.18	<0.0001	1.43	0.99 to 2.07	0.056
log(proBNP/ng/L)	1.76	1.66 to 1.87	<0.0001	1.44	1.34 to 1.55	<0.0001	1.28	1.19 to 1.39	<0.0001
log(hs-cTnT/ng/L)	2.31	2.16 to 2.47	<0.0001	1.73	1.56 to 1.92	<0.0001	1.46	1.30 to 1.65	<0.0001
PAPP-A_binary ^c	1.84	1.53 to 2.21	<0.0001	1.39	1.15 to 1.68	0.0007	0.85	0.69 to 1.03	0.10
log (YKL40/μg/L)	1.76	1.59 to 1.95	<0.0001	1.32	1.17 to 1.49	<0.0001	1.10	0.97 to 1.25	0.15
log (NGAL/ng/L)	1.33	1.12 to 1.57	0.0011	1.03	0.85 to 1.24	0.78	0.90	0.74 to 1.10	0.30
log(Calprotectin/)	1.08	0.95 to 1.23	0.25	1.02	0.89 to 1.18	0.74	Not included in analysis		
log (Cathepsin-B/μg/L)	2.81	2.40 to 3.28	<0.0001	1.43	1.19 to 1.73	0.0002	1.09	0.89 to 1.33	0.42
log (Cathepsin-S/μg/L)	1.12	0.86 to 1.47	0.40	1.10	0.83 to 1.45	0.51	Not included in analysis		

Legend to Table 2

All-cause mortality hazard ratios (HR) of newer biochemical predictors not routinely used in clinical work when each of these predictors is used alone (columns 2 to 4), and when it is used in combination with the 'standard predictors' (column 5 to 7). Two of them were then discarded and each of the remaining 10 was assessed when used in combination with the standard predictors and the remaining 9 of the 10 newer biochemical predictors selected among the 12 candidates (columns 8 to 10).

- a) The standard predictors are shown in Table 1.
- b) Hazard ratio associated with unit increase on log scale, except for PAPP-A (binary).
- c) Binary quantity. 1: PAPP-A was ≥ 4 mIU/L, 0: PAPP-A was < 4 mIU/L.

Newer biochemical candidate predictor	When candidate predictor is the only predictor included in the model (stratified by centre)			When 'standard predictors' is added to the model (stratified by centre)			When in addition the 11 ^a selected predictors are added to the model (stratified by centre)		
	HR	95% CI of HR	P	HR	95% CI of HR	P	HR	95% CI of HR	P
log (Endostatin/ng/mL)	2.18	1.84 to 2.58	<0.0001	1.44	1.17 to 1.72	0.0006	1.23	0.99 to 1.54	0.062
log (OPG/ng/L)	1.34	1.05 to 1.71	0.019	0.94	0.70 to 1.26	0.67	0.78	0.58 to 1.04	0.094
log (OPG/ng/L) ·time/year ^b	1.11	1.06 to 1.16	<0.0001	1.09	1.03 to 1.16	0.0022	1.104	1.044 to 1.168	0.0005
log (sTNFR1/pg/mL)	2.14	1.86 to 2.46	<0.0001	1.33	1.11 to 1.60	0.0021	1.05	0.84 to 1.32	0.67
log (sTNFR2/pg/mL)	2.56	2.15 to 3.03	<0.0001	1.49	1.19 to 1.85	0.0004	1.13	0.85 to 1.50	0.40
log (proBNP/ng/L)	1.37	1.31 to 1.44	<0.0001	1.26	1.19 to 1.33	<0.0001	1.18	1.11 to 1.25	<0.0001
log (hs-cTnT/ng/L)	1.83	1.70 to 1.97	<0.0001	1.49	1.35 to 1.64	<0.0001	1.31	1.17 to 1.46	<0.0001
PaPP-A (binary) ^c	1.45	1.24 to 1.70	<0.0001	1.24	1.06 to 1.46	0.0077	0.89	0.75 to 1.05	0.15
log (YKL40/μg/L)	1.35	1.24 to 1.47	<0.0001	1.13	1.03 to 1.24	0.013	1.01	0.91 to 1.11	0.93
log (NGAL/ng/L)	1.23	1.08 to 1.40	0.0023	1.03	0.89 to 1.19	0.73	0.97	0.84 to 1.13	0.74
log (Calprotectin/)	1.06	0.95 to 1.17	0.32	1.00	0.90 to 1.12	0.95	Not included in analysis		
log (cathepsin-B/μg/L)	1.70	1.50 to 1.93	<0.0001	1.17	1.01 to 1.35	0.040	0.99	0.85 to 1.16	0.92
log (cathepsin-S/μg/L)	1.06	0.86 to 1.31	0.59	0.98	0.79 to 1.22	0.88	Not included in analysis		

Legend to Table 3

The composite outcome (comprising first occurrence of acute myocardial infarction, unstable angina pectoris, cerebro-vascular disease, and death). Hazard ratios of each of 13 biochemical predictors not routinely used in clinical work when each of these predictors is used alone (columns 2 to 4), and when it is used in combination with the 'standard predictors' (column 5 to 7). Two of them were then discarded and each of the remaining 11 was assessed when used in combination with the standard predictors and the remaining 10 of the 11 newer biochemical predictors selected among the 13 candidates (columns 8 to 10).

- 1
2
3 a) Note that now a time dependent covariate has been added [$\log(\text{OPG}/\text{ng/L}) \cdot \text{time}/\text{year}$] to the 10 original predictors.
4 b) $\log(\text{OPG}/\text{ng/L})$ significantly violated the proportional hazard assumption. We found a significant linear relationship between
5 $\log(\text{OPG}/\text{ng/L})$ and time since randomisation which may explain the violation. The product of $\log(\text{OPG}/\text{ng/L})$ and time/year
6 was therefore included in the inference analysis. However, when the Cox model is used for prediction, time dependent
7 covariates are not allowed (SAS 9.4). Therefore, in the latter context we only include $\log(\text{OPG}/\text{ng/L})$.
8
9 c) Binary quantity. 1: PAPP-A was ≥ 4 mIU/L, 0: PAPP-A was < 4 mIU/L.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

For peer review only

(1) Number of predictions made	(2) Time at which prediction was made	(3) Correctly predicted patient status	(4) Data without covariates included Both models N (%)	(5) Data including Standard predictors as covariates Cox model N (%)	(6) Data including Standard predictors + advanced biochemical predictors as covariates Cox model N (%)	(7) Data including Standard predictors + advanced biochemical predictors as covariates Parametric model N (%)	(8) Data including Standard predictors + log (hsTnT) and log(proBNP) as covariates Cox Model N (%)
1996	Three years	Favorable status	1825 (91.4)	1821 (91.2)	1816 (91.0)	1814 (90.9)	1816 (91.0)
		Unfavorable status	0 (0.00)	10 (0.50)	19 (0.95)	14 (0.70)	19 (0.95)
1989	Six years	Favorable status	1601 (80.5)	1555 (78.2)	1551 (78.0)	1538 (77.3)	1553 (78.1)
		Unfavorable status	0 (0.00)	85 (4.27)	120 (6.03)	118 (5.93)	113 (5.68)
1987	Nine years	Favorable status	1342 (67.5)	1192 (60.0)	1219 (61.3)	1217 (61.2)	1212 (61.0)
		Unfavorable status	0 (0.00)	297 (14.9)	331(16.7)	323 (16.3)	339 (17.1)
5972	All three times combined	Favorable status	4768 (79.8)	4585 (76.8)	4586 (76.8)	4569 (76.5)	4581 (76.7)
		Unfavorable status	0 (0.00)	392 (6.56)	470 (7.87)	364 (6.10)	471 (7.89)
		Total	4768 (79.8)	4977 (83.3)	5056 (84.7)	4933 (82.6)	5052 (84.6)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Legend to table 4

All-cause death. Correct predictions of favorable (alive) and unfavorable (not alive) status made at 3 years, at 6 years, and at 9 years following randomisation in the 2199 placebo patients from the CLARICOR trial. Four covariate scenarios were examined with Cox regression (see text of columns 4, 5, 6, and 8). For comparison with the results of column 6, column 7 shows the corresponding results when the accelerated failures model was used.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

(1) Number of predictions made	(2) Time at which prediction was made	(3) Correctly predicted patient status	(4) Data without covariates included Both models N (%)	(5) Data including Standard predictors as covariates Cox model N (%)	(6) Data including Standard predictors + advanced biochemical predictors as covariates Cox model N (%)	(7) Data including Standard predictors + advanced biochemical predictors as covariates Parametric model N (%)	(8) Data including Standard predictors + Log(OPG/ng/L), Log(hsTnT/ng/L), and log(proBNP/ng/L) as covariates Cox model N (%)
1996	Three years	Favorable status	1514 (75.9)	1471 (73.7)	1464 (73.3)	1479 (74.1)	1463 (73.3)
		Unfavorable status	0 (0)	51 (2.56)	77 (3.86)	57 (2.86)	76 (3.81)
1989	Six years	Favorable status	1144 (57.5)	935 (47.0)	920 (46.3)	916 (46.1)	925 (46.5)
		Unfavorable status	0 (0)	349 (17.5)	370 (18.6)	368 (18.5)	367 (18.5))
1987	Nine years	Favorable status	0 (0)	504 (25.4)	542 (27.3)	550 (27.7)	549 (27.6)
		Unfavorable status	1115 (56.1)	774 (39.0)	792 (39.9)	803 (40.4)	779 (39.2)
5972	All three times combined	Favorable status	2658 (44.5)	2910 (48.7)	2926 (49.0)	2945 (49.3)	2937 (49.2)
		Unfavorable status	1115 (18.7)	1174 (19.7)	1239 (20.7)	1228 (20.6)	1222 (20.5)
		Total	3773 (63.2)	4084 (68.4)	4165 (69.7))	4173 (69.9)	4159 (69.6)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Legend to table 5

The composite outcome of AMI, UAP, CeVD, and all-cause death. Correct predictions of favorable (no outcome so far) and unfavorable status made at 3, 6 and 9 years. Cox model: four covariate scenarios as in Table 4; and parametric model (column 7) for comparison with column 6. Note that log (OPG) qualified for inclusion in column 8.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

STROBE Statement items 1 to 12

Title and abstract	Item no	Recommendation	
	1	(a) Design in title	See page 1 the term 'placebo receiving' implies that controls from a trial were used
		(b) Abstract: informative and balanced summary of what was done and found	See abstract methods and results sections p 2 and p 3
Introduction			
Background/rationale	2	Scientific background and rationale	See introduction first section on page 5
Objectives	3	objectives	See introduction last section page 5
Methods			
Study design	4	Key elements of study design	See first section on the patients in material page 5
Setting	5	Setting, location, relevant dates, period of recruitment, follow-up, and data collection	See first section on the patients in material page 5 and the two sections on predictors and on the outcomes pages 6 and 7
Participants	6	(a) Cohort study eligibility, selection, follow-up	See first section on page 6 and introduction page 4 second section
Variables	7	Outcomes, predictors	See section 'the outcomes' on page 7 and the section on predictors on page 6 and 7, and table 1
Data sources/measurement	8	Sources of data, methods of assessment	See section on the outcomes on page 7 and the section on predictors on page 6 and 7, and table 1 plus references to methods.
Bias	9	Addressing potential sources of bias	See page 9 second section from above. Assessment of the potential bias due to missing values.
Study size	10	How study size was arrived at	See Hansen S et al: the CLARICOR trial design. HeartDrug 2001; 1:14-9
Quantitative variables	11	How quantitative variables were handled	They were all handled as continuous variables except for PAP-A which was dichotomized into normal vs elevated values (see table 1 and page 7 line 3)
Statistical methods	12	Statistical methods	See 'statistical analysis'

STROBE Statement items 1 to 12

			page 8
		Missing data	See item 9
		Loss to follow-up	See page 6 last line of first section

For peer review only

STROBE Statement items 13 to 22

Results			
	Item no	Recommendation	
Participants	13	Flow diagram during enrolment, randomisation, and follow-up in original trial of 2006.	See BMJ 2006;332;22-27 (paper is enclosed)
Descriptive data	14	(a) Characteristics of study participants (b) Number of participants with missing data for each variable (c) Summary of follow-up time	(a) See table 1 (b) See table 1 (c) See page 9 line 3 to 5
Outcome data	15	Number of outcome events	See page 9 line 11 to 14
Main results	16	(a) Hazard rates (b) Results of predictions	(a) See tables 2, 3 (b) See tables 4 and 5
Other analyses	17	interaction	See inferential impact of the newer biomarkers page 9 first 3 lines
Discussion			
Key results	18	Summary of key results	See discussion page 11 first section
limitations	19	(a) Positive bias due to development of model and test of model using same data (b) Methodology (c) Selection bias (d) Prognosis may be worse than at present time (e) Only questionnaire data were collected at randomisation	(a) See page 12 last two lines 6 to 13 (b) See section on methodology page 12 (c) See limitations page 13 first two sections (d) See last 6 lines on page 13 and first two at page 14 (e) See page 14 line 3 to 14
Interpretations	20		See last section of discussion page 14
Generalisability	21		See (a), (b), (c), and (d) item 19
Other information			
Funding	22		See the section on acknowledgements and section on funding, both on page 19

BMJ Open

Prognostic value of 12 novel cardiological biomarkers in stable coronary disease. A 10-year follow-up of the placebo group of the Copenhagen CLARICOR trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-033720.R1
Article Type:	Original research
Date Submitted by the Author:	10-Feb-2020
Complete List of Authors:	Winkel, Per; Copenhagen University Hospital Rigshospitalet, The Copenhagen Trial Unit, Centre for Clinical Intervention Research Jakobsen, Janus; Copenhagen Trial Unit, 7812 Hilden, Jørgen; Section of Biostatistics, Department of Public Health Research, University of Copenhagen, Copenhagen, Denmark. Jensen, Gorm; Department of Cardiology, Hvidovre Hospital, Copenhagen University Hospital, Copenhagen, Denmark Kjøller, Erik; Herlev and Gentofte Hospital, Cardiology Sajadieh, Ahmad; Department of Cardiology, Bispebjerg Hospital, University Hospital, Copenhagen, Denmark Kastrup, Jens; Rigshospitalet, University of Copenhagen Kolmos, Hans; Department of Clinical Microbiology, Odense University Hospital, Odense, Denmark. Iversen, Kasper; Herlev Hospital, Cardiology Bjerre, Mette; The Medical Research Laboratory, Department of Clinical Medicine, Aarhus University, Denmark Larsson, Anders; Department of Medical Sciences, Uppsala University, Uppsala, Sweden Ärnlöv, Johan; Karolinska Universitetssjukhuset, Family Medicine and Primary Care Gluud, Christian; Copenhagen University Hospital Rigshospitalet, The Copenhagen Trial Unit, Centre for Clinical Intervention Research
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Evidence based practice
Keywords:	biomarker, Cardiology < INTERNAL MEDICINE, Coronary heart disease < CARDIOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1

2
3
4 **Prognostic value of 12 novel cardiological biomarkers in stable coronary disease. A**
5
6 **10-year follow-up of the placebo group of the Copenhagen CLARICOR trial.**
7
8
9

10
11
12
13 Per Winkel,¹ Janus Christian Jakobsen,^{1,2,3} Jørgen Hilden,⁴ Gorm Boje Jensen,⁵ Erik
14 Kjøller,^{1,6} Ahmad Sajadieh,⁷ Jens Kastrup,⁸ Hans Jørn Kolmos,⁹ Kasper K Iversen⁶, Mette
15 Bjerre¹⁰, Anders Larsson,¹¹ Johan Ärnlöv,^{12,13} Christian Gluud¹
16
17
18
19
20
21
22
23
24
25
26

27 Corresponding author: Per Winkel

28
29 Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet,
30 Copenhagen University Hospital, Copenhagen, Denmark
31
32
33
34
35
36
37

38 Correspondence

39
40
41 E-Mail pwinkel@ctu.dk
42
43

44 Telephone number +45 35457166
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

2

ABSTRACT

Objective

to assess if 12 novel circulating biomarkers , when added to 'standard predictors' available in general practice, could improve the 10-year prediction of cardiovascular events and mortality in patients with stable coronary heart disease.

Design

The patients participated as placebo receiving patients in the randomised CLARICOR trial at a random time in their disease trajectory.

Setting

Five Copenhagen University cardiology departments and a coordinating centre

Participants

2199 participants with stable coronary artery disease.

Outcomes

Death and composite of myocardial infarction, unstable angina pectoris, cerebrovascular disease, and death.

Results

When only 'standard predictors' were included, 83.4% of all-cause death predictions and 68.4% of composite outcome predictions were correct. Log(calprotectin) and log(cathepsin

3

S) were not associated ($P \geq 0.01$) with the outcomes, not even as single predictors. Adding the remaining ten biomarkers (high-sensitive assay cardiac troponin T; neutrophil gelatinase-associated lipocalin; osteoprotegerin; N-terminal pro-B-type natriuretic peptide; tumor necrosis factor receptor 1 and 2; PAPP-A; endostatin; YKL40; cathepsin-B), which were all individually significantly associated with the prediction of the two outcomes, increased the figures to 84.7% and 69.7%.

Conclusion

When 'standard predictors' routinely available in general practices are used for risk assessment in consecutively sampled patients with stable coronary heart disease, the addition of 10 novel biomarkers to the prediction model improved the correct prediction of all-cause death and the composite outcome by less than 1.5%.

Trial registration ClinicalTrials.gov, NCT00121550. Date of registration 13 July 2005

Date of enrolment of first participant 12 October 1999

Keywords CLARICOR, cardiovascular disease, cardiovascular risk prediction, ischaemic heart disease, predictors, mortality.

Strengths and limitations of this study

- Use of multiple biomarkers
- Well established cohort
- Comprehensive statistical approach
- Missing external validation
- Relative old cohort

INTRODUCTION

Previously we have studied the prognostic impact of routinely available 'standard predictors' when added to a prediction model void of covariates using the placebo receiving participants from the CLARICOR trial¹⁻⁴. The impact, however, was quite modest¹. For risk assessment of patients with coronary artery disease (CAD), there are a number of advanced biomarkers, including several from outside cardiology, which may help identifying CAD patients at high risk of cardiovascular (CV) disease manifestations.² Here we assess the prognostic impact – relative to standard clinical predictors usually available during routine clinical work – of 12 newer biomarkers in predicting death and other serious cardiovascular events in patients suffering from CAD sampled while their disease was stable.

Briefly, the biomarkers are (1) serum N-terminal pro-B-type natriuretic peptide (pro-BNP), a marker of left ventricular dysfunction, and heart failure; (2) high-sensitive assay cardiac troponin T (hs-cTnT) indicating myocardial ischaemia; (3) YKL40 found to be predictive of AMI, CV-death, and non-CV death; (4) the glycoprotein osteoprotegerin (OPG), which is positively related to coronary calcification, vascular stiffness, and the presence of unstable atherosclerotic plaques; (5) pregnancy-associated plasma protein A (PAPP-A), a marker of vulnerable plaques in coronary arteries; (6) cathepsin B and (7) cathepsin S, a group of

5

1
2
3
4 proteinases that have been suggested to be causally involved in the different stages of the
5
6 atherosclerotic process; (8) endostatin, an endogenous angiogenesis inhibitor suggested to
7
8 mirror an increased neovascularisation induced by vascular or myocardial ischaemia; the
9
10 soluble receptors, (9) sTNFR1 and (10) sTNFR2, suggested to portray information about a
11
12 systemic inflammatory state that is independent of other more established inflammatory
13
14 markers; (11) calprotectin and (12) neutrophil gelatinase-associated lipocalin (NGAL), both
15
16 released from neutrophils when the cells are activated. Circulating levels of neutrophils and
17
18 their activation products have been shown to be markers for plaque instability in both primary
19
20 and secondary prevention of cardiovascular diseases.
21
22
23

24
25 All of these have been claimed to add some prognostic information in patients with stable
26
27 coronary artery heart disease. Our group has tested the individual importance of many of
28
29 these biomarkers, and in many studies statistical inference supports the view that
30
31 biomarkers may improve the prediction⁵⁻¹²
32
33
34

35 Our objectives were to clarify: (1) which of these newer biomarkers maintain their prognostic
36
37 importance if all of them were simultaneously available and were combined with the routinely
38
39 available clinical and laboratory information, and (2) what would then be their relative
40
41 practical contribution if they were added to the 'standard predictors' such as age, smoking,
42
43 plasma lipids, etc. In accordance with our published statistical analysis plan² our analysis
44
45 focusses on all-cause death and on a composite outcome comprising acute myocardial
46
47 infarction (AMI), unstable angina pectoris (UAP), cerebrovascular vascular disease (Ce-VD)
48
49 and death.
50
51
52
53
54
55
56
57
58
59
60

6

MATERIAL

The patients

The study population is the placebo patients from the CLARICOR-study.^{3,4} Patients aged 18 to 85 years, from the Copenhagen area, who had a discharge diagnosis of myocardial infarction or angina pectoris during 1993-1999 and were alive in August 1999 were invited by letter for an interview and a 14-days trial of clarithromycin versus placebo.^{3,4} Out of the 4372 who were randomised during October 1999 through April 2000, 2201 were in the placebo group.

The main results of the trial were that clarithromycin increased the risk of cardiovascular as well as all-cause death.¹³⁻¹⁵ Therefore, we here focus on the placebo group.

For the CLARICOR trial only patients who were in a stable state of their coronary heart disease were selected. Thus, patients were excluded if they fulfilled one or more of the following conditions: (1) had suffered from acute myocardial infarction or unstable angina pectoris within the previous 3 months; (2) had had intra-coronary interventions within the previous 6 months; (3) had impaired renal function; (4) had hepatic dysfunction; (5) had congestive heart failure (New York Heart Association (NYHA) IV classification of heart failure); (6) had active malignancy; (7) were without capacity to manage own affairs; (8) were breast feeding; and (9) were possibly pregnant.

15 of the 2201 participants were lost track of, due to emigration.

The predictors

7

Information on smoking status, current medication, known hypertension, diabetes, sex, age, and myocardial infarction at index hospitalisation or unstable angina pectoris was obtained from the local hospital files and patient interviews.

Biochemical measurements on serum collected at enrolment visit

Biochemical data were obtained from analysis of serum specimens sampled at inclusion of the patients and stored at -80 degrees C. The quantities measured include lipoproteins,¹⁶ high-sensitivity-C-reactive-protein/mg/L (hs-CRP/mg/L),⁷ and glomerular filtration /rate/mL/min (GFR/mL/min) using creatinine.¹⁷ Along with variables already mentioned, these quantities are those collectively referred to as 'standard predictors'.

Biomarkers included as newer biomarkers were YKL40/ μ g/L)⁸; high-sensitive assay cardiac troponin T/ng/L (hs-cTnT/ng/L)⁹; binary pregnancy associated plasma protein-A (binary-PAPP-A); which is coded as 1 if PAPP-A was ≥ 4 mIU/L or 0 otherwise¹⁰; N-terminal pro-B-type natriuretic peptide/ng/L (proBNP/ng/L)⁹; cathepsin-B/ μ g/L^{6,18}; endostatin/ng/mL¹⁹; cathepsin-S/ μ g/L^{6,20}; soluble TNF receptor 1/pg/mL and soluble TNF receptor 2/pg/mL (sTNFR1/pg./mL and sTNFR2/pg/mL)^{5,21}; neutrophil gelatinase-associated lipocalin/ng/L (NGAL/ng/L)²²; calprotectin/mg/L¹¹; and osteoprotegerin/ng/L (OPG/ng/L)¹². Due to storage problems some marker data are missing on some patients.

The outcomes

Initial follow-up of the patients lasted for approximately 2.6 years, during which outcomes were collected through hospital and death registries and assessed by an adjudication committee.⁴ Corresponding register data later produced similar results.^{23,24} The adjudicated outcomes were therefore replaced and augmented by register outcomes to cover up to 10

8

1
2
3
4 years +/- 3 months of follow-up. Last register follow-up was December 31, 2009. The public
5
6 registers have an almost 100% coverage and the quality of these are described
7
8 elsewhere.^{25,26} The algorithm used to get from the International Statistical Classification of
9
10 Diseases used in the national registries to the events of the composite outcome is described
11
12 in detail previously.¹³
13
14
15

16 We assessed (1) the time from randomisation to all-cause death and (2) the time from
17
18 randomisation until the first occurrence of one of the following outcomes: acute myocardial
19
20 infarction (AMI), unstable angina pectoris (UAP), cerebrovascular disease (CeVD), or all-
21
22 cause death.
23
24
25
26
27

28 29 **METHODS**

30 31 **Statistical analysis**

32
33 The statistical principles and techniques used have previously been published.^{1,2} While our
34
35 previous publication¹ dealt with the prognostic impact of the 'standard predictors,' we here
36
37 use the same techniques to quantify the effect of adding biomarker information to the
38
39 'standard predictors.'
40
41
42
43

44 We used Cox regressions (SAS 9.4) where all analyses that included covariates were
45
46 stratified by centre. The assumption of proportional hazards over time covering all covariates
47
48 included in a Cox analysis and the chosen functional form of quantitative covariates was
49
50 tested using cumulative sums of martingale-based residuals over follow-up time and/or
51
52 covariate values²⁷.
53
54

55 We also analysed data using a parametric, accelerated failure-time model using the
56
57 generalized gamma model of error.²⁸ A significance level of 0.01 was used to pinpoint
58
59
60

1
2
3
4 empirical trends worthy of note. The logarithms of the present text are natural logarithms,
5
6 so whenever the predictor is a log(serum concentration/unit), the hazard ratio is the factor
7
8 by which the hazard increases when the logarithm increases by 1, i.e., when the
9
10 concentration increases by a factor $e = 2.72$.
11
12
13
14
15

16 Biomarkers with a hazard **ratio** with P value ≥ 0.01 when used alone as covariate as well
17
18 as when used in combination with the 'standard predictors' were excluded from further
19
20 analyses. The remaining biomarkers were considered prognostic.
21
22
23

24 Assessment of the practical impact of using the set of newer biomarkers was obtained by
25
26 comparing the percent correct predictions obtained when the standard predictors were used
27
28 alone with the percentage obtained when they were combined with the novel biomarkers
29
30 using the method described earlier.¹
31
32
33

34 Secondly, we report the areas under the ROCs (receiver operating characteristics), also
35
36 known as AUCs or C-indices, obtained when the Cox-Breslow risk estimates are applied to
37
38 the same time window 0-to-9 years. The conventional 'observed' AUCs summarizes a ROC
39
40 plot of cumulative events against the cumulative event-free contingency, with cumulation
41
42 from large to small estimated risks. The corresponding 'predicted' AUC is based on
43
44 cumulating the predicted risks. AUCs represent the pairwise concordance rate between risks
45
46 and outcomes. In order to reward correct prediction of time of event, we further determined
47
48 a 'dynamic' C-index, alias risk concordance within any pair of participants whose event order
49
50 is deducible from the 9-year data window.
51
52
53
54
55
56
57
58
59
60

10

1
2
3
4 It is noted that in the ROC analysis it was not possible to add two time dependent covariates
5
6 which were needed because both age and log(OPG/ng/L) violated the assumption of
7
8 proportional hazard.
9

15 **Ethics and safety**

16
17
18 Ethics approval and consent to participate was given by
19
20 VEKKF01-076/99; Danish Medicines Agency 2612-975; Danish Data Protection
21
22 Agency 1999-1200-174; VEK H-B-2009-015.
23
24

25 **Patient and public involvement**

26
27
28 There was no direct patient involvement in the design of the trial, but the majority of the
29
30 investigators had daily contact with patients comparable to those included in the trial and
31
32 therefore knew their needs and preferences well. Moreover, there were patient
33
34 representatives as part of the regional ethics committee approving the trial. The public
35
36 involvement was through the approvals given by the regional ethics committee (KF 01-076/99
37
38 and journal no. H-12012125), the Danish Medicines Agency (2612-975), and the Danish
39
40 Data Protection Agency (1999-1200-174).
41
42
43
44
45
46
47
48
49
50

51 **RESULTS**

52
53
54 **Table 1** Distributions of demographics, previous history, current medication, standard
55
56 biochemical predictors, and newer biochemical predictors in 2201 placebo receiving
57
58
59
60

11

patients from the CLARICOR trial. Abbreviations as in section on abbreviations in the main paper.

Quantity	Distribution
Demographics and previous history	
Sex (male) N (%)	1518 (69.0%)
Age/year mean (SD)	65.2 (10.4) 2199
Smoking status N (%)	Smokers 753 (34.2%) Ex-smokers 1011 (46.0%) Never smoked 435 (19.8%)
Hypertension N (%)	883 (40.2%)
Diabetes N (%)	337 (15.3%)
Previous AMI N (%)	1494 (67.9%)
Current medication	
Aspirin N (%)	1937 (88.1%)
Beta-blocker N (%)	681 (31.0%)
Calcium-antagonist N (%)	772 (35.1%)
ACE-inhibitor N (%)	577 (26.3%)
Long-lasting nitrate N (%)	457 (20.8%)
Diuretics N (%)	773 (35.2%)
Digoxin N (%)	126 (5.7%)
Statins N (%)	904 (41.1%)
Anti-arrhythmic drugs N (%)	51 (2.3%)
Standard biochemical predictors	
log (CRP/mg/L) mean (SD) N ^a	1.03 (1.12) 2159
ApoA1/mg/dL mean (SD) N	1.70 (0.34) 2076
log (ApoB/mg/dL) mean (SD) N	0.16 (0.27) 2075
Chol-HDL/mmol/L mean (SD) N	1.02 (0.32) 2074
Chol-LDL/mmol/L mean (SD) N	2.56 (0.72) 2079
log (Cholesterol/mmol/L) mean (SD) N	1.73 (0.20) 2075
log (Tri-glyceride/mmol/L) mean (SD) N	0.73 (0.53) 2078
Glomerular filtration rate (GFR/mL/min) mean (SD) N	71.8 (19.2) 2079
Newer biochemical predictors	
log (proBNP/ng/L) mean (SD) N	5.26 (1.37) 2149
log (hs-cTnT/ng/L) mean (SD) N	2.01 (0.78) 2111
log (endostatin/ng/mL) mean (SD) N	10.3 (0.34) 2121
log (OPG/ng/L) mean (SD) N	7.49 (0.40) 2108
log (TNFR1/pg/mL) mean (SD) N	7.40 (0.40) 2120
log (TNFR2/pg/mL) mean (SD) N	8.54 (0.33) 2120
PAPP-A ≥ 4mIU/L count (%) N	288 (13.1%) 2140
log (YKL40/μg/L) mean (SD) N	4.75 (0.66) 2163
log (NGAL/ng/L) mean (SD) N	11.6 (0.46) 2121
log (Cathepsin B/μg/L) mean (SD) N	10.6 (0.45) 2120
log (Cathepsin S/μg/L) mean (SD) N	9.48 (0.27) 2121
log (Calprotectin/mg/L) mean (SD) N	0.77 (0.59) 2086

12

FOOTNOTES

- a) The value of N varies because the laboratory tests have missing values (mostly due to storage problems). log: natural logarithm.

Table 1 presents an overview of the covariates expected to be available from stable cardiovascular disease patients during clinical routine work ('standard predictors') plus the 12 newer biochemical quantities under investigation. The data revealed that at 3 years, 2073 (94.2%) were still alive and 1826 (83.0%) had not yet suffered a composite outcome. At 6 years, 1758 (79.9%) were still alive and 1261 (57.3%) had not yet suffered a composite outcome. At 9 years, the numbers were 1487 (67.6%) and 969 (44.0%).

Out of 2201 placebo patients, 1998 had complete biochemical data. As Little's test²⁹ had $P = 0.49$, suggesting that the values were missing completely at random, we used complete case analyses in the following. The composition of the two groups appears consistent.

Two of the 12 newer biomarkers (log(Calprotectin) and log(Cathepsin-S) did not contribute significantly ($P > 0.01$) to the prediction of any of the two outcomes neither when used in combination with the 'standard predictors' nor when used alone (see supplementary file S1, tables S1 and S2). They were therefore removed from the subsequent analyses. In the analysis of log (OPG/ng/L) we found that the assumption of proportional hazard was significantly violated. This was remedied when we included the time dependent covariate log (OPG/ng/L) •time/year in the subsequent regression equation (see table 2S in

13

supplementary file S1). The latter equation now included the 'standard predictors', plus the remaining 10 newer biomarkers and the

above-mentioned time dependent covariates. It appears from supplementary table S2 that only log (proBNP/ng/L), log (hs-cTnT/ng/L), and log (OPG/ng/L) •time/year contributed significantly to the prediction.

Table 2 The two outcomes (1) all-cause death and (2) the composite outcome of AMI, UAP, CeVD, and all-cause death were studied. The results shown are the number and percentages of correct predictions (P of prediction =0.5 used as cut off) of favorable (no outcome so far) and unfavorable status (the outcome occurred during the interval) made at 3, 6 and 9 years. Using the Cox model three covariate scenarios were compared.

Model and covariates included in model	Total number of predictions made per outcome	Number and percent of correct predictions of events	
		All-cause death N (%)	Composite of AMI ^a , UAP ^b , Ce-VD ^c , and all-cause death N (%)
Model 1: Cox model void of covariates	5972	4768 (79.8)	3773 (63.2)
Model 2: Cox model with 'Standard predictors(SP)' added to model	5972	4977 (83.3)	4084 (68.4)
Model 3: Cox model with SP + 10 newer biomarkers added to model	5972	5056 (84.7)	4165 (69.9)

a) AMI acute myocardial infarction

b) UAP unstable angina pectoris

c) Ce-VD cerebrovascular disease

14

1
2
3
4 Table 2 (see also supplementary file S1 tables 3S and 4S) compares the number and
5 percentages of correct predictions between various prediction models. In each model
6
7 predictions were made at 3, 6, and 9 years for each of the two outcomes (death and the
8
9 composite). Model 1 shows the results obtained using a model void of covariates. 79.8% of
10
11 the predictions were correct for the outcome death and 63.2% for the composite outcome.
12
13 Model 2 shows the results obtained when model 1 was augmented by the 'standard
14
15 predictors'. Now the percent correct predictions have been improved by $83.3 - 79.8\% = 3.5\%$
16
17 for the outcome death and $68.4 - 63.2\% = 5.2\%$ for the composite outcome. When model 2
18
19 was improved by adding the 10 newer biomarkers the additional gain in correct predictions
20
21 amounted to 1.4% for death and 1.3% for the composite outcome.
22
23
24
25
26
27

28 Using the parametric model in place of the Cox model we obtained quite similar results (see
29
30 tables S3 and S4 in supplementary file S1). The same was true if we only included log
31
32 (proBNP/ng/L), log (hs-cTnT/ng/L), and log (OPG/ng/L) instead of all 10 biomarkers when
33
34 the Cox model was used (see tables S3 and S4 in the supplementary file S1).
35
36
37
38
39
40

41 **Table 3.** C-indices. Cox model estimates applied to the 0-9-year follow-up window ($n =$
42 1998).
43
44
45
46

	Binary-outcome C (AUC), observed (predicted)	Dynamic C, observed
Composite outcome (1115 events) ^a		
Standard predictors (SP) only	0.711 (0.707)	0.640
The 10 newer markers & SP	0.732 (0.732)	0.657
Log(hsTnT/ng/L) + log(proBNP/ng/L) + SP	0.730 (0.730)	0.656

All-cause death (644 deaths)		
SP only	0.792 (0.793)	0.737
The 10 newer markers & SP	0.824 (0.816)	0.765
Log(hsTnT/ng/L) + log(proBNP/ng/L) + SP	0.821 (0.813)	0.762

a) Composite outcome: first occurrence of acute myocardial infarction, unstable angina pectoris, cerebrovascular disease or death. SP: 'standard predictors,' see table 1.

Table 3 summarizes the ROC analyses; For prediction of the composite outcome (yes / no), the area under the ROC increases from 0.711 to 0.732 when the 10 novel biomarkers are added to the 'standard predictors,' but again almost all the marker information is contained in log(hsTnT/ng/L) and log(proBNP/ng/L) (AUC = 0.730). The 'dynamic' C-index values are smaller as prediction of event times is more difficult, but the gains are similar. All-cause death shows the same general pattern.

DISCUSSION

In this study we assessed the combined value of 12 newer biomarkers not routinely used in clinical work to predict all-cause death and a composite outcome (AMI, UAP, CeVD, or all-cause death). We used a cut value of $P=0.5$ to separate correct predictions of the observed patient status from incorrect ones. When we combined the biomarkers with the 'standard predictors' routinely available for a general practitioner when he/she meets a patient with stable coronary heart disease, 84.7 % of the survival status were correctly predicted. In case of the composite outcome the number was 68.4%. In both cases, the combined contribution of the newer biomarkers amounted to less than 1.5%.

16

1
2
3
4 Our patients resemble those of The Prospective Observational Longitudinal Registry of
5 Patients with Stable Coronary Heart Disease (CLARIFY) study³⁰ which enrolled 20,291
6
7 patients. The CLARIFY patients had been observed with a median of 24.1 months. However,
8
9 enrollment took place 10 years later than in the CLARICOR trial and the incidence of
10
11 cardiovascular deaths or myocardial infarctions in these patients was considerably lower,³⁰
12
13 probably reflecting improved quality of treatment and more frequent statin treatment in the
14
15 CLARIFY patients (84% compared to only 41% in the CLARICOR material). So, the age of
16
17 our material is a weakness.
18
19
20
21
22
23
24
25
26

27 In our present study, we are using our data to develop a prediction model. Then we use the
28
29 same data that we used to develop the model. Clearly this is bound to produce overly
30
31 optimistic results compared to testing our model using independent data. But we argue that
32
33 the aim of this study was not to present a prediction model but to assess the newer
34
35 biomarkers' contribution to model performance when added on top of routinely available
36
37 clinical and laboratory data. Therefore, if tested on independent data, the contribution of the
38
39 newer biomarkers to prognosis of patients with stable coronary heart disease are likely going
40
41 to be worse than observed here.
42
43
44
45
46
47
48

49 **Methodology**

50
51
52 Regarding our methodology, the performance statistics reported here are minimal, but they
53
54 suffice to show that the results are meagre. Prediction at 3, 6, and 9 years covers the follow-
55
56 up as well as would a sophisticated integral over continuous time.
57
58
59
60

Strengths

The strengths of the CLARICOR trial are the size of the patient population, the long duration of follow-up, few losses to follow-up (0.1%), the ethnic homogeneity of the patient population (most being Caucasians), rarity of missing values, with focus on an operationally defined, homogeneous and relevant patient category. The design implies that the patients are sampled at random, presumably uneventful, time points during their stable state (as defined by the CLARICOR trial).

Limitations

Among those 7586 patients who declined our invitation to visit a cardiology centre, many must have been eligible for the CLARICOR trial, and we do not know how they looked and fared. With a response rate about 50%, the cohort could represent a prognostic elite if responders were mostly mobile and health-conscious patients. So, selection bias cannot be excluded.

Furthermore, users of these data should remain aware of one feature: patients if any who became eligible for the CLARICOR trial during the period 1993 to 1999 and then died before August 1999 are absent. Thus, our data do not represent patients as they enter a stable disease state (as delimited by CLARICOR exclusion criteria); instead, they may be regarded as community patients (subject to some self-selection) seen by their physician or at an outpatient clinic on a random date during their stable state.

1
2
3
4 The patients recruited for the CLARICOR trial were diagnosed with coronary heart disease
5 about 20 years ago. Because of the developments in treatment and rehabilitation, there has
6 been a very significant and gradual improvement in the prognosis of such patients as shown
7 in national data.³¹ Given these uncertainties, prognostic findings in the CLARICOR cohort
8 may not be directly applied to present-day patients. However, the overall, somewhat
9 disappointing, picture presented by the predictive performance of standard¹ and newer
10 biochemical predictors studied 10-20 years ago would hardly be much different if studied
11 today.
12
13
14
15
16
17
18
19
20
21
22

23 Potential weaknesses of the present cohort within the context of prognostication of stable
24 coronary heart disease patients as here defined include the fact that only questionnaire data
25 were collected at randomisation. No data are available concerning left ventricle function,
26 body mass index, blood pressure, and general health. These shortcomings are mitigated by
27 the fact that, by design, the present study sees the patient in a situation where (s)he visits a
28 physician for reasons unrelated to the coronary disease, as already stressed. In such
29 situations, counselling and decisions must typically be made without access to
30 echocardiography or other special investigations. Furthermore, if this information had been
31 available, the prognostic gain we study would probably have been still poorer. Moreover, we
32 included age, sex, hypertension, prior myocardial infarction, information about current
33 medication which has previously been shown to be a fair replacement for prognostication
34 instead of left ventricular ejection fraction.³²
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51 It is noted that the patients studied by us were all in a stable state of their disease, without
52 cardiac complaints. Therefore, one should not conclude from this study that the biomarkers
53 studied here may not be useful in many other clinical contexts, although biomarkers have
54
55
56
57
58
59
60

19

1
2
3
4 been shown to of modest help in evaluating cardiovascular risk assessment in asymptomatic
5
6 people not suffering from CAD.³³
7
8
9

10
11
12
13 **Conclusions** In the present clinical context the contribution of the 12 biomarkers not yet
14
15 used in clinical routine work proved to be minimal. Furthermore, of the 10 novel biomarkers
16
17 all except for osteoprotegerin could be replaced by hs-cTnT and proBNP.
18
19

20 21 **Author affiliations**

22
23
24 1 Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet.
25
26 Copenhagen University hospital, Blegdamsvej 9, Copenhagen, Denmark.

27
28
29 2 Department of Cardiology, Holbæk Hospital, Holbæk, Denmark.

30
31
32 3 Department of Regional Health Research, The Faculty of Health Sciences, University of
33
34 Southern Denmark
35

36
37
38 4 Section of Biostatistics, Department of Public
39
40 Health Research, University of Copenhagen, Copenhagen, Denmark.

41
42
43 5 Department of Cardiology, Hvidovre Hospital, Copenhagen University Hospital,
44
45 Copenhagen, Denmark.

46
47
48 6 Department of Cardiology S, Herlev Hospital,
49
50
51
52 Copenhagen University Hospital, Copenhagen, Denmark.

53
54
55 7 Department of Cardiology,
56
57
58
59 Bispebjerg Hospital, University Hospital, Copenhagen, Denmark.
60

20

1
2
3
4 8 Department of Cardiology B, The Heart Centre, Rigshospitalet, Copenhagen
5
6
7 University Hospital, Copenhagen, Denmark.
8
9

10 9 Department of Clinical
11
12
13 Microbiology, Odense University Hospital, Odense, Denmark.
14
15

16 10 The Medical Research Laboratory, Department of Clinical Medicine, Aarhus University,
17
18 Denmark.
19
20

21
22 11 Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
23
24

25 12 Division of Family Medicine and Primary Care, Department of Neurobiology, Care
26
27 Sciences and Society, Karolinska Institutet, Huddinge, Sweden
28
29

30 13 Division of Family Medicine and Primary Care, Department of Neurobiology, Care
31
32 Science and Society, Karolinska Institutet, Huddinge, Sweden.
33
34
35
36
37
38

39 **Abbreviations**

40
41 AMI: acute myocardial infarct; Apo A1: apoprotein A1; Apo B: apoprotein B; CeVD: cerebro-
42
43 vascular disease; Chol-HDL: cholesterol high density lipoprotein; Chol-LDL: cholesterol low
44
45 density lipoprotein; CLARICOR: Clarithromycin for patients with stable coronary heart
46
47 disease; CRP: c-reactive protein; GFR: Glomerular filtration rate; hs-cTnT: High-sensitive
48
49 assay cardiac troponin T; NGAL: neutrophil gelatinase-associated lipocalin; NYHA: New
50
51 York Heart Association; OPG: osteoprotegerin; PREMAC: Predictors for major
52
53 cardiovascular outcomes in stable ischaemic heart disease; proBNP: N-terminal pro-B-type
54
55 natriuretic peptide;
56
57
58
59
60

21

TNFR1: tumor necrosis factor receptor 1; TNFR2: tumor necrosis factor receptor 2; UAP: unstable angina pectoris.

Acknowledgements

We thank the CLARICOR trial participants. We thank the investigators and other staff involved during the first phases of the CLARICOR trial (for full list of names, please see references 6, 11, and 13). We also thank our original funders of the CLARICOR trial (see references 6, 11, and 13). The Copenhagen Trial Unit, Centre for Clinical Intervention Research, is thanked for providing monetary support for part of the biochemical analyses for the PREMAC study as well as wages for Per Winkel, Janus C. Jacobsen, and Christian Gluud.

Funding

This study was funded by the Copenhagen Trial Unit, Centre for Clinical Intervention Research; original funders of the CLARICOR trial; and The Swedish Research Council, Swedish Heart-Lung foundation; Thuréus Foundation; Marianne and Marcus Wallenberg Foundation, Dalarna University; and Uppsala University.

Availability of data and materials

All pertinent anonymised data will be uploaded at ZENODO (<http://zenodo.org/>) when the individual manuscripts have been published.

Authors' contributions

PW, JH, JCJ, and CG contributed substantially to the concept and design and

1
2
3
4 drafted the manuscript, PW and JH contributed equally to this paper, and conducted the
5
6 statistical analyses. AL and JÄ conducted the analysis of lipids and creatinine. PW, JCJ, JH,
7
8 GBJ, EK, AS, JK, HJK, KKI, MB, AL, JÄ, CG revised the manuscript critically for important
9
10 intellectual content, gave final approval of version to be published, and
11
12 agreed to be accountable for all aspects of the work in assuring that questions related to
13
14 the accuracy or integrity of any part of the work are appropriately investigated and
15
16 resolved. PW, JCJ, JH, GBJ, EK, AS, JK, HJK, KKI, MB, AL, JÄ, CG contributed
17
18 substantially to the interpretation of the data.
19
20
21
22

23 **Competing interests**

24
25 The authors declare that they have no competing interests.
26

27 **REFERENCES**

- 28
29
30 1. Winkel P, Jakobsen JC, Hilden J, et al. Prognostic value of routinely available
31
32 data in patients with stable coronary heart disease. A 10-year follow-up of patients sampled
33
34 at random times during their disease course. *Open Heart* 2018:e000808.
35
36 Doi:10.1136/openhrt-2018-000808
37
38
39
40 2. Winkel P, Jakobsen JC, Hilden J, Lange T, Jensen GB, Kjølner E, et al:
41
42 Predictors for major cardiovascular outcomes in stable ischaemic heart disease (PREMAC):
43
44 statistical analysis plan for data originating from the CLARICOR (clarithromycin for patients
45
46 with stable coronary heart disease) trial: *Diagnostic and Prognostic Research* (2017) 1:10
47
48 DOI 10.1186/s41512-017-0009-y.
49
50
51
52 3. Jespersen CM, Als-Nielsen B, Damgaard M, Hansen JF, Hansen S, Helø OH,
53
54 et al: Randomised placebo controlled multicentre trial to assess short term clarithromycin
55
56 for patients with stable coronary heart disease: CLARICOR trial. *BMJ*. 2006; 332:22–7.
57
58
59
60

23

- 1
2
3
4 4. Hansen S, Als-Nielsen B, Damgaard M, Helø OH, Petersen L, Jespersen CM,
5 et al: Intervention with clarithromycin in patients with stable coronary heart disease: the
6 CLARICOR trial design. *Heart Drug*. 2001; 1:14–9.
7
8
- 9
10
11
12 5. Carlsson AC, Ruge T, Kjølner E, Hilden J, Kolmos HJ, Sajadieh A o. a. 10-year
13 associations between tumor necrosis factor receptors 1 and 2 and cardiovascular events in
14 patients with stable coronary heart disease: a CLARICOR (effect of clarithromycin on
15 mortality and morbidity in patients with coronary heart disease) trial substudy. *Journal of the*
16 *American Heart Association* 2018 apr 23;7(9): e 008299 Doi:10. 116/JAHA 127.008299
17
18
19
20
21
22
23
- 24 6. Wuopio J, Hilden J, Bring C, Kastrup J, Sajadieh A, Jensen GB o.a. Cathepsin
25 B and S as markers for cardiovascular risk and all-cause mortality in patients with stable
26 coronary heart disease during 10 years: a CLARICOR trial substudy. *Atherosclerosis*. 2018
27 nov 1:278: 97 to 102. Tilgængelig fra, DOI: 10. 1016/j. atherosclerosis. 2018.09.006
28
29
30
31
32
33
- 34 7. Harutyunyan MJ, Mathiasen AB, Winkel P, Gøtze JP, Hansen JF, Hildebrandt
35 P, et al: High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in
36 patients with stable coronary heart disease: a prognostic study within the CLARICOR trial.
37 *Scand J Clin Lab Invest*. 2011; 71:52–62.
38
39
40
41
42
43
- 44 8. Kastrup J, Johansen JS, Winkel P, Hansen JF, Hildebrandt P, Jensen GB, et
45 al.High serum YKL40 concentration is associated with cardiovascular and all-cause
46 mortality in patients with stable coronary artery disease. *Eur. Heart J*. 2009; 30:1066-72.
47
48
49
50
51
- 52 9. Lyngbaek S, Winkel P, Gotze JP, Kastrup J, Gluud C, Kolmos HJ, et al. Risk
53 stratification in stable coronary artery disease is possible at cardiac troponin levels below
54 conventional detection and is improved by use of N-terminal pro-B-type natriuretic peptide.
55 *European Journal of Preventive Cardiology* 2014; 21:1275-1284.
56
57
58
59
60

24

- 1
2
3
4 10. Iversen KK, Teisner B, Winkel P, Gluud C, Kjoller E, Kolmos HJ, et al.
5
6 Pregnancy associated plasma protein-A as a marker for myocardial infarction and death in
7
8 patients with stable coronary artery disease: a prognostic study within the CLARICOR Trial.
9
10 Atherosclerosis 2011; 214:203-208.
11
12
- 13
14 11. Larsen SB, Grove EL, Pareek M, Kristensen SD, Hvas AM. Calprotectin and
15
16 platelet aggregation in patients with stable coronary artery disease. PloS ONE 2015;
17
18 10(5):e0125992.
19
20
- 21
22 12. Bjerre M, Hilden J, Kastrup J, Skoog M, Hansen JF, Kolmos HJ, et al.
23
24 Osteoprotegerin independently predicts mortality in patients with stable coronary artery
25
26 disease: the CLARICOR trial. Scandinavian Journal of Clinical and Laboratory Investigation
27
28 2014; 74:657-664.
29
30
- 31
32
33
34
35 13. Winkel P, Hilden J, Hansen JF, Kastrup J, Kolmos HJ, Kjoller E, et al.
36
37 Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular
38
39 mortality and cerebrovascular morbidity over 10years in the CLARICOR randomised,
40
41 blinded clinical trial. International Journal of Cardiology 2015, 182:459-465.
42
43
44
- 45 14. Winkel P, Hilden J, Fischer Hansen J, Hildebrandt P, Kastrup J, Kolmos HJ, et
46
47 al: Excess sudden cardiac deaths after short-term clarithromycin administration in the
48
49 CLARICOR trial: why is this so, and why are statins protective? Cardiology. 2011; 118:63–
50
51 67.
52
53
- 54
55 15. Gluud C, Als-Nielsen B, Damgaard M, Fischer Hansen J, Hansen S, Helø OH,
56
57 et al: Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the
58
59
60

25

1
2
3
4 CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart
5
6 disease. *Cardiology*. 2008; 111:280
7
8

9
10 16. Helmersson-Karlqvist J, Ridefelt P, Lind L, Larsson A. Reference values for 34
11 frequently used laboratory tests in 80-year-old men and women. *Maturitas*. 2016; 92: 97-
12
13 101.
14

15
16
17 17. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al:
18 Estimating glomerular filtration rate from serum creatinine and cystatin C. *N Engl J Med*.
19
20 2012;367:20–9.
21
22

23
24
25 18. Wang N, Bai X, Jin B, Han W, Sun X, Chen X. The association of serum
26 cathepsin-B concentration with age-related cardiovascular-renal subclinical state in a
27
28 healthy Chinese population. *Arch Gerontol Geriatr*. 2016; 65:146-55.
29
30

31
32
33 19. Arnlov J, Ruge T, Ingelsson E, Sundstrom J, Lind L. Serum endostatin and risk
34 of mortality in the elderly: findings from 2 community-based cohorts. *Arterioscler Thromb*
35
36 *Vasc Biol*.2013, 33: 2689-95.
37
38

39
40
41 20. Jobs E, Ingelsson E, Risérus U, Nerpin E, Jobs M, Sundström J, et al.
42 Association between serum cathepsin S and mortality in older adults. *JAMA*. 2011;
43
44 306:1113-21.
45
46

47
48
49 21. Carlsson AC, Larsson TE, Helmersson-Karlqvist J, Larsson A, Lind L, Ärnlöv J.
50 Soluble TNF receptors and kidney dysfunction in the elderly. *J Am Soc Nephrol*.
51
52 2014;25:1313-20.
53
54

55
56
57 22. Helmersson-Karlqvist J, Larsson A, Carlsson AC, Venge P, Sundstrom J,
58
59 Ingelsson E, et al. Urinary neutrophil gelatinase-associated lipocalin (NGAL) is associated
60

26

1
2
3
4 with mortality in a community-based cohort of older Swedish men. *Atherosclerosis* 2013;
5
6 227:408-13.
7

8
9 23. Kjølner E, Hilden J, Winkel P, Frandsen NJ, Galatius S, Jensen G, et al: Good
10 interobserver agreement was attainable on outcome adjudication in patients with stable
11 coronary heart disease. *J Clin Epidemiol.* 2012; 65:444–53.
12
13
14

15
16
17 24. Kjølner E, Hilden J, Winkel P, Galatius S, Frandsen NJ, Jensen GB, et al:
18 Agreement between public register and adjudication committee outcome in a cardiovascular
19 randomized clinical trial. *Am Heart J.* 2014; 168:197–204.ok
20
21
22

23
24
25 25. Helweg-Larsen K: The Danish register of causes of death. *Scand J Public*
26
27 *Health.* 2011;39(7 30. Suppl):26-9.
28

29
30 26. Lynge E, Sandegaard JL, Rebolj M: The Danish National Patient Register.
31
32 *Scand J Public Health.* 2011;39(7 suppl):30–3.
33

34
35
36 27. Lin DY, Wei LJ, Ying Z: Checking the Cox model with cumulative sums of
37
38 martingale-based residuals. *Biometrika.* 1993; 80:557–72.
39

40
41
42
43
44 28. Allison PD: *Survival Analysis Using SAS: A Practical Guide*, second edition
45
46 2010 SAS institute Inc. Cary, NC, USA.
47

48
49
50 29. Little R: A test of missing completely at random for multivariate data with missing
51
52 values. *J Am Stat Assoc.* 1988; 83:1198–1202.
53

54
55
56 30. Steg PG, Greenlaw N, Tendera M, et al. Prevalence of anginal symptoms and
57
58 myocardial ischemia and their effect on clinical outcomes in outpatients with stable coronary
59
60

27

artery disease. Data from the International Observational CLARIFY Registry. JAMA Intern Med. 2014;174(10):1651-1659. doi:10.1001/jamainternmed.2014.3773

31. Schmidt M, Jacobsen JB, Lash TL, Bøtker HE, Sørensen HT: 25-year trends in first time hospitalisation for acute myocardial infarction, subsequent short and long-term mortality, and the prognostic impact of sex and comorbidity: a Danish nationwide cohort study. BMJ. 2012;344: e356.

32. Solomon SD, Claggett B, Desai AS, *et al.* Influence of ejection fraction on outcomes and efficacy of sacubitril/valsartan (Ic2696) in heart failure with reduced ejection fraction. Circulation 2016;9:e00274.

33. Scott IA. Evaluating cardiovascular risk assessment in asymptomatic people. BMJ 2009;a2844doi:10.1136/bmj.a2844

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

<Winkel P. & al. * Supplementary file S1>

Supplementary file S1

Table 1S All-cause mortality hazard ratios (HR) of newer biochemical predictors not routinely used in clinical work when each of these predictors is used alone (columns 2 to 4), and when it is used in combination with the 'standard predictors'^a (column 5 to 7). Two of them were then discarded and each of the remaining 10 was assessed when used in combination with the standard predictors and the remaining 9 of the 10 newer biochemical predictors selected among the 12 candidates (columns 8 to 10).

Newer biochemical candidate predictor	When candidate predictor is the only predictor included in the model (stratified by centre)			When 'standard predictors' is added to the model (stratified by centre)			When in addition the 10 selected predictors are added to the model (stratified by centre)		
	HR ^b	95% CI	P	HR	95% CI	P	HR	95% CI	P
log (endostatin/ng/mL)	3.49	2.81 to 4.33	<0.0001	1.75	1.34 to 2.27	<0.0001	1.23	0.92 to 1.63	0.16
log (OPG/ng/L)	3.37	2.88 to 3.94	<0.0001	1.68	1.35 to 2.09	<0.0001	1.21	0.97 to 1.63	0.092
log (sTNFR1/pg/mL)	3.80	3.19 to 4.54	<0.0001	1.84	1.46 to 2.33	<0.0001	1.10	0.81 to 1.48	0.55
log (sTNFR2/pg/mL)	5.45	4.40 to 6.76	<0.0001	2.39	1.80 to 3.18	<0.0001	1.43	0.99 to 2.07	0.056
log(proBNP/ng/L)	1.76	1.66 to 1.87	<0.0001	1.44	1.34 to 1.55	<0.0001	1.28	1.19 to 1.39	<0.0001
log(hs-cTnT/ng/L)	2.31	2.16 to 2.47	<0.0001	1.73	1.56 to 1.92	<0.0001	1.46	1.30 to 1.65	<0.0001
PAPP-A_binary ^c	1.84	1.53 to 2.21	<0.0001	1.39	1.15 to 1.68	0.0007	0.85	0.69 to 1.03	0.10
log (YKL40/μg/L)	1.76	1.59 to 1.95	<0.0001	1.32	1.17 to 1.49	<0.0001	1.10	0.97 to 1.25	0.15
log (NGAL/ng/L)	1.33	1.12 to 1.57	0.0011	1.03	0.85 to 1.24	0.78	0.90	0.74 to 1.10	0.30
log(Calprotectin/)	1.08	0.95 to 1.23	0.25	1.02	0.89 to 1.18	0.74	Not included in analysis		
log (Cathepsin-B/μg/L)	2.81	2.40 to 3.28	<0.0001	1.43	1.19 to 1.73	0.0002	1.09	0.89 to 1.33	0.42
log (Cathepsin-S/μg/L)	1.12	0.86 to 1.47	0.40	1.10	0.83 to 1.45	0.53	Not included in analysis		

a) The standard predictors are shown in Table 1.

b) Hazard ratio associated with unit increase on log scale, except for PAPP-A (binary).

<Winkel P. & al. * Supplementary file S1>

c) Binary quantity. 1: PAPP-A was ≥ 4 mIU/L, 0: PAPP-A was < 4 mIU/L.

1. Inferential impact of the newer biomarkers

As the proportional hazard's assumption was violated for age²⁹ and age interacted significantly with time since randomisation, we included an interaction between age at entry and time (since randomisation) in the inference analyses.

Table 1S shows the results of a Cox regression of all-cause death on each of the 12 biomarkers when the biomarker was used alone as a covariate (columns 2 through 4), and when it was used in combination with the 'standard predictors' (columns 5 through 7).

Columns 8 through 10 in Table 1S shows the result of a regression of the outcome on the 'standard predictors' and the 10 best biochemical predictors. Now only log (proBNP /ng/L) and log(hs-cTnT/ng/L) have a HR significantly ($P < 0.01$) different from 1. Log(calprotectin/mg/L) and log(cathepsin-S/ μ g/L) did not have an inferential impact ($P < 0.01$ not attained), not even when used alone.

<Winkel P. & al. * Supplementary file S1>

Table 2S the composite outcome (comprising first occurrence of acute myocardial infarction, unstable angina pectoris, cerebro-vascular disease, and death). Hazard ratios of each of 13 biochemical predictors not routinely used in clinical work when each of these predictors is used alone (columns 2 to 4), and when it is used in combination with the 'standard predictors' (column 5 to 7). Two of them were then discarded and each of the remaining 11 was assessed when used in combination with the standard predictors and the remaining 10 of the 11 newer biochemical predictors selected among the 13 candidates (columns 8 to 10)

Newer biochemical candidate predictor	When candidate predictor is the only predictor included in the model (stratified by centre)			When 'standard predictors' is added to the model (stratified by centre)			When in addition the 11 ^a selected predictors are added to the model (stratified by centre)		
	HR	95% CI of HR	P	HR	95% CI of HR	P	HR	95% CI of HR	P
log (Endostatin/ng/mL)	2.18	1.84 to 2.58	<0.0001	1.44	1.17 to 1.72	0.0006	1.23	0.99 to 1.54	0.062
log (OPG/ng/L)	1.34	1.05 to 1.71	0.019	0.94	0.70 to 1.26	0.67	0.78	0.58 to 1.04	0.094
log (OPG/ng/L) ·time/year ^b	1.11	1.06 to 1.16	<0.0001	1.09	1.03 to 1.16	0.0022	1.104	1.044 to 1.168	0.0005
log (sTNFR1/pg/mL)	2.14	1.86 to 2.46	<0.0001	1.33	1.11 to 1.60	0.0021	1.05	0.84 to 1.32	0.67
log (sTNFR2/pg/mL)	2.56	2.15 to 3.03	<0.0001	1.49	1.19 to 1.85	0.0004	1.13	0.85 to 1.50	0.40
log (proBNP/ng/L)	1.37	1.31 to 1.44	<0.0001	1.26	1.19 to 1.33	<0.0001	1.18	1.11 to 1.25	<0.0001
log (hs-cTnT/ng/L)	1.83	1.70 to 1.97	<0.0001	1.49	1.35 to 1.64	<0.0001	1.31	1.17 to 1.46	<0.0001
PaPP-A (binary) ^c	1.45	1.24 to 1.70	<0.0001	1.24	1.06 to 1.46	0.0077	0.89	0.75 to 1.05	0.15
log (YKL40/μg/L)	1.35	1.24 to 1.47	<0.0001	1.13	1.03 to 1.24	0.013	1.01	0.91 to 1.11	0.93
log (NGAL/ng/L)	1.23	1.08 to 1.40	0.0023	1.03	0.89 to 1.19	0.73	0.97	0.84 to 1.13	0.74
log (Calprotectin/)	1.06	0.95 to 1.17	0.32	1.00	0.90 to 1.12	0.95	Not included in analysis		
log (cathepsin-B/μg/L)	1.70	1.50 to 1.93	<0.0001	1.17	1.01 to 1.35	0.040	0.99	0.85 to 1.16	0.92
log (cathepsin-S/μg/L)	1.06	0.86 to 1.31	0.59	0.98	0.79 to 1.22	0.88	Not included in analysis		

<Winkel P. & al. * Supplementary file S1>

- a) Note that now a time dependent covariate has been added [$\log(\text{OPG}/\text{ng/L}) \cdot \text{time}/\text{year}$] to the 10 original predictors.
- b) $\log(\text{OPG}/\text{ng/L})$ significantly violated the proportional hazard assumption. We found a significant linear relationship between $\log(\text{OPG}/\text{ng/L})$ and time since randomisation which may explain the violation. The product of $\log(\text{OPG}/\text{ng/L})$ and time/year was therefore included in the inference analysis. However, when the Cox model is used for prediction, time dependent covariates are not allowed (SAS 9.4). Therefore, in the latter context we only include $\log(\text{OPG}/\text{ng/L})$.
- c) Binary quantity. 1: PAPP-A was ≥ 4 mIU/L, 0: PAPP-A was < 4 mIU/L.

Table 2S corresponds to Table 1S except that the outcome is the composite outcome. It is noted that a time-dependent covariate is now included because $\log(\text{OPG}/\text{ng/L})$ violated the proportional hazard assumption. This was remedied by including the covariate $\log(\text{OPG}/\text{ng/L}) \cdot \text{time}/\text{year}$. It is seen that when all the biomarkers were included in the Cox analysis $\log(\text{OPG}/\text{ng/L}) \cdot \text{time}/\text{year}$, $\log(\text{proBNP}/\text{ng/L})$, and $\log(\text{hs-cTnT}/\text{ng/L})$ were the only ones which had a P value below the threshold of 0.01. Again $\log(\text{calprotectin}/\text{ng/L})$ and $\log(\text{cathepsin-S}/\mu\text{g/L})$ could be excluded from the final analysis, the result of which is shown in columns 8 through 10.

2. Practical impact of the novel biomarkers

Table 3S All-cause death. Correct predictions of favorable (alive) and unfavorable (not alive) status made at 3 years, at 6 years, and at 9 years following randomisation in the 1998 placebo patients from the CLARICOR trial. Four covariate scenarios were examined with Cox regression (see text of columns 4, 5, 6, and 8). For comparison with the results of column 6, column 7 shows the corresponding results when the accelerated failures model was used.

<Winkel P. & al. * Supplementary file S1>

(1) Number of predictions made	(2) Time at which prediction was made	(3) Correctly predicted patient status	(4) Data without covariates included Both models N (%)	(5) Data including Standard predictors as covariates Cox model N (%)	(6) Data including Standard predictors + advanced biochemical predictors as covariates Cox model N (%)	(7) Data including Standard predictors + advanced biochemical predictors as covariates Parametric model N (%)	(8) Data including Standard predictors log(OPG/ng/L) log (hs-cTnT/ng/L) and log(proBNP/ng/L) as covariates Cox Model N (%)
1996	Three years	Favorable status	1825 (91.4)	1821 (91.2)	1816 (91.0)	1814 (90.9)	1816 (91.0)
		Unfavorable status	0 (0.00)	10 (0.50)	19 (0.95)	14 (0.70)	19 (0.95)
1989	Six years	Favorable status	1601 (80.5)	1555 (78.2)	1551 (78.0)	1538 (77.3)	1553 (78.1)
		Unfavorable status	0 (0.00)	85 (4.27)	120 (6.03)	118 (5.93)	113 (5.68)
1987	Nine years	Favorable status	1342 (67.5)	1192 (60.0)	1219 (61.3)	1217 (61.2)	1212 (61.0)
		Unfavorable status	0 (0.00)	297 (14.9)	331 (16.7)	323 (16.3)	339 (17.1)
5972	All three times combined	Favorable status	4768 (79.8)	4585 (76.8)	4586 (76.8)	4569 (76.5)	4581 (76.7)
		Unfavorable status	0 (0.00)	392 (6.56)	470 (7.87)	364 (6.10)	471 (7.89)
		Total	4768 (79.8)	4977 (83.3)	5056 (84.7)	4933 (82.6)	5052 (84.6)

bmjopen-2019-033820
 on 21 August 2019
 Protected by copyright.

<Winkel P. & al. * Supplementary file S1>

The results of the predictions of survival status made at 3 years, at 6 years, and at 9 years following randomisation in the 1998 placebo patients are summarized in Table 3S.

When the 'standard predictors' were included as covariates (column 5) for all-cause mortality, 83.3% of the predictions were correct.


Adding the 10 newer biochemical predictors (column 6) the percentage was increased by 1.4% to 84.7%.

For peer review only

bmjopen-2019-033720 on 20 August 2020. Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.

<Winkel P. & al. * Supplementary file S1>

Figure 1S A



bmjopen-2019-033720 on 20 August 2020. Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.

<Winkel P. & al. * Supplementary file S1>


Figure 1S B

For peer review only

bmjopen-2019-033720 on 20 August 2020. Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

<Winkel P. & al. * Supplementary file S1>



bmjopen-2019-033720 on 20 August 2020. Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.

<Winkel P. & al. * Supplementary file S1>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15 The parametric model fitted the data reasonably well (see figure 1S A and B). The distribution of years to outcome using the accelerated
16 failure model where the error term is modelled using the general gamma distribution showed that for both outcomes all values were within
17 the 95% confidence limits. However, in case of all-cause death (see figure 1S A) the distribution was upwards biased but still within the 95%
18 confidence limits.
19
20
21
22
23
24
25
26
27

28 It is noted that the results obtained with the parametric model (column 7 Tables S3 and S4) are not dramatically different from the
29 corresponding results in column 6, when this theoretically equally valid model is used. When only the three significant predictors
30 $\log(\text{OPG}/\text{ng/L})$, $\log(\text{proBNP}/\text{ng/L})$, and $\log(\text{hs-cTnT}/\text{ng/L})$ were used in the Cox model in place of all 10 (column 8), the results were
31 practically unaffected (compare columns 8 and 6).
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

<Winkel P. & al. * Supplementary file S1>

Table 4S the composite outcome of AMI, UAP, CeVD, and all-cause death. Correct predictions of favorable (no outcome so far) and unfavorable status made at 3, 6 and 9 years. Cox model: four covariate scenarios as in Table 4; and parametric model (column 7) for comparison with column 6. Note that log (OPG) qualified for inclusion in column 8.

(1) Number of predictions made	(2) Time at which prediction was made	(3) Correctly predicted patient status	(4) Data without covariates included Both models N (%)	(5) Data including Standard predictors as covariates Cox model N (%)	(6) Data including Standard predictors + advanced biochemical predictors as covariates Cox model N (%)	(7) Data including Standard predictors + advanced biochemical predictors as covariates Parametric model N (%)	(8) Data including Standard predictors + Log(OPG/ng/L), Log(hcTnT/ng/L), and log(pBNP/ng/L) as covariates Cox model N (%)
1996	Three years	Favorable status	1514 (75.9)	1471 (73.7)	1464 (73.3)	1479 (74.1)	1463 (73.3)
		Unfavorable status	0 (0)	51 (2.56)	77 (3.86)	57 (2.86)	77 (3.81)
1989	Six years	Favorable status	1144 (57.5)	935 (47.0)	920 (46.3)	916 (46.1)	925 (46.5)
		Unfavorable status	0 (0)	349 (17.5)	370 (18.6)	368 (18.5)	367 (18.5))
1987	Nine years	Favorable status	0 (0)	504 (25.4)	542 (27.3)	550 (27.7)	529 (27.6)
		Unfavorable status	1115 (56.1)	774 (39.0)	792 (39.9)	803 (40.4)	799 (39.2)
5972	All three times combined	Favorable status	2658 (44.5)	2910 (48.7)	2926 (49.0)	2945 (49.3)	2927 (49.2)
		Unfavorable status	1115 (18.7)	1174 (19.7)	1239 (20.7)	1228 (20.6)	1222 (20.5)
		Total	3773 (63.2)	4084 (68.4)	4165 (69.7))	4173 (69.9)	4159 (69.6)

<Winkel P. & al. * Supplementary file S1>

1
2 Table 4S shows the results corresponding to Table 3S obtained when the composite outcome was used. Including the 'standard
3
4 predictors' in the model increases the percent correct predictions from 63.2 (see column 4, Table 4S) to 68.4 (see column 5, Table 4S), i.e.
5
6 an increase of 5.2%. Adding the 10 newer biomarkers to the model increases the number of correct predictions by 1.3%. Using the
7
8 parametric model does not change the results appreciably and neither does a reduction of the biomarkers to include only the three
9
10 significant ones.
11
12
13
14
15
16
17
18

19 **Legend to figure 1S**

20
21 Figure 1S A Distribution of years to death using the accelerated failure model where the error term is modelled using the general gamma distribution.

22
23 Figure 1S B Distribution of years to composite outcome (AMI, UAP, CeVD, death) using the accelerated failure model where the error term is modelled
24
25 using the general gamma distribution.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

STROBE Statement items 1 to 12

Title and abstract	Item no	Recommendation	
	1	(a) Design in title	See page 1 the term 'placebo receiving' implies that controls from a trial were used
		(b) Abstract: informative and balanced summary of what was done and found	See abstract methods and results sections p 2 and p 3
Introduction			
Background/rationale	2	Scientific background and rationale	See introduction first section on page 5
Objectives	3	objectives	See introduction last section page 5
Methods			
Study design	4	Key elements of study design	See first section on the patients in material page 5
Setting	5	Setting, location, relevant dates, period of recruitment, follow-up, and data collection	See first section on the patients in material page 5 and the two sections on predictors and on the outcomes pages 6 and 7
Participants	6	(a) Cohort study eligibility, selection, follow-up	See first section on page 6 and introduction page 4 second section
Variables	7	Outcomes, predictors	See section 'the outcomes' on page 7 and the section on predictors on page 6 and 7, and table 1
Data sources/measurement	8	Sources of data, methods of assessment	See section on the outcomes on page 7 and the section on predictors on page 6 and 7, and table 1 plus references to methods.
Bias	9	Addressing potential sources of bias	See page 9 second section from above. Assessment of the potential bias due to missing values.
Study size	10	How study size was arrived at	See Hansen S et al: the CLARICOR trial design. HeartDrug 2001; 1:14-9
Quantitative variables	11	How quantitative variables were handled	They were all handled as continuous variables except for PAP-A which was dichotomized into normal vs elevated values (see table 1 and page 7 line 3)
Statistical methods	12	Statistical methods	See 'statistical analysis'

STROBE Statement items 1 to 12

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

			page 8
		Missing data	See item 9
		Loss to follow-up	See page 6 last line of first section

For peer review only

STROBE Statement items 13 to 22

Results			
	Item no	Recommendation	
Participants	13	Flow diagram during enrolment, randomisation, and follow-up in original trial of 2006.	See BMJ 2006;332;22-27 (paper is enclosed)
Descriptive data	14	(a) Characteristics of study participants (b) Number of participants with missing data for each variable (c) Summary of follow-up time	(a) See table 1 (b) See table 1 (c) See page 9 line 3 to5
Outcome data	15	Number of outcome events	See page 9 line 11 to 14
Main results	16	(a) Hazard rates (b) Results of predictions	(a) See tables 2, 3 (b) See tables 4 and 5
Other analyses	17	interaction	See inferential impact of the newer biomarkers page 9 first 3 lines
Discussion			
Key results	18	Summary of key results	See discussion page 11 first section
limitations	19	(a) Positive bias due to development of model and test of model using same data (b) Methodology (c) Selection bias (d) Prognosis may be worse than at present time (e) Only questionnaire data were collected at randomisation	(a) See page 12 last two lines 6 to 13 (b) See section on methodology page 12 (c) See limitations page 13 first two sections (d) See last 6 lines on page 13 and first two at page 14 (e) See page 14 line 3 to 14
Interpretations	20		See last section of discussion page 14
Generalisability	21		See (a), (b), (c), and (d) item 19
Other information			
Funding	22		See the section on acknowledgements and section on funding, both on page 19

BMJ Open

Prognostic value of 12 novel cardiological biomarkers in stable coronary disease. A 10-year follow-up of the placebo group of the Copenhagen CLARICOR trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-033720.R2
Article Type:	Original research
Date Submitted by the Author:	18-Mar-2020
Complete List of Authors:	Winkel, Per; Copenhagen University Hospital Rigshospitalet, The Copenhagen Trial Unit, Centre for Clinical Intervention Research Jakobsen, Janus; Copenhagen Trial Unit, 7812 Hilden , Jørgen; Section of Biostatistics, Department of Public Health Research, University of Copenhagen, Copenhagen, Denmark. Jensen , Gorm; Department of Cardiology, Hvidovre Hospital, Copenhagen University Hospital, Copenhagen, Denmark Kjøller, Erik; Herlev and Gentofte Hospital, Cardiology Sajadieh, Ahmad; Department of Cardiology, Bispebjerg Hospital, University Hospital, Copenhagen, Denmark Kastrup, Jens; Rigshospitalet, University of Copenhagen Kolmos, Hans; Department of Clinical Microbiology, Odense University Hospital, Odense, Denmark. Iversen, Kasper; Herlev Hospital, Cardiology Bjerre, Mette; The Medical Research Laboratory, Department of Clinical Medicine, Aarhus University, Denmark Larsson, Anders; Department of Medical Sciences, Uppsala University, Uppsala, Sweden Ärnlöv, Johan; Karolinska Universitetssjukhuset, Family Medicine and Primary Care Gluud, Christian; Copenhagen University Hospital Rigshospitalet, The Copenhagen Trial Unit, Centre for Clinical Intervention Research
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Evidence based practice
Keywords:	biomarker, Cardiology < INTERNAL MEDICINE, Coronary heart disease < CARDIOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1

2
3
4 **Prognostic value of 12 novel cardiological biomarkers in stable coronary disease. A**
5
6 **10-year follow-up of the placebo group of the Copenhagen CLARICOR trial.**
7
8
9

10
11
12
13
14
15
16
17
18
19
20 Per Winkel,¹ Janus Christian Jakobsen,^{1,2,3} Jørgen Hilden,⁴ Gorm Boje Jensen,⁵ Erik
21
22 Kjøller,^{1,6} Ahmad Sajadieh,⁷ Jens Kastrup,⁸ Hans Jørn Kolmos,⁹ Kasper K Iversen⁶, Mette
23
24 Bjerre¹⁰, Anders Larsson,¹¹ Johan Ärnlöv,^{12,13} Christian Gluud¹
25
26
27
28
29
30
31
32
33

34 Corresponding author: Per Winkel

35
36 Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet,
37
38 Copenhagen University Hospital, Copenhagen, Denmark
39
40
41
42
43
44

45 Correspondence

46
47
48 E-Mail pwinkel@ctu.dk
49

50
51 Telephone number +45 35457166
52
53
54
55
56
57
58
59
60

2

ABSTRACT

Objective

to assess if 12 novel circulating biomarkers , when added to 'standard predictors' available in general practice, could improve the 10-year prediction of cardiovascular events and mortality in patients with stable coronary heart disease.

Design

The patients participated as placebo receiving patients in the randomised CLARICOR trial at a random time in their disease trajectory.

Setting

Five Copenhagen University cardiology departments and a coordinating centre

Participants

1998 participants with stable coronary artery disease.

Outcomes

Death and composite of myocardial infarction, unstable angina pectoris, cerebrovascular disease, and death.

Results

When only 'standard predictors' were included, 83.4% of all-cause death predictions and 68.4% of composite outcome predictions were correct. Log(calprotectin) and log(cathepsin

3

S) were not associated ($P \geq 0.01$) with the outcomes, not even as single predictors. Adding the remaining ten biomarkers (high-sensitive assay cardiac troponin T; neutrophil gelatinase-associated lipocalin; osteoprotegerin; N-terminal pro-B-type natriuretic peptide; tumor necrosis factor receptor 1 and 2; PAPP-A; endostatin; YKL40; cathepsin-B), which were all individually significantly associated with the prediction of the two outcomes, increased the figures to 84.7% and 69.7%.

Conclusion

When 'standard predictors' routinely available in general practices are used for risk assessment in consecutively sampled patients with stable coronary heart disease, the addition of 10 novel biomarkers to the prediction model improved the correct prediction of all-cause death and the composite outcome by less than 1.5%.

Trial registration ClinicalTrials.gov, NCT00121550. Date of registration 13 July 2005

Date of enrolment of first participant 12 October 1999

Keywords CLARICOR, cardiovascular disease, cardiovascular risk prediction, ischaemic heart disease, predictors, mortality.

Strengths and limitations of this study

- Use of multiple biomarkers
- Well established cohort
- Comprehensive statistical approach
- Missing external validation
- Relatively old cohort

INTRODUCTION

Previously we have studied the prognostic impact of routinely available 'standard predictors' when added to a prediction model void of covariates using the placebo receiving participants from the CLARICOR trial¹⁻⁴. The impact, however, was quite modest¹. For risk assessment of patients with coronary artery disease (CAD), there are a number of advanced biomarkers, including several from outside cardiology, which may help identifying CAD patients at high risk of cardiovascular (CV) disease manifestations.² Here we assess the prognostic impact – relative to standard clinical predictors usually available during routine clinical work – of 12 newer biomarkers in predicting death and other serious cardiovascular events in patients suffering from CAD sampled while their disease was stable.

Briefly, the biomarkers are (1) serum N-terminal pro-B-type natriuretic peptide (pro-BNP), a marker of left ventricular dysfunction, and heart failure; (2) high-sensitive assay cardiac troponin T (hs-cTnT) indicating myocardial ischaemia; (3) YKL40 found to be predictive of AMI, CV-death, and non-CV death; (4) the glycoprotein osteoprotegerin (OPG), which is positively related to coronary calcification, vascular stiffness, and the presence of unstable atherosclerotic plaques; (5) pregnancy-associated plasma protein A (PAPP-A), a marker of vulnerable plaques in coronary arteries; (6) cathepsin B and (7) cathepsin S, a group of

5

1
2
3
4 proteinases that have been suggested to be causally involved in the different stages of the
5
6 atherosclerotic process; (8) endostatin, an endogenous angiogenesis inhibitor suggested to
7
8 mirror an increased neovascularisation induced by vascular or myocardial ischaemia; the
9
10 soluble receptors, (9) sTNFR1 and (10) sTNFR2, suggested to portray information about a
11
12 systemic inflammatory state that is independent of other more established inflammatory
13
14 markers; (11) calprotectin and (12) neutrophil gelatinase-associated lipocalin (NGAL), both
15
16 released from neutrophils when the cells are activated. Circulating levels of neutrophils and
17
18 their activation products have been shown to be markers for plaque instability in both primary
19
20 and secondary prevention of cardiovascular diseases.
21
22
23

24
25 All of these have been claimed to add some prognostic information in patients with stable
26
27 coronary artery heart disease. Our group has tested the individual importance of many of
28
29 these biomarkers, and in many studies statistical inference supports the view that
30
31 biomarkers may improve the prediction⁵⁻¹²
32
33
34

35 Our objectives were to clarify: (1) which of these newer biomarkers maintain their prognostic
36
37 importance if all of them were simultaneously available and were combined with the routinely
38
39 available clinical and laboratory information, and (2) what would then be their relative
40
41 practical contribution if they were added to the 'standard predictors' such as age, smoking,
42
43 plasma lipids, etc. In accordance with our published statistical analysis plan² our analysis
44
45 focusses on all-cause death and on a composite outcome comprising acute myocardial
46
47 infarction (AMI), unstable angina pectoris (UAP), cerebrovascular vascular disease (Ce-VD)
48
49 and death.
50
51
52
53
54
55
56
57
58
59
60

6

MATERIAL

The patients

The study population is the placebo patients from the CLARICOR-study.^{3,4} Patients aged 18 to 85 years, from the Copenhagen area, who had a discharge diagnosis of myocardial infarction or angina pectoris during 1993-1999 and were alive in August 1999 were invited by letter for an interview and a 14-days trial of clarithromycin versus placebo.^{3,4} Out of the 4372 who were randomised during October 1999 through April 2000, 2200 were in the placebo group.

The main results of the trial were that clarithromycin increased the risk of cardiovascular as well as all-cause death.¹³⁻¹⁵ Therefore, we here focus on the placebo group.

For the CLARICOR trial only patients who were in a stable state of their coronary heart disease were selected. Thus, patients were excluded if they fulfilled one or more of the following conditions: (1) had suffered from acute myocardial infarction or unstable angina pectoris within the previous 3 months; (2) had had intra-coronary interventions within the previous 6 months; (3) had impaired renal function; (4) had hepatic dysfunction; (5) had congestive heart failure (New York Heart Association (NYHA) IV classification of heart failure); (6) had active malignancy; (7) were without capacity to manage own affairs; (8) were breast feeding; and (9) were possibly pregnant.

Of the 2200 participants one had garbled study data, and further 201 had one or more missing biomarker measurements (see below), leaving 1998 participants for the present analysis. Only 15 of these were lost track of due to emigration or disappearance.

7

The predictors

Information on smoking status, current medication, known hypertension, diabetes, sex, age, and myocardial infarction at index hospitalisation or unstable angina pectoris was obtained from the local hospital files and patient interviews.

Biochemical measurements on serum collected at enrolment visit

Biochemical data were obtained from analysis of serum specimens sampled at inclusion of the patients and stored at -80 degrees C. The quantities measured include lipoproteins,¹⁶ high-sensitivity-C-reactive-protein/mg/L (hs-CRP/mg/L),⁷ and glomerular filtration /rate/mL/min (GFR/mL/min) using creatinine.¹⁷ Along with variables already mentioned, these quantities are those collectively referred to as 'standard predictors'.

Biomarkers included as newer biomarkers were YKL40/ μ g/L)⁸; high-sensitive assay cardiac troponin T/ng/L (hs-cTnT/ng/L)⁹; binary pregnancy associated plasma protein-A (binary-PAPP-A); which is coded as 1 if PAPP-A was ≥ 4 mIU/L or 0 otherwise¹⁰; N-terminal pro-B-type natriuretic peptide/ng/L (proBNP/ng/L)⁹; cathepsin-B/ μ g/L^{6,18}; endostatin/ng/mL¹⁹; cathepsin-S/ μ g/L^{6,20}; soluble TNF receptor 1/pg/mL and soluble TNF receptor 2/pg/mL (sTNFR1/pg./mL and sTNFR2/pg/mL)^{5,21}; neutrophil gelatinase-associated lipocalin/ng/L (NGAL/ng/L)²²; calprotectin/mg/L¹¹; and osteoprotegerin/ng/L (OPG/ng/L)¹². Due to storage problems some marker data are missing on some patients.

The outcomes

Initial follow-up of the patients lasted for approximately 2.6 years, during which outcomes were collected through hospital and death registries and assessed by an adjudication committee.⁴ Corresponding register data later produced similar results.^{23,24} The adjudicated

8

1
2
3
4 outcomes were therefore replaced and augmented by register outcomes to cover up to 10
5
6 years +/- 3 months of follow-up. Last register follow-up was December 31, 2009. The public
7
8 registers have an almost 100% coverage and the quality of these is described
9
10 elsewhere.^{25,26} The algorithm used to get from the International Statistical Classification of
11
12 Diseases used in the national registries to the events of the composite outcome is described
13
14 in detail previously.¹³
15
16

17
18 We assessed (1) the time from randomisation to all-cause death and (2) the time from
19
20 randomisation until the first occurrence of one of the following outcomes: acute myocardial
21
22 infarction (AMI), unstable angina pectoris (UAP), cerebrovascular disease (CeVD), or all-
23
24 cause death.
25
26
27
28
29
30

31 **METHODS**

32 **Statistical analysis**

33
34
35 The statistical principles and techniques used have previously been published.^{1,2} While our
36
37 previous publication¹ dealt with the prognostic impact of the 'standard predictors,' we here
38
39 use the same techniques to quantify the effect of adding biomarker information to the
40
41 'standard predictors.'
42
43
44
45

46 We used Cox regressions (SAS 9.4) where all analyses that included covariates were
47
48 stratified by centre. The assumption of proportional hazards over time covering all covariates
49
50 included in a Cox analysis and the chosen functional form of quantitative covariates was
51
52 tested using cumulative sums of martingale-based residuals over follow-up time and/or
53
54 covariate values²⁷.
55
56
57
58
59
60

1
2
3
4 We also analysed data using a parametric, accelerated failure-time model using the
5 generalized gamma model of error.²⁸ A significance level of 0.01 was used to pinpoint
6 empirical trends worthy of note. The logarithms of the present text are natural logarithms,
7 so whenever the predictor is a log(serum concentration/unit), the hazard ratio is the factor
8 by which the hazard increases when the logarithm increases by 1, i.e., when the
9 concentration increases by a factor $e = 2.72$.
10
11
12
13
14
15
16
17
18
19
20

21 Biomarkers with a hazard ratio with P value ≥ 0.01 when used alone as covariate as well
22 as when used in combination with the 'standard predictors' were excluded from further
23 analyses. The remaining biomarkers were considered prognostic.
24
25
26
27
28

29 Assessment of the practical impact of using the set of newer biomarkers was obtained by
30 comparing the percent correct predictions obtained when the standard predictors were used
31 alone with the percentage obtained when they were combined with the novel biomarkers
32 using the method described earlier.¹
33
34
35
36
37
38

39 Secondly, we report the areas under the ROCs (receiver operating characteristics), also
40 known as AUCs or C-indices, which one obtains when the Cox-Breslow risk estimates are
41 matched against the events seen in the time window 0-to-9 years. The much-used binary
42 (event vs. no event) C-index is the concordance rate between risks and outcomes. It shows
43 how frequently an event participant has a poorer prediction score than a non-event
44 participant. In order to reward correct prediction of time of event, we further report Harrell's
45 'dynamic' (or 'overall') C-index^{29,30}. It shows how frequently an earlier-event participant has
46 a poorer prediction than a later-or-never-event participant. In other words, it is the
47
48
49
50
51
52
53
54
55
56
57
58
59
60

10

1
2
3
4 concordance between risk score and event time. It is calculated across all pairs of
5
6 participants where the time order of the pair is deducible from the 9-year data window.
7
8
9

10
11 It is noted that in the ROC analysis it was not possible to add two time dependent covariates
12
13 which were needed to compensate for the fact that both age and log(OPG/ng/L) violated the
14
15 assumption of proportional hazard. However, the output obtainable from the SAS procedure
16
17 did not allow the inclusion of time dependent covariates.
18
19
20
21
22

23 24 **Ethics and safety**

25
26
27 Ethics approval and consent to participate was given by
28
29 VEKKF01-076/99; Danish Medicines Agency 2612-975; Danish Data Protection
30
31 Agency 1999-1200-174; VEK H-B-2009-015.
32
33
34
35

36 37 **Patient and public involvement**

38
39 There was no direct patient involvement in the design of the trial, but the majority of the
40
41 investigators had daily contact with patients comparable to those included in the trial and
42
43 therefore knew their needs and preferences well. Moreover, there were patient
44
45 representatives as part of the regional ethics committee approving the trial. The public
46
47 involvement was through the approvals given by the regional ethics committee (KF 01-076/99
48
49 and journal no. H-12012125), the Danish Medicines Agency (2612-975), and the Danish
50
51 Data Protection Agency (1999-1200-174).
52
53
54
55
56
57
58
59
60

RESULTS

Quantity	Distribution
Demographics and previous history	
Sex (male) N (%)	1518 (69.0%)
Age/year mean (SD)	65.2 (10.4) 2199
Smoking status N (%)	Smokers 753 (34.2%) Ex-smokers 1011 (46.0%) Never smoked 435 (19.8%)
Hypertension N (%)	883 (40.2%)
Diabetes N (%)	337 (15.3%)
Previous AMI N (%)	1494 (67.9%)
Current medication	
Aspirin N (%)	1937 (88.1%)
Beta-blocker N (%)	681 (31.0%)
Calcium-antagonist N (%)	772 (35.1%)
ACE-inhibitor N (%)	577 (26.3%)
Long-lasting nitrate N (%)	457 (20.8%)
Diuretics N (%)	773 (35.2%)
Digoxin N (%)	126 (5.7%)
Statins N (%)	904 (41.1%)
Anti-arrhythmic drugs N (%)	51 (2.3%)
Standard biochemical predictors	
log (CRP/mg/L) mean (SD) N ^a	1.03 (1.12) 2159
ApoA1/mg/dL mean (SD) N	1.70 (0.34) 2076
log (ApoB/mg/dL) mean (SD) N	0.16 (0.27) 2075
Chol-HDL/mmol/L mean (SD) N	1.02 (0.32) 2074
Chol-LDL/mmol/L mean (SD) N	2.56 (0.72) 2079
log (Cholesterol/mmol/L) mean (SD) N	1.73 (0.20) 2075
log (Tri-glyceride/mmol/L) mean (SD) N	0.73 (0.53) 2078
Glomerular filtration rate (GFR/mL/min) mean (SD) N	71.8 (19.2) 2079
Newer biochemical predictors	
log (proBNP/ng/L) mean (SD) N	5.26 (1.37) 2149
log (hs-cTnT/ng/L) mean (SD) N	2.01 (0.78) 2111
log (endostatin/ng/mL) mean (SD) N	10.3 (0.34) 2121
log (OPG/ng/L) mean (SD) N	7.49 (0.40) 2108
log (TNFR1/pg/mL) mean (SD) N	7.40 (0.40) 2120
log (TNFR2/pg/mL) mean (SD) N	8.54 (0.33) 2120
PAPP-A \geq 4mIU/L count (%) N	288 (13.1%) 2140
log (YKL40/ μ g/L) mean (SD) N	4.75 (0.66) 2163

Table 1 Distributions of demographics, previous history, current medication, standard biochemical predictors, and newer biochemical predictors in 2199 placebo receiving patients from the CLARICOR trial. Abbreviations as in section on abbreviations.

12

log (NGAL/ng/L) mean (SD) N	11.6 (0.46) 2121
log (Cathepsin B/ μ g/L) mean (SD) N	10.6 (0.45) 2120
log (Cathepsin S/ μ g/L) mean (SD) N	9.48 (0.27) 2121
log (Calprotectin/mg/L) mean (SD) N	0.77 (0.59) 2086

For peer review only

FOOTNOTES

- 1
2
3
4 a) The value of N varies because the laboratory tests have missing values (mostly due to storage
5 problems). log: natural logarithm.
6
7
8
9
10

11
12
13
14
15 Table 1 presents an overview of the covariates expected to be available from stable
16 cardiovascular disease patients during clinical routine work ('standard predictors') plus the
17 12 newer biochemical quantities under investigation. The data revealed that at 3 years, 2073
18 (94.2%) were still alive and 1826 (83.0%) had not yet suffered a composite outcome. At 6
19 years, 1758 (79.9%) were still alive and 1261 (57.3%) had not yet suffered a composite
20 outcome. At 9 years, the numbers were 1487 (67.6%) and 969 (44.0%).
21
22
23
24
25
26
27
28
29
30
31

32
33 Out of 2099 placebo patients, 1998 had complete biochemical data. As Little's test³¹ had P
34 = 0.49, suggesting that the values were missing completely at random, we used complete
35 case analyses in the following. The composition of the two groups appears consistent.
36
37
38
39

40
41 Two of the 12 newer biomarkers (log(Calprotectin) and log(Cathepsin-S)) did not contribute
42 significantly ($P > 0.01$) to the prediction of any of the two outcomes, neither when used in
43 combination with the 'standard predictors' nor when used alone (see supplementary file S1,
44 tables 1S and 2S). They were therefore removed from the subsequent analyses. In the
45 analysis of log (OPG/ng/L) we found that the assumption of proportional hazard was
46 significantly violated. This was remedied when we included the time dependent covariate
47 log (OPG/ng/L) in the subsequent regression equation (see table 2S in supplementary file
48 S1). The latter equation now included the 'standard predictors', plus the remaining 10 newer
49 biomarkers and the above-mentioned time dependent covariates. It appears from
50
51
52
53
54
55
56
57
58
59
60

14

supplementary table 2S that only log (proBNP/ng/L), log (hs-cTnT/ng/L), and log (OPG/ng/L) contributed significantly to the prediction.

Table 2 The two outcomes (1) all-cause death and (2) the composite outcome of AMI, UAP, CeVD, and all-cause death were studied.

Model and covariates included in model	Total number of predictions made per outcome	Number and percent of correct predictions of events	
		All-cause death N (%)	Composite of AMI ^a , UAP ^b , Ce-VD ^c , and all-cause death N (%)
<i>Model 1:</i> Cox model void of covariates	5972	4768 (79.8)	3773 (63.2)
<i>Model 2:</i> Cox model with 'Standard predictors(SP)' added to model	5972	4977 (83.3)	4084 (68.4)
<i>Model 3:</i> Cox model with SP + 10 newer biomarkers added to model	5972	5056 (84.7)	4165 (69.9)

- a) AMI acute myocardial infarction
- b) UAP unstable angina pectoris
- c) Ce-VD cerebrovascular disease

Table 2 (see also supplementary file S1 tables 3S and 4S) compares the number and percentages of correct predictions between various prediction models. In each model predictions were made at 3, 6, and 9 years for each of the two outcomes (death and the composite). Model 1 shows the results obtained using a model void of covariates. 79.8% of the predictions were correct for the outcome death and 63.2% for the composite outcome. Model 2 shows the results obtained when model 1 was augmented by the 'standard predictors'. Now the percent correct predictions have been improved by $83.3 - 79.8\% = 3.5\%$ for the outcome death and $68.4 - 63.2\% = 5.2\%$ for the composite outcome. When model 2

15

was improved by adding the 10 newer biomarkers the additional gain in correct predictions amounted to 1.4% for death and 1.3% for the composite outcome.

Using the parametric model in place of the Cox model we obtained quite similar results (see tables 3S and 4S in supplementary file S1 and figure 1S A-B). The same was true if we only included log (proBNP/ng/L), log (hs-cTnT/ng/L), and log (OPG/ng/L) instead of all 10 biomarkers when the Cox model was used (see tables 3S and 4S in the supplementary file S1).

Table 3. C-indices. Cox model estimates applied to the 0-9-year follow-up window ($n = 1998$).

	Binary-outcome C (AUC), observed (predicted)^a	Dynamic C, Observed^b
Composite outcome^c (1115 events)		
Standard predictors (SP) only	0.711 (0.707)	0.640
The 10 newer markers & SP	0.732 (0.732)	0.657
Log(hsTnT/ng/L) + log(proBNP/ng/L) + SP	0.730 (0.730)	0.656
All-cause death (644 deaths)		
SP only	0.792 (0.793)	0.737
The 10 newer markers & SP	0.824 (0.816)	0.765
Log(hsTnT/ng/L) + log(proBNP/ng/L) + SP	0.821 (0.813)	0.762

a) The 'observed' AUCs summarize a ROC plot of cumulative events against cumulative non-events, with cumulation from large to small estimated risks. The corresponding 'predicted' AUC cumulates the predicted risks instead. Discrepancies between the two curves would suggest a model failure (calibration problems). The curves (not shown) were practically identical.

b) Analogous concordance rate between time to event and predicted risk.

c) Composite outcome: first occurrence of acute myocardial infarction, unstable angina pectoris, cerebrovascular disease or death. SP 'standard predictors', see table 1.

16

1
2
3
4 Table 3 summarizes the ROC analyses. For prediction of the composite outcome (yes / no),
5
6 the area under the ROC increases from 0.711 to 0.732 when the 10 novel biomarkers are
7
8 added to the 'standard predictors,' but almost all the marker information is contained in
9
10 log(hsTNT/ng/L), and log(proBNP/ng/L) (AUC = 0.730). The 'dynamic' C-index values are
11
12 smaller as prediction of event times is more difficult, but the gains are similar. All-cause
13
14 death shows the same general pattern.
15
16

17 18 **DISCUSSION**

19
20
21 In this study we assessed the combined value of 12 newer biomarkers not routinely used in
22
23 clinical work to predict all-cause death and a composite outcome (AMI, UAP, CeVD, or all-
24
25 cause death). We used a cut value of predicted risk = 0.5 to separate correct predictions of
26
27 the observed patient status from incorrect ones. When we combined the biomarkers with
28
29 the 'standard predictors' routinely available for a general practitioner when he/she meets a
30
31 patient with stable coronary heart disease, 84.7 % of the survival status were correctly
32
33 predicted. In case of the composite outcome the number was 68.4%. In both cases, the
34
35 combined contribution of the newer biomarkers amounted to less than 1.5%.
36
37
38
39
40
41

42 Our patients resemble those of The Prospective Observational Longitudinal Registry of
43
44 Patients with Stable Coronary Heart Disease (CLARIFY) study³² which enrolled 20,291
45
46 patients. The CLARIFY patients had been observed with a median of 24.1 months. However,
47
48 enrollment took place 10 years later than in the CLARICOR trial and the incidence of
49
50 cardiovascular deaths or myocardial infarctions in these patients was considerably lower,³²
51
52 probably reflecting improved quality of treatment and more frequent statin treatment in the
53
54 CLARIFY patients (84% compared to only 41% in the CLARICOR material). So, the age of
55
56 our material is a weakness.
57
58
59
60

1
2
3
4
5
6
7
8 In our present study, we are using our data to develop a prediction model. Then we evaluate
9
10 the performance using the same data that we used to develop the model. Clearly this is
11
12 bound to produce overly optimistic results compared to testing our model using independent
13
14 data. But we argue that the aim of this study was not to present a prediction model but to
15
16 assess the newer biomarkers' contribution to model performance when added on top of
17
18 routinely available clinical and laboratory data. Therefore, if tested on independent data, the
19
20 contribution of the newer biomarkers to prognosis of patients with stable coronary heart
21
22 disease are likely going to be worse than observed here.
23
24
25
26
27
28
29

30 **Methodology**

31
32
33 Regarding our methodology, the performance statistics reported here are minimal, but they
34
35 suffice to show that the results are meagre. Prediction at 3, 6, and 9 years covers the follow-
36
37 up as well as would a sophisticated integral over continuous time.
38
39
40
41
42
43

44 **Strengths**

45
46
47 The strengths of the CLARICOR trial are the size of the patient population, the long duration
48
49 of follow-up, few losses to follow-up (1%), the ethnic homogeneity of the patient population
50
51 (most being Caucasians), rarity of missing values, with focus on an operationally defined,
52
53 homogeneous and relevant patient category. The design implies that the patients are
54
55 sampled at random, presumably uneventful, time points during their stable state (as defined
56
57 by the CLARICOR trial).
58
59
60

Limitations

Among those 7586 patients who declined our invitation to visit a cardiology centre, many must have been eligible for the CLARICOR trial, and we do not know how they looked and fared. With a response rate about 50%, the cohort could represent a prognostic elite if responders were mostly mobile and health-conscious patients. So, selection bias cannot be excluded.

Furthermore, users of these data should remain aware of one feature: patients if any who became eligible for the CLARICOR trial during the period 1993 to 1999 and then died before August 1999 are absent. Thus, our data do not represent patients as they enter a stable disease state (as delimited by CLARICOR exclusion criteria); instead, they may be regarded as community patients (subject to some self-selection) seen by their physician or at an outpatient clinic on a random date during their stable state.

The patients recruited for the CLARICOR trial were diagnosed with coronary heart disease about 20 years ago. Because of the developments in treatment and rehabilitation, there has been a very significant and gradual improvement in the prognosis of such patients as shown in national data.³³ Given these uncertainties, prognostic findings in the CLARICOR cohort may not be directly applied to present-day patients. However, the overall, somewhat disappointing, picture presented by the predictive performance of standard¹ and newer biochemical predictors studied 10-20 years ago would hardly be much different if studied today.

Potential weaknesses of the present cohort within the context of prognostication of stable coronary heart disease patients as here defined include the fact that only questionnaire data

1
2
3
4 were collected at randomisation. No data are available concerning left ventricle function,
5
6 body mass index, blood pressure, and general health. These shortcomings are mitigated by
7
8 the fact that, by design, the present study sees the patient in a situation where (s)he visits a
9
10 physician for reasons unrelated to the coronary disease, as already stressed. In such
11
12 situations, counselling and decisions must typically be made without access to
13
14 echocardiography or other special investigations. Furthermore, if this information had been
15
16 available, the prognostic gain we study would probably have been still poorer. Moreover, we
17
18 included age, sex, hypertension, prior myocardial infarction, information about current
19
20 medication which has previously been shown to be a fair replacement for prognostication
21
22 instead of left ventricular ejection fraction.³⁴
23
24
25
26
27

28 It is noted that the patients studied by us were all in a stable state of their disease, without
29
30 cardiac complaints. Therefore, one should not conclude from this study that the biomarkers
31
32 studied here may not be useful in many other clinical contexts, although biomarkers have
33
34 been shown to of modest help in evaluating cardiovascular risk assessment in asymptomatic
35
36 people not suffering from CAD.³⁵
37
38
39
40
41
42

43 **Conclusions** In the present clinical context the contribution of the 12 biomarkers not yet
44
45 used in clinical routine work proved to be minimal. Furthermore, of the 10 statistically
46
47 promising novel biomarkers all could be replaced by hs-cTnT and proBNP, possibly
48
49 supplemented by osteoprotegerin.
50
51
52
53
54
55

56 **Author affiliations**

57
58
59
60

20

1
2
3
4 1 Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet.

5
6 Copenhagen University hospital, Blegdamsvej 9, Copenhagen, Denmark.
7
8

9
10 2 Department of Cardiology, Holbæk Hospital, Holbæk, Denmark.
11

12
13 3 Department of Regional Health Research, The Faculty of Health Sciences, University of
14
15 Southern Denmark
16

17
18 4 Section of Biostatistics, Department of Public
19

20
21 Health Research, University of Copenhagen, Copenhagen, Denmark.
22
23

24
25 5 Department of Cardiology, Hvidovre Hospital, Copenhagen University Hospital,
26
27 Copenhagen, Denmark.
28

29
30 6 Department of Cardiology S, Herlev Hospital,
31

32
33 Copenhagen University Hospital, Copenhagen, Denmark.
34
35

36
37 7 Department of Cardiology,
38

39
40 Bispebjerg Hospital, University Hospital, Copenhagen, Denmark.
41

42
43 8 Department of Cardiology B, The Heart Centre, Rigshospitalet, Copenhagen
44

45
46 University Hospital, Copenhagen, Denmark.
47

48
49 9 Department of Clinical
50

51
52 Microbiology, Odense University Hospital, Odense, Denmark.
53
54

55
56 10 The Medical Research Laboratory, Department of Clinical Medicine, Aarhus University,
57
58 Denmark.
59
60

21

11 Department of Medical Sciences, Uppsala University, Uppsala, Sweden.

12 Division of Family Medicine and Primary Care, Department of Neurobiology, Care
Sciences and Society, Karolinska Institutet, Huddinge, Sweden

13 Division of Family Medicine and Primary Care, Department of Neurobiology, Care
Science and Society, Karolinska Institutet, Huddinge, Sweden.

Abbreviations

AMI: acute myocardial infarct; Apo A1: apoprotein A1; Apo B: apoprotein B; CeVD: cerebrovascular disease; Chol-HDL: cholesterol high density lipoprotein; Chol-LDL: cholesterol low density lipoprotein; CLARICOR: Clarithromycin for patients with stable coronary heart disease; CRP: c-reactive protein; GFR: Glomerular filtration rate; hs-cTnT: High-sensitive assay cardiac troponin T; NGAL: neutrophil gelatinase-associated lipocalin; NYHA: New York Heart Association; OPG: osteoprotegerin; PREMAC: Predictors for major cardiovascular outcomes in stable ischaemic heart disease; proBNP: N-terminal pro-B-type natriuretic peptide;

TNFR1: tumor necrosis factor receptor 1; TNFR2: tumor necrosis factor receptor 2; UAP: unstable angina pectoris.

Acknowledgements

We thank the CLARICOR trial participants. We thank the investigators and other staff involved during the first phases of the CLARICOR trial (for full list of names, please see references 6, 11, and 13). We also thank our original funders of the

22

1
2
3
4 CLARICOR trial (see references 6, 11, and 13). The Copenhagen Trial Unit, Centre for
5
6 Clinical Intervention Research, is thanked for providing monetary support for part of the
7
8 biochemical analyses for the PREMAC study as well as wages for Per Winkel, Janus C.
9
10 Jacobsen, and Christian Gluud.
11
12

13 14 **Funding**

15
16 This study was funded by the Copenhagen Trial Unit, Centre for Clinical
17
18 Intervention Research; original funders of the CLARICOR trial; and The
19
20 Swedish Research Council, Swedish Heart-Lung foundation; Thuréus
21
22 Foundation; Marianne and Marcus Wallenberg Foundation, Dalarna
23
24 University; and Uppsala University.
25
26
27
28
29

30 31 **Availability of data and materials**

32
33 All pertinent anonymised data will be uploaded at ZENODO (<http://zenodo.org/>)
34
35 when the individual manuscripts have been published.
36
37
38
39

40 41 **Authors' contributions**

42
43 PW, JH, JCJ, and CG contributed substantially to the concept and design and
44
45 drafted the manuscript, PW and JH contributed equally to this paper, and conducted the
46
47 statistical analyses. AL and JÄ conducted the analysis of lipids and creatinine. PW, JCJ, JH,
48
49 GBJ, EK, AS, JK, HJK, KKI, MB, AL, JÄ, CG revised the manuscript critically for important
50
51 intellectual content, gave final approval of version to be published, and
52
53 agreed to be accountable for all aspects of the work in assuring that questions related to
54
55 the accuracy or integrity of any part of the work are appropriately investigated and
56
57
58
59
60

resolved. PW, JCJ, JH, GBJ, EK, AS, JK, HJK, KKI, MB, AL, JÄ, CG contributed substantially to the interpretation of the data.

Competing interests

The authors declare that they have no competing interests.

REFERENCES

1. Winkel P, Jakobsen JC, Hilden J, et al. Prognostic value of routinely available data in patients with stable coronary heart disease. A 10-year follow-up of patients sampled at random times during their disease course. *Open Heart* 2018:e000808. Doi:10.1136/openhrt-2018-000808
2. Winkel P, Jakobsen JC, Hilden J, Lange T, Jensen GB, Kjøller E, et al: Predictors for major cardiovascular outcomes in stable ischaemic heart disease (PREMAC): statistical analysis plan for data originating from the CLARICOR (clarithromycin for patients with stable coronary heart disease) trial: Diagnostic and Prognostic Research (2017) 1:10 DOI 10.1186/s41512-017-0009-y.
3. Jespersen CM, Als-Nielsen B, Damgaard M, Hansen JF, Hansen S, Helø OH, et al: Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial. *BMJ*. 2006; 332:22–7.
4. Hansen S, Als-Nielsen B, Damgaard M, Helø OH, Petersen L, Jespersen CM, et al: Intervention with clarithromycin in patients with stable coronary heart disease: the CLARICOR trial design. *Heart Drug*. 2001; 1:14–9.
5. Carlsson AC, Ruge T, Kjøller E, Hilden J, Kolmos HJ, Sajadieh A o. a. 10-year associations between tumor necrosis factor receptors 1 and 2 and cardiovascular events in patients with stable coronary heart disease: a CLARICOR (effect of clarithromycin on

24

mortality and morbidity in patients with coronary heart disease) trial substudy. Journal of the American Heart Association 2018 apr 23;7(9): e 008299 Doi:10. 116/JAHA 127.008299

6. Wuopio J, Hilden J, Bring C, Kastrup J, Sajadieh A, Jensen GB o.a. Cathepsin B and S as markers for cardiovascular risk and all-cause mortality in patients with stable coronary heart disease during 10 years: a CLARICOR trial substudy. *Atherosclerosis*. 2018 nov 1;278: 97 to 102. Tilgængelig fra, DOI: 10. 1016/j atherosclerosis. 2018.09.006

7. Harutyunyan MJ, Mathiasen AB, Winkel P, Gøtze JP, Hansen JF, Hildebrandt P, et al: High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary heart disease: a prognostic study within the CLARICOR trial. *Scand J Clin Lab Invest*. 2011; 71:52–62.

8. Schroder J, Jakobsen CJ, Winkel P, Hilden J, Jensen GB, Sajadieh A, et al. Prognosis and Reclassification by YKL-40 in Stable Coronary Artery Disease. *J Am Heart Assoc*. 2020;9: e014634. DOI: 10.1161/JAHA.119.014634.

9. Lyngbaek S, Winkel P, Gotze JP, Kastrup J, Gluud C, Kolmos HJ, et al. Risk stratification in stable coronary artery disease is possible at cardiac troponin levels below conventional detection and is improved by use of N-terminal pro-B-type natriuretic peptide. *European Journal of Preventive Cardiology* 2014; 21:1275-1284.

10. Iversen KK, Teisner B, Winkel P, Gluud C, Kjoller E, Kolmos HJ, et al. Pregnancy associated plasma protein-A as a marker for myocardial infarction and death in patients with stable coronary artery disease: a prognostic study within the CLARICOR Trial. *Atherosclerosis* 2011; 214:203-208.

25

- 1
2
3
4 11. Larsen SB, Grove EL, Pareek M, Kristensen SD, Hvas AM. Calprotectin and
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
10(5):e0125992.
12. Bjerre M, Hilden J, Kastrup J, Skoog M, Hansen JF, Kolmos HJ, et al.
Osteoprotegerin independently predicts mortality in patients with stable coronary artery
disease: the CLARICOR trial. *Scandinavian Journal of Clinical and Laboratory Investigation*
2014; 74:657-664.
13. Winkel P, Hilden J, Hansen JF, Kastrup J, Kolmos HJ, Kjoller E, et al.
Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular
mortality and cerebrovascular morbidity over 10years in the CLARICOR randomised,
blinded clinical trial. *International Journal of Cardiology* 2015, 182:459-465.
14. Winkel P, Hilden J, Fischer Hansen J, Hildebrandt P, Kastrup J, Kolmos HJ, et
al: Excess sudden cardiac deaths after short-term clarithromycin administration in the
CLARICOR trial: why is this so, and why are statins protective? *Cardiology*. 2011; 118:63–
67.
15. Glud C, Als-Nielsen B, Damgaard M, Fischer Hansen J, Hansen S, Helø OH,
et al: Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the
CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart
disease. *Cardiology*. 2008; 111:280

26

- 1
2
3
4 16. Helmersson-Karlqvist J, Ridefelt P, Lind L, Larsson A. Reference values for 34
5 frequently used laboratory tests in 80-year-old men and women. *Maturitas*. 2016; 92: 97-
6
7 101.
8
- 9
10
11 17. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al:
12 Estimating glomerular filtration rate from serum creatinine and cystatin C. *N Engl J Med*.
13 2012;367:20–9.
14
15
- 16 18. Wang N, Bai X, Jin B, Han W, Sun X, Chen X. The association of serum
17 cathepsin-B concentration with age-related cardiovascular-renal subclinical state in a
18 healthy Chinese population. *Arch Gerontol Geriatr*. 2016; 65:146-55.
19
- 20 19. Arnlov J, Ruge T, Ingelsson E, Sundstrom J, Lind L. Serum endostatin and risk
21 of mortality in the elderly: findings from 2 community-based cohorts. *Arterioscler Thromb*
22 *Vasc Biol*.2013, 33: 2689-95.
23
24
- 25 20. Jobs E, Ingelsson E, Risérus U, Nerpin E, Jobs M, Sundström J, et al.
26 Association between serum cathepsin S and mortality in older adults. *JAMA*. 2011;
27 306:1113-21.
28
29
- 30 21. Carlsson AC, Larsson TE, Helmersson-Karlqvist J, Larsson A, Lind L, Ärnlöv J.
31 Soluble TNF receptors and kidney dysfunction in the elderly. *J Am Soc Nephrol*.
32 2014;25:1313-20.
33
34
- 35 22. Helmersson-Karlqvist J, Larsson A, Carlsson AC, Venge P, Sundstrom J,
36 Ingelsson E, et al. Urinary neutrophil gelatinase-associated lipocalin (NGAL) is associated
37 with mortality in a community-based cohort of older Swedish men. *Atherosclerosis* 2013;
38 227:408-13.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

27

- 1
2
3
4 23. Kjølner E, Hilden J, Winkel P, Frandsen NJ, Galatius S, Jensen G, et al: Good
5 interobserver agreement was attainable on outcome adjudication in patients with stable
6 coronary heart disease. *J Clin Epidemiol.* 2012; 65:444–53.
7
8
9
10
11
12 24. Kjølner E, Hilden J, Winkel P, Galatius S, Frandsen NJ, Jensen GB, et al:
13 Agreement between public register and adjudication committee outcome in a cardiovascular
14 randomized clinical trial. *Am Heart J.* 2014; 168:197–204.ok
15
16
17
18
19
20 25. Helweg-Larsen K: The Danish register of causes of death. *Scand J Public*
21 *Health.* 2011;39(7 30. Suppl):26-9.
22
23
24
25 26. Lynge E, Sandegaard JL, Rebolj M: The Danish National Patient Register.
26 *Scand J Public Health.* 2011;39(7 suppl):30–3.
27
28
29
30 27. Lin DY, Wei LJ, Ying Z: Checking the Cox model with cumulative sums of
31 martingale-based residuals. *Biometrika.* 1993; 80:557–72.
32
33
34
35
36
37
38
39 28. Allison PD: *Survival Analysis Using SAS: A Practical Guide*, second edition
40 2010 SAS institute Inc. Cary, NC, USA.
41
42
43
44 29. Harrell FE Jr, Lee KL, Mark DB. *Multivariable prognostic models: issues in*
45 *developing models, evaluating assumptions and adequacy, and measuring and reducing*
46 *errors.* *Stat Med.* 1996;15: 361-87.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

28

1
2
3
4 30. Pencina MJ, d'Agostino RB. Overall C as a measure of discrimination in
5 survival analysis: model specific population value and confidence interval estimation. *Stat*
6
7
8
9 *Med.* 2004; 23: 2109 -23.

10
11
12
13
14
15 31. Little R: A test of missing completely at random for multivariate data with missing
16 values. *J Am Stat Assoc.* 1988; 83:1198–1202.

17
18
19
20 32. Steg PG, Greenlaw N, Tendera M, et al. Prevalence of anginal symptoms and
21 myocardial ischemia and their effect on clinical outcomes in outpatients with stable coronary
22 artery disease. Data from the International Observational CLARIFY Registry. *JAMA Intern*
23
24
25
26
27
28 *Med.* 2014;174(10):1651-1659. doi:10.1001/jamainternmed.2014.3773

29
30 33. Schmidt M, Jacobsen JB, Lash TL, Bøtker HE, Sørensen HT: 25-year trends in
31 first time hospitalisation for acute myocardial infarction, subsequent short and long-term
32 mortality, and the prognostic impact of sex and comorbidity: a Danish nationwide cohort
33 study. *BMJ.* 2012;344: e356.

34
35
36
37
38 34. Solomon SD, Claggett B, Desai AS, et al. Influence of ejection fraction on
39 outcomes and efficacy of sacubitril/valsartan (Ic2696) in heart failure with reduced ejection
40 fraction. *Circulation* 2016;9:e00274.

41
42
43
44
45
46
47
48 35. Scott IA. Evaluating cardiovascular risk assessment in asymptomatic
49 people. *BMJ* 2009;a2844doi:10.1136/bmj.a2844

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

<Winkel P. & al. * Supplementary file S1>

Supplementary file S1

Table 1S All-cause mortality hazard ratios (HR) of newer biochemical predictors not routinely used in clinical work when each of these predictors is used alone (columns 2 to 4), and when it is used in combination with the 'standard predictors'^a (column 5 to 7). Two of them were then discarded and each of the remaining 10 was assessed when used in combination with the standard predictors and the remaining 9 of the 10 newer biochemical predictors selected among the 12 candidates (columns 8 to 10).

Newer biochemical candidate predictor	When candidate predictor is the only predictor included in the model (stratified by centre)			When 'standard predictors' is added to the model (stratified by centre)			When in addition the 10 selected predictors are added to the model (stratified by centre)		
	HR ^b	95% CI	P	HR	95% CI	P	HR	95% CI	P
log (endostatin/ng/mL)	3.49	2.81 to 4.33	<0.0001	1.75	1.34 to 2.27	<0.0001	1.23	0.92 to 1.63	0.16
log (OPG/ng/L)	3.37	2.88 to 3.94	<0.0001	1.68	1.35 to 2.09	<0.0001	1.21	0.97 to 1.63	0.092
log (sTNFR1/pg/mL)	3.80	3.19 to 4.54	<0.0001	1.84	1.46 to 2.33	<0.0001	1.10	0.81 to 1.48	0.55
og (sTNFR2/pg/mL)	5.45	4.40 to 6.76	<0.0001	2.39	1.80 to 3.18	<0.0001	1.43	0.99 to 2.07	0.056
log(proBNP/ng/L)	1.76	1.66 to 1.87	<0.0001	1.44	1.34 to 1.55	<0.0001	1.28	1.19 to 1.39	<0.0001
log(hs-cTnT/ng/L)	2.31	2.16 to 2.47	<0.0001	1.73	1.56 to 1.92	<0.0001	1.46	1.30 to 1.65	<0.0001
PAPP-A_binary ^c	1.84	1.53 to 2.21	<0.0001	1.39	1.15 to 1.68	0.0007	0.85	0.69 to 1.03	0.10
log (YKL40/μg/L)	1.76	1.59 to 1.95	<0.0001	1.32	1.17 to 1.49	<0.0001	1.10	0.97 to 1.25	0.15
log (NGAL/ng/L)	1.33	1.12 to 1.57	0.0011	1.03	0.85 to 1.24	0.78	0.90	0.74 to 1.10	0.30
log(Calprotectin/)	1.08	0.95 to 1.23	0.25	1.02	0.89 to 1.18	0.74	Not included in analysis		
log (Cathepsin-B/μg/L)	2.81	2.40 to 3.28	<0.0001	1.43	1.19 to 1.73	0.0002	1.09	0.89 to 1.33	0.42
log (Cathepsin-S/μg/L)	1.12	0.86 to 1.47	0.40	1.10	0.83 to 1.45	0.53	Not included in analysis		

a) The standard predictors are shown in Table 1.

b) Hazard ratio associated with unit increase on log scale, except for PAPP-A (binary).

<Winkel P. & al. * Supplementary file S1>

c) Binary quantity. 1: PAPP-A was ≥ 4 mIU/L, 0: PAPP-A was < 4 mIU/L.

1. Inferential impact of the newer biomarkers

As the proportional hazard's assumption was violated for age²⁹ and age interacted significantly with time since randomisation, we included an interaction between age at entry and time (since randomisation) in the inference analyses.

Table 1S shows the results of a Cox regression of all-cause death on each of the 12 biomarkers when the biomarker was used alone as a covariate (columns 2 through 4), and when it was used in combination with the 'standard predictors' (columns 5 through 7).

Columns 8 through 10 in Table 1S shows the result of a regression of the outcome on the 'standard predictors' and the 10 best biochemical predictors. Now only log (proBNP /ng/L) and log(hs-cTnT/ng/L) have a HR significantly ($P < 0.01$) different from 1. Log(calprotectin/mg/L) and log(cathepsin-S/ μ g/L) did not have an inferential impact ($P < 0.01$ not attained), not even when used alone.

<Winkel P. & al. * Supplementary file S1>

Table 2S the composite outcome (comprising first occurrence of acute myocardial infarction, unstable angina pectoris, cerebro-vascular disease, and death). Hazard ratios of each of 13 biochemical predictors not routinely used in clinical work when each of these predictors is used alone (columns 2 to 4), and when it is used in combination with the 'standard predictors' (column 5 to 7). Two of them were then discarded and each of the remaining 11 was assessed when used in combination with the standard predictors and the remaining 10 of the 11 newer biochemical predictors selected among the 13 candidates (columns 8 to 10)

Newer biochemical candidate predictor	When candidate predictor is the only predictor included in the model (stratified by centre)			When 'standard predictors' is added to the model (stratified by centre)			When in addition the 11 ^a selected predictors are added to the model (stratified by centre)		
	HR	95% CI of HR	P	HR	95% CI of HR	P	HR	95% CI of HR	P
log (Endostatin/ng/mL)	2.18	1.84 to 2.58	<0.0001	1.44	1.17 to 1.72	0.0006	1.23	0.99 to 1.54	0.062
log (OPG/ng/L)	1.34	1.05 to 1.71	0.019	0.94	0.70 to 1.26	0.67	0.78	0.58 to 1.04	0.094
log (OPG/ng/L) ·time/year ^b	1.11	1.06 to 1.16	<0.0001	1.09	1.03 to 1.16	0.0022	1.104	1.044 to 1.168	0.0005
log (sTNFR1/pg/mL)	2.14	1.86 to 2.46	<0.0001	1.33	1.11 to 1.60	0.0021	1.05	0.84 to 1.32	0.67
log (sTNFR2/pg/mL)	2.56	2.15 to 3.03	<0.0001	1.49	1.19 to 1.85	0.0004	1.13	0.85 to 1.50	0.40
log (proBNP/ng/L)	1.37	1.31 to 1.44	<0.0001	1.26	1.19 to 1.33	<0.0001	1.18	1.11 to 1.25	<0.0001
log (hs-cTnT/ng/L)	1.83	1.70 to 1.97	<0.0001	1.49	1.35 to 1.64	<0.0001	1.31	1.17 to 1.46	<0.0001
PaPP-A (binary) ^c	1.45	1.24 to 1.70	<0.0001	1.24	1.06 to 1.46	0.0077	0.89	0.75 to 1.05	0.15
log (YKL40/μg/L)	1.35	1.24 to 1.47	<0.0001	1.13	1.03 to 1.24	0.013	1.01	0.91 to 1.11	0.93
log (NGAL/ng/L)	1.23	1.08 to 1.40	0.0023	1.03	0.89 to 1.19	0.73	0.97	0.84 to 1.13	0.74
log (Calprotectin/)	1.06	0.95 to 1.17	0.32	1.00	0.90 to 1.12	0.95	Not included in analysis		
log (cathepsin-B/μg/L)	1.70	1.50 to 1.93	<0.0001	1.17	1.01 to 1.35	0.040	0.99	0.85 to 1.16	0.92
log (cathepsin-S/μg/L)	1.06	0.86 to 1.31	0.59	0.98	0.79 to 1.22	0.88	Not included in analysis		

<Winkel P. & al. * Supplementary file S1>

- a) Note that now a time dependent covariate has been added [$\log(\text{OPG}/\text{ng/L}) \cdot \text{time}/\text{year}$] to the 10 original predictors.
- b) $\log(\text{OPG}/\text{ng/L})$ significantly violated the proportional hazard assumption. We found a significant linear relationship between $\log(\text{OPG}/\text{ng/L})$ and time since randomisation which may explain the violation. The product of $\log(\text{OPG}/\text{ng/L})$ and time/year was therefore included in the inference analysis. However, when the Cox model is used for prediction, time dependent covariates are not allowed (SAS 9.4). Therefore, in the latter context we only include $\log(\text{OPG}/\text{ng/L})$.
- c) Binary quantity. 1: PAPP-A was ≥ 4 mIU/L, 0: PAPP-A was < 4 mIU/L.

Table 2S corresponds to Table 1S except that the outcome is the composite outcome. It is noted that a time-dependent covariate is now included because $\log(\text{OPG}/\text{ng/L})$ violated the proportional hazard assumption. This was remedied by including the covariate $\log(\text{OPG}/\text{ng/L}) \cdot \text{time}/\text{year}$. It is seen that when all the biomarkers were included in the Cox analysis $\log(\text{OPG}/\text{ng/L}) \cdot \text{time}/\text{year}$, $\log(\text{proBNP}/\text{ng/L})$, and $\log(\text{hs-cTnT}/\text{ng/L})$ were the only ones which had a P value below the threshold of 0.01. Again $\log(\text{calprotectin}/\text{ng/L})$ and $\log(\text{cathepsin-S}/\mu\text{g/L})$ could be excluded from the final analysis, the result of which is shown in columns 8 through 10.

2. Practical impact of the novel biomarkers

Table 3S All-cause death. Correct predictions of favorable (alive) and unfavorable (not alive) status made at 3 years, at 6 years, and at 9 years following randomisation in the 1998 placebo patients from the CLARICOR trial. Four covariate scenarios were examined with Cox regression (see text of columns 4, 5, 6, and 8). For comparison with the results of column 6, column 7 shows the corresponding results when the accelerated failures model was used.

<Winkel P. & al. * Supplementary file S1>

(1) Number of predictions made	(2) Time at which prediction was made	(3) Correctly predicted patient status	(4) Data without covariates included Both models N (%)	(5) Data including Standard predictors as covariates Cox model N (%)	(6) Data including Standard predictors + advanced biochemical predictors as covariates Cox model N (%)	(7) Data including Standard predictors + advanced biochemical predictors as covariates Parametric model N (%)	(8) Data including Standard predictors log(OPG/ng/L) log (hs-cTnT/ng/L) and log(proBNP/ng/L) as covariates Cox Model N (%)
1996	Three years	Favorable status	1825 (91.4)	1821 (91.2)	1816 (91.0)	1814 (90.9)	1816 (91.0)
		Unfavorable status	0 (0.00)	10 (0.50)	19 (0.95)	14 (0.70)	19 (0.95)
1989	Six years	Favorable status	1601 (80.5)	1555 (78.2)	1551 (78.0)	1538 (77.3)	1553 (78.1)
		Unfavorable status	0 (0.00)	85 (4.27)	120 (6.03)	118 (5.93)	113 (5.68)
1987	Nine years	Favorable status	1342 (67.5)	1192 (60.0)	1219 (61.3)	1217 (61.2)	1212 (61.0)
		Unfavorable status	0 (0.00)	297 (14.9)	331 (16.7)	323 (16.3)	339 (17.1)
5972	All three times combined	Favorable status	4768 (79.8)	4585 (76.8)	4586 (76.8)	4569 (76.5)	4581 (76.7)
		Unfavorable status	0 (0.00)	392 (6.56)	470 (7.87)	364 (6.10)	471 (7.89)
		Total	4768 (79.8)	4977 (83.3)	5056 (84.7)	4933 (82.6)	5052 (84.6)

<Winkel P. & al. * Supplementary file S1>

The results of the predictions of survival status made at 3 years, at 6 years, and at 9 years following randomisation in the 1998 placebo patients are summarized in Table 3S.

When the 'standard predictors' were included as covariates (column 5) for all-cause mortality, 83.3% of the predictions were correct.


Adding the 10 newer biochemical predictors (column 6) the percentage was increased by 1.4% to 84.7%.

For peer review only

bmjopen-2019-033720 on 20 August 2020. Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.

<Winkel P. & al. * Supplementary file S1>

Figure 1S A



bmjopen-2019-033720 on 20 August 2020. Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.

<Winkel P. & al. * Supplementary file S1>


Figure 1S B

For peer review only

bmjopen-2019-033720 on 20 August 2020. Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

<Winkel P. & al. * Supplementary file S1>



bmjopen-2019-033720 on 20 August 2020. Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.

<Winkel P. & al. * Supplementary file S1>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15 The parametric model fitted the data reasonably well (see figure 1S A and B). The distribution of years to outcome using the accelerated
16 failure model where the error term is modelled using the general gamma distribution showed that for both outcomes all values were within
17 the 95% confidence limits. However, in case of all-cause death (see figure 1S A) the distribution was upwards biased but still within the 95%
18 confidence limits.
19
20
21
22
23
24
25
26
27

28 It is noted that the results obtained with the parametric model (column 7 Tables S3 and S4) are not dramatically different from the
29 corresponding results in column 6, when this theoretically equally valid model is used. When only the three significant predictors
30 $\log(\text{OPG}/\text{ng/L})$, $\log(\text{proBNP}/\text{ng/L})$, and $\log(\text{hs-cTnT}/\text{ng/L})$ were used in the Cox model in place of all 10 (column 8), the results were
31 practically unaffected (compare columns 8 and 6).
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

bmjopen-2019-033720 on 20 August 2020. Downloaded from <http://bmjopen.bmj.com/> on April 9, 2024 by guest. Protected by copyright.

<Winkel P. & al. * Supplementary file S1>

Table 4S the composite outcome of AMI, UAP, CeVD, and all-cause death. Correct predictions of favorable (no outcome so far) and unfavorable status made at 3, 6 and 9 years. Cox model: four covariate scenarios as in Table 4; and parametric model (column 7) for comparison with column 6. Note that log (OPG) qualified for inclusion in column 8.

(1) Number of predictions made	(2) Time at which prediction was made	(3) Correctly predicted patient status	(4) Data without covariates included	(5) Data including Standard predictors as covariates	(6) Data including Standard predictors + advanced biochemical predictors as covariates	(7) Data including Standard predictors + advanced biochemical predictors as covariates Parametric model	(8) Data including Standard predictors + Log(OPG/ng/L), Log(hcTnT/ng/L), and log(pBNP/ng/L) as covariates Cox model
			Both models N (%)	Cox model N (%)	Cox model N (%)	Parametric model N (%)	Cox model N (%)
1996	Three years	Favorable status	1514 (75.9)	1471 (73.7)	1464 (73.3)	1479 (74.1)	1463 (73.3)
		Unfavorable status	0 (0)	51 (2.56)	77 (3.86)	57 (2.86)	77 (3.81)
1989	Six years	Favorable status	1144 (57.5)	935 (47.0)	920 (46.3)	916 (46.1)	925 (46.5)
		Unfavorable status	0 (0)	349 (17.5)	370 (18.6)	368 (18.5)	367 (18.5))
1987	Nine years	Favorable status	0 (0)	504 (25.4)	542 (27.3)	550 (27.7)	529 (27.6)
		Unfavorable status	1115 (56.1)	774 (39.0)	792 (39.9)	803 (40.4)	799 (39.2)
5972	All three times combined	Favorable status	2658 (44.5)	2910 (48.7)	2926 (49.0)	2945 (49.3)	2927 (49.2)
		Unfavorable status	1115 (18.7)	1174 (19.7)	1239 (20.7)	1228 (20.6)	1222 (20.5)
		Total	3773 (63.2)	4084 (68.4)	4165 (69.7))	4173 (69.9)	4159 (69.6)

<Winkel P. & al. * Supplementary file S1>

1
2 Table 4S shows the results corresponding to Table 3S obtained when the composite outcome was used. Including the 'standard
3
4 predictors' in the model increases the percent correct predictions from 63.2 (see column 4, Table 4S) to 68.4 (see column 5, Table 4S), i.e.
5
6 an increase of 5.2%. Adding the 10 newer biomarkers to the model increases the number of correct predictions by 1.3%. Using the
7
8 parametric model does not change the results appreciably and neither does a reduction of the biomarkers to include only the three
9
10 significant ones.
11
12
13
14
15
16
17
18

19 **Legend to figure 1S**

20
21 Figure 1S A Distribution of years to death using the accelerated failure model where the error term is modelled using the general gamma distribution.

22
23 Figure 1S B Distribution of years to composite outcome (AMI, UAP, CeVD, death) using the accelerated failure model where the error term is modelled
24
25 using the general gamma distribution.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

STROBE Statement items 1 to 12

Title and abstract	Item no	Recommendation	
	1	(a) Design in title	See page 1 the term 'placebo receiving' implies that controls from a trial were used
		(b) Abstract: informative and balanced summary of what was done and found	See abstract methods and results sections p 2 and p 3
Introduction			
Background/rationale	2	Scientific background and rationale	See introduction first section on page 5
Objectives	3	objectives	See introduction last section page 5
Methods			
Study design	4	Key elements of study design	See first section on the patients in material page 5
Setting	5	Setting, location, relevant dates, period of recruitment, follow-up, and data collection	See first section on the patients in material page 5 and the two sections on predictors and on the outcomes pages 6 and 7
Participants	6	(a) Cohort study eligibility, selection, follow-up	See first section on page 6 and introduction page 4 second section
Variables	7	Outcomes, predictors	See section 'the outcomes' on page 7 and the section on predictors on page 6 and 7, and table 1
Data sources/measurement	8	Sources of data, methods of assessment	See section on the outcomes on page 7 and the section on predictors on page 6 and 7, and table 1 plus references to methods.
Bias	9	Addressing potential sources of bias	See page 9 second section from above. Assessment of the potential bias due to missing values.
Study size	10	How study size was arrived at	See Hansen S et al: the CLARICOR trial design. HeartDrug 2001; 1:14-9
Quantitative variables	11	How quantitative variables were handled	They were all handled as continuous variables except for PAP-A which was dichotomized into normal vs elevated values (see table 1 and page 7 line 3)
Statistical methods	12	Statistical methods	See 'statistical analysis'

STROBE Statement items 1 to 12

			page 8
		Missing data	See item 9
		Loss to follow-up	See page 6 last line of first section

For peer review only

STROBE Statement items 13 to 22

Results			
	Item no	Recommendation	
Participants	13	Flow diagram during enrolment, randomisation, and follow-up in original trial of 2006.	See BMJ 2006;332;22-27 (paper is enclosed)
Descriptive data	14	(a) Characteristics of study participants (b) Number of participants with missing data for each variable (c) Summary of follow-up time	(a) See table 1 (b) See table 1 (c) See page 9 line 3 to 5
Outcome data	15	Number of outcome events	See page 9 line 11 to 14
Main results	16	(a) Hazard rates (b) Results of predictions	(a) See tables 2, 3 (b) See tables 4 and 5
Other analyses	17	interaction	See inferential impact of the newer biomarkers page 9 first 3 lines
Discussion			
Key results	18	Summary of key results	See discussion page 11 first section
limitations	19	(a) Positive bias due to development of model and test of model using same data (b) Methodology (c) Selection bias (d) Prognosis may be worse than at present time (e) Only questionnaire data were collected at randomisation	(a) See page 12 last two lines 6 to 13 (b) See section on methodology page 12 (c) See limitations page 13 first two sections (d) See last 6 lines on page 13 and first two at page 14 (e) See page 14 line 3 to 14
Interpretations	20		See last section of discussion page 14
Generalisability	21		See (a), (b), (c), and (d) item 19
Other information			
Funding	22		See the section on acknowledgements and section on funding, both on page 19

BMJ Open

Prognostic value of 12 novel cardiological biomarkers in stable coronary disease. A 10-year follow-up of the placebo group of the Copenhagen CLARICOR trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-033720.R3
Article Type:	Original research
Date Submitted by the Author:	22-Apr-2020
Complete List of Authors:	Winkel, Per; Copenhagen University Hospital Rigshospitalet, The Copenhagen Trial Unit, Centre for Clinical Intervention Research Jakobsen, Janus; Copenhagen Trial Unit, 7812 Hilden , Jørgen; Section of Biostatistics, Department of Public Health Research, University of Copenhagen, Copenhagen, Denmark. Jensen , Gorm; Department of Cardiology, Hvidovre Hospital, Copenhagen University Hospital, Copenhagen, Denmark Kjøller, Erik; Herlev and Gentofte Hospital, Cardiology Sajadieh, Ahmad; Department of Cardiology, Bispebjerg Hospital, University Hospital, Copenhagen, Denmark Kastrup, Jens; Rigshospitalet, University of Copenhagen Kolmos, Hans; Department of Clinical Microbiology, Odense University Hospital, Odense, Denmark. Iversen, Kasper; Herlev Hospital, Cardiology Bjerre, Mette; The Medical Research Laboratory, Department of Clinical Medicine, Aarhus University, Denmark Larsson, Anders; Department of Medical Sciences, Uppsala University, Uppsala, Sweden Ärnlöv, Johan; Karolinska Universitetssjukhuset, Family Medicine and Primary Care Gluud, Christian; Copenhagen University Hospital Rigshospitalet, The Copenhagen Trial Unit, Centre for Clinical Intervention Research
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Evidence based practice
Keywords:	biomarker, Cardiology < INTERNAL MEDICINE, Coronary heart disease < CARDIOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1

2
3
4 **Prognostic value of 12 novel cardiological biomarkers in stable coronary disease. A**
5
6 **10-year follow-up of the placebo group of the Copenhagen CLARICOR trial.**
7
8
9

10
11
12
13
14
15
16
17
18
19
20 Per Winkel,¹ Janus Christian Jakobsen,^{1,2,3} Jørgen Hilden,⁴ Gorm Boje Jensen,⁵ Erik
21
22 Kjøller,^{1,6} Ahmad Sajadieh,⁷ Jens Kastrup,⁸ Hans Jørn Kolmos,⁹ Kasper K Iversen⁶, Mette
23
24 Bjerre¹⁰, Anders Larsson,¹¹ Johan Ärnlöv,^{12,13} Christian Gluud¹
25
26
27
28
29
30
31
32
33

34 Corresponding author: Per Winkel

35
36 Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet,
37
38 Copenhagen University Hospital, Copenhagen, Denmark
39
40
41
42
43
44

45 Correspondence

46
47
48 E-Mail pwinkel@ctu.dk
49

50
51 Telephone number +45 35457166
52
53
54
55
56
57
58
59
60

2

ABSTRACT

Objective

to assess if 12 novel circulating biomarkers , when added to 'standard predictors' available in general practice, could improve the 10-year prediction of cardiovascular events and mortality in patients with stable coronary heart disease.

Design

The patients participated as placebo receiving patients in the randomised CLARICOR trial at a random time in their disease trajectory.

Setting

Five Copenhagen University cardiology departments and a coordinating centre

Participants

1998 participants with stable coronary artery disease.

Outcomes

Death and composite of myocardial infarction, unstable angina pectoris, cerebrovascular disease, and death.

Results

When only 'standard predictors' were included, 83.4% of all-cause death predictions and 68.4% of composite outcome predictions were correct. Log(calprotectin) and log(cathepsin

3

S) were not associated ($P \geq 0.01$) with the outcomes, not even as single predictors. Adding the remaining ten biomarkers (high-sensitive assay cardiac troponin T; neutrophil gelatinase-associated lipocalin; osteoprotegerin; N-terminal pro-B-type natriuretic peptide; tumor necrosis factor receptor 1 and 2; PAPP-A; endostatin; YKL40; cathepsin-B), which were all individually significantly associated with the prediction of the two outcomes, increased the figures to 84.7% and 69.7%.

Conclusion

When 'standard predictors' routinely available in general practices are used for risk assessment in consecutively sampled patients with stable coronary heart disease, the addition of 10 novel biomarkers to the prediction model improved the correct prediction of all-cause death and the composite outcome by less than 1.5%.

Trial registration ClinicalTrials.gov, NCT00121550. Date of registration 13 July 2005

Date of enrolment of first participant 12 October 1999

Keywords CLARICOR, cardiovascular disease, cardiovascular risk prediction, ischaemic heart disease, predictors, mortality.

Strengths and limitations of this study

- Use of multiple biomarkers
- Well established cohort
- Comprehensive statistical approach
- Missing external validation
- Relatively old cohort

INTRODUCTION

Previously we have studied the prognostic impact of routinely available 'standard predictors' when added to a prediction model void of covariates using the placebo receiving participants from the CLARICOR trial¹⁻⁴. The impact, however, was quite modest¹. For risk assessment of patients with coronary artery disease (CAD), there are a number of advanced biomarkers, including several from outside cardiology, which may help identifying CAD patients at high risk of cardiovascular (CV) disease manifestations.² Here we assess the prognostic impact – relative to standard clinical predictors usually available during routine clinical work – of 12 newer biomarkers in predicting death and other serious cardiovascular events in patients suffering from CAD sampled while their disease was stable.

Briefly, the biomarkers are (1) serum N-terminal pro-B-type natriuretic peptide (pro-BNP), a marker of left ventricular dysfunction, and heart failure; (2) high-sensitive assay cardiac troponin T (hs-cTnT) indicating myocardial ischaemia; (3) YKL40 found to be predictive of AMI, CV-death, and non-CV death; (4) the glycoprotein osteoprotegerin (OPG), which is positively related to coronary calcification, vascular stiffness, and the presence of unstable atherosclerotic plaques; (5) pregnancy-associated plasma protein A (PAPP-A), a marker of vulnerable plaques in coronary arteries; (6) cathepsin B and (7) cathepsin S, a group of

5

1
2
3
4 proteinases that have been suggested to be causally involved in the different stages of the
5
6 atherosclerotic process; (8) endostatin, an endogenous angiogenesis inhibitor suggested to
7
8 mirror an increased neovascularisation induced by vascular or myocardial ischaemia; the
9
10 soluble receptors, (9) sTNFR1 and (10) sTNFR2, suggested to portray information about a
11
12 systemic inflammatory state that is independent of other more established inflammatory
13
14 markers; (11) calprotectin and (12) neutrophil gelatinase-associated lipocalin (NGAL), both
15
16 released from neutrophils when the cells are activated. Circulating levels of neutrophils and
17
18 their activation products have been shown to be markers for plaque instability in both primary
19
20 and secondary prevention of cardiovascular diseases.
21
22
23

24
25 All of these have been claimed to add some prognostic information in patients with stable
26
27 coronary artery heart disease. Our group has tested the individual importance of many of
28
29 these biomarkers, and in many studies statistical inference supports the view that
30
31 biomarkers may improve the prediction⁵⁻¹²
32
33
34

35 Our objectives were to clarify: (1) which of these newer biomarkers maintain their prognostic
36
37 importance if all of them were simultaneously available and were combined with the routinely
38
39 available clinical and laboratory information, and (2) what would then be their relative
40
41 practical contribution if they were added to the 'standard predictors' such as age, smoking,
42
43 plasma lipids, etc. In accordance with our published statistical analysis plan² our analysis
44
45 focusses on all-cause death and on a composite outcome comprising acute myocardial
46
47 infarction (AMI), unstable angina pectoris (UAP), cerebrovascular vascular disease (Ce-VD)
48
49 and death.
50
51
52
53
54
55
56
57
58
59
60

6

MATERIAL

The patients

The study population is the placebo patients from the CLARICOR-study.^{3,4} Patients aged 18 to 85 years, from the Copenhagen area, who had a discharge diagnosis of myocardial infarction or angina pectoris during 1993-1999 and were alive in August 1999 were invited by letter for an interview and a 14-days trial of clarithromycin versus placebo.^{3,4} Out of the 4372 who were randomised during October 1999 through April 2000, 2200 were in the placebo group.

The main results of the trial were that clarithromycin increased the risk of cardiovascular as well as all-cause death.¹³⁻¹⁵ Therefore, we here focus on the placebo group.

For the CLARICOR trial only patients who were in a stable state of their coronary heart disease were selected. Thus, patients were excluded if they fulfilled one or more of the following conditions: (1) had suffered from acute myocardial infarction or unstable angina pectoris within the previous 3 months; (2) had had intra-coronary interventions within the previous 6 months; (3) had impaired renal function; (4) had hepatic dysfunction; (5) had congestive heart failure (New York Heart Association (NYHA) IV classification of heart failure); (6) had active malignancy; (7) were without capacity to manage own affairs; (8) were breast feeding; and (9) were possibly pregnant.

Of the 2200 participants one had garbled study data, and further 201 had one or more missing biomarker measurements (see below), leaving 1998 participants for the present analysis. Only 15 of these were lost track of due to emigration or disappearance.

7

The predictors

Information on smoking status, current medication, known hypertension, diabetes, sex, age, and myocardial infarction at index hospitalisation or unstable angina pectoris was obtained from the local hospital files and patient interviews.

Biochemical measurements on serum collected at enrolment visit

Biochemical data were obtained from analysis of serum specimens sampled at inclusion of the patients and stored at -80 degrees C. The quantities measured include lipoproteins,¹⁶ high-sensitivity-C-reactive-protein/mg/L (hs-CRP/mg/L),⁷ and glomerular filtration /rate/mL/min (GFR/mL/min) using creatinine.¹⁷ Along with variables already mentioned, these quantities are those collectively referred to as 'standard predictors'.

Biomarkers included as newer biomarkers were YKL40/ μ g/L)⁸; high-sensitive assay cardiac troponin T/ng/L (hs-cTnT/ng/L)⁹; binary pregnancy associated plasma protein-A (binary-PAPP-A); which is coded as 1 if PAPP-A was ≥ 4 mIU/L or 0 otherwise¹⁰; N-terminal pro-B-type natriuretic peptide/ng/L (proBNP/ng/L)⁹; cathepsin-B/ μ g/L^{6,18}; endostatin/ng/mL¹⁹; cathepsin-S/ μ g/L^{6,20}; soluble TNF receptor 1/pg/mL and soluble TNF receptor 2/pg/mL (sTNFR1/pg./mL and sTNFR2/pg/mL)^{5,21}; neutrophil gelatinase-associated lipocalin/ng/L (NGAL/ng/L)²²; calprotectin/mg/L¹¹; and osteoprotegerin/ng/L (OPG/ng/L)¹². Due to storage problems some marker data are missing on some patients.

The outcomes

Initial follow-up of the patients lasted for approximately 2.6 years, during which outcomes were collected through hospital and death registries and assessed by an adjudication committee.⁴ Corresponding register data later produced similar results.^{23,24} The adjudicated

8

1
2
3
4 outcomes were therefore replaced and augmented by register outcomes to cover up to 10
5
6 years +/- 3 months of follow-up. Last register follow-up was December 31, 2009. The public
7
8 registers have an almost 100% coverage and the quality of these is described
9
10 elsewhere.^{25,26} The algorithm used to get from the International Statistical Classification of
11
12 Diseases used in the national registries to the events of the composite outcome is described
13
14 in detail previously.¹³
15
16
17

18 We assessed (1) the time from randomisation to all-cause death and (2) the time from
19
20 randomisation until the first occurrence of one of the following outcomes: acute myocardial
21
22 infarction (AMI), unstable angina pectoris (UAP), cerebrovascular disease (CeVD), or all-
23
24 cause death.
25
26
27
28
29
30

31 **METHODS**

32 **Statistical analysis**

33
34
35 The statistical principles and techniques used have previously been published.^{1,2} While our
36
37 previous publication¹ dealt with the prognostic impact of the 'standard predictors,' we here
38
39 use the same techniques to quantify the effect of adding biomarker information to the
40
41 'standard predictors.'
42
43
44
45

46 We used Cox regressions (SAS 9.4) where all analyses that included covariates were
47
48 stratified by centre. The assumption of proportional hazards over time covering all covariates
49
50 included in a Cox analysis and the chosen functional form of quantitative covariates was
51
52 tested using cumulative sums of martingale-based residuals over follow-up time and/or
53
54 covariate values²⁷.
55
56
57
58
59
60

1
2
3
4 We also analysed data using a parametric, accelerated failure-time model using the
5 generalized gamma model of error.²⁸ A significance level of 0.01 was used to pinpoint
6 empirical trends worthy of note. The logarithms of the present text are natural logarithms,
7 so whenever the predictor is a log(serum concentration/unit), the hazard ratio is the factor
8 by which the hazard increases when the logarithm increases by 1, i.e., when the
9 concentration increases by a factor $e = 2.72$.

10
11
12
13
14
15
16
17
18
19
20
21 Biomarkers with a hazard ratio with P value ≥ 0.01 when used alone as covariate as well
22 as when used in combination with the 'standard predictors' were excluded from further
23 analyses. The remaining biomarkers were considered prognostic.

24
25
26
27
28
29 Assessment of the practical impact of using the set of newer biomarkers was obtained by
30 comparing the percent correct predictions obtained when the standard predictors were used
31 alone with the percentage obtained when they were combined with the novel biomarkers
32 using the method described earlier.¹

33
34
35
36
37
38
39 Secondly, we report the areas under the ROCs (receiver operating characteristics), also
40 known as AUCs or C-indices, which one obtains when the Cox-Breslow risk estimates are
41 matched against the events seen in the time window 0-to-9 years. The much-used binary
42 (event vs. no event) C-index is the concordance rate between risks and outcomes. It shows
43 how frequently an event participant has a poorer prediction score than a non-event
44 participant. In order to reward correct prediction of time of event, we further report Harrell's
45 'dynamic' (or 'overall') C-index^{29,30}. It shows how frequently an earlier-event participant has
46 a poorer prediction than a later-or-never-event participant. In other words, it is the
47
48
49
50
51
52
53
54
55
56
57
58
59
60

10

1
2
3
4 concordance between risk score and event time. It is calculated across all pairs of
5
6 participants where the time order of the pair is deducible from the 9-year data window.
7
8
9

10
11 It is noted that in the ROC analysis it was not possible to add two time dependent covariates
12
13 which were needed to compensate for the fact that both age and log(OPG/ng/L) violated the
14
15 assumption of proportional hazard. However, the output obtainable from the SAS procedure
16
17 did not allow the inclusion of time dependent covariates.
18
19
20
21
22

23 24 **Ethics and safety**

25
26
27 Ethics approval and consent to participate was given by
28
29 VEKKF01-076/99; Danish Medicines Agency 2612-975; Danish Data Protection
30
31 Agency 1999-1200-174; VEK H-B-2009-015.
32
33
34
35

36 37 **Patient and public involvement**

38
39
40 There was no direct patient involvement in the design of the trial, but the majority of the
41
42 investigators had daily contact with patients comparable to those included in the trial and
43
44 therefore knew their needs and preferences well. Moreover, there were patient
45
46 representatives as part of the regional ethics committee approving the trial. The public
47
48 involvement was through the approvals given by the regional ethics committee (KF 01-076/99
49
50 and journal no. H-12012125), the Danish Medicines Agency (2612-975), and the Danish
51
52 Data Protection Agency (1999-1200-174).
53
54
55
56
57
58
59
60

RESULTS

Table 1 Distributions of demographics, previous history, current medication, standard biochemical predictors, and newer biochemical predictors in 2199 placebo receiving patients from the CLARICOR trial. Abbreviations as in section on abbreviations.

Quantity	Distribution
Demographics and previous history	
Sex (male) N (%)	1518 (69.0%)
Age/year mean (SD)	65.2 (10.4) 2199
Smoking status N (%)	Smokers 753 (34.2%) Ex-smokers 1011 (46.0%) Never smoked 435 (19.8%)
Hypertension N (%)	883 (40.2%)
Diabetes N (%)	337 (15.3%)
Previous AMI N (%)	1494 (67.9%)
Current medication	
Aspirin N (%)	1937 (88.1%)
Beta-blocker N (%)	681 (31.0%)
Calcium-antagonist N (%)	772 (35.1%)
ACE-inhibitor N (%)	577 (26.3%)
Long-lasting nitrate N (%)	457 (20.8%)
Diuretics N (%)	773 (35.2%)
Digoxin N (%)	126 (5.7%)
Statins N (%)	904 (41.1%)
Anti-arrhythmic drugs N (%)	51 (2.3%)
Standard biochemical predictors	
log (CRP/mg/L) mean (SD) N ^a	1.03 (1.12) 2159
ApoA1/mg/dL mean (SD) N	1.70 (0.34) 2076
log (ApoB/mg/dL) mean (SD) N	0.16 (0.27) 2075
Chol-HDL/mmol/L mean (SD) N	1.02 (0.32) 2074
Chol-LDL/mmol/L mean (SD) N	2.56 (0.72) 2079
log (Cholesterol/mmol/L) mean (SD) N	1.73 (0.20) 2075
log (Tri-glyceride/mmol/L) mean (SD) N	0.73 (0.53) 2078
Glomerular filtration rate (GFR/mL/min) mean (SD) N	71.8 (19.2) 2079
Newer biochemical predictors	
log (proBNP/ng/L) mean (SD) N	5.26 (1.37) 2149
log (hs-cTnT/ng/L) mean (SD) N	2.01 (0.78) 2111
log (endostatin/ng/mL) mean (SD) N	10.3 (0.34) 2121
log (OPG)/ng/L mean (SD) N	7.49 (0.40) 2108
log (TNFR1/pg/mL) mean (SD) N	7.40 (0.40) 2120
log (TNFR2/pg/mL) mean (SD) N	8.54 (0.33) 2120
PAPP-A \geq 4mIU/L count (%) N	288 (13.1%) 2140
log (YKL40/ μ g/L) mean (SD) N	4.75 (0.66) 2163
log (NGAL/ng/L) mean (SD) N	11.6 (0.46) 2121
log (Cathepsin B/ μ g/L) mean (SD) N	10.6 (0.45) 2120
log (Cathepsin S/ μ g/L) mean (SD) N	9.48 (0.27) 2121
log (Calprotectin/mg/L) mean (SD) N	0.77 (0.59) 2086

12

FOOTNOTES

- a) The value of N varies because the laboratory tests have missing values (mostly due to storage problems). log: natural logarithm.

Table 1 presents an overview of the covariates expected to be available from stable cardiovascular disease patients during clinical routine work ('standard predictors') plus the 12 newer biochemical quantities under investigation. The data revealed that at 3 years, 2073 (94.2%) were still alive and 1826 (83.0%) had not yet suffered a composite outcome. At 6 years, 1758 (79.9%) were still alive and 1261 (57.3%) had not yet suffered a composite outcome. At 9 years, the numbers were 1487 (67.6%) and 969 (44.0%).

Out of 2099 placebo patients, 1998 had complete biochemical data. As Little's test³¹ had $P = 0.49$, suggesting that the values were missing completely at random, we used complete case analyses in the following. The composition of the two groups appears consistent.

Two of the 12 newer biomarkers (log(Calprotectin) and log(Cathepsin-S)) did not contribute significantly ($P > 0.01$) to the prediction of any of the two outcomes, neither when used in combination with the 'standard predictors' nor when used alone (see supplementary file S1, tables 1S and 2S). They were therefore removed from the subsequent analyses. In the analysis of log (OPG/ng/L) we found that the assumption of proportional hazard was significantly violated. This was remedied when we included the time dependent covariate log (OPG/ng/L) in the subsequent regression equation (see table 2S in supplementary file S1). The latter equation now included the 'standard predictors', plus the remaining 10 newer biomarkers and the above-mentioned time dependent covariates. It appears from

13

supplementary table 2S that only log (proBNP/ng/L), log (hs-cTnT/ng/L), and log (OPG/ng/L) contributed significantly to the prediction.

Table 2 The two outcomes (1) all-cause death and (2) the composite outcome of AMI, UAP, CeVD, and all-cause death were studied.

Model and covariates included in model	Total number of predictions made per outcome	Number and percent of correct predictions of events	
		All-cause death N (%)	Composite of AMI ^a , UAP ^b , Ce-VD ^c , and all-cause death N (%)
Model 1: Cox model void of covariates	5972	4768 (79.8)	3773 (63.2)
Model 2: Cox model with 'Standard predictors(SP)' added to model	5972	4977 (83.3)	4084 (68.4)
Model 3: Cox model with SP + 10 newer biomarkers added to model	5972	5056 (84.7)	4165 (69.9)

- a) AMI acute myocardial infarction
- b) UAP unstable angina pectoris
- c) Ce-VD cerebrovascular disease

Table 2 (see also supplementary file S1 tables 3S and 4S) compares the number and percentages of correct predictions between various prediction models. In each model predictions were made at 3, 6, and 9 years for each of the two outcomes (death and the composite). Model 1 shows the results obtained using a model void of covariates. 79.8% of the predictions were correct for the outcome death and 63.2% for the composite outcome. Model 2 shows the results obtained when model 1 was augmented by the 'standard predictors'. Now the percent correct predictions have been improved by $83.3 - 79.8\% = 3.5\%$ for the outcome death and $68.4 - 63.2\% = 5.2\%$ for the composite outcome. When model 2

14

was improved by adding the 10 newer biomarkers the additional gain in correct predictions amounted to 1.4% for death and 1.3% for the composite outcome.

Using the parametric model in place of the Cox model we obtained quite similar results (see tables 3S and 4S in supplementary file S1 and figure 1S A-B). The same was true if we only included log (proBNP/ng/L), log (hs-cTnT/ng/L), and log (OPG/ng/L) instead of all 10 biomarkers when the Cox model was used (see tables 3S and 4S in the supplementary file S1).

Table 3. C-indices. Cox model estimates applied to the 0-9-year follow-up window ($n = 1998$).

	Binary-outcome C (AUC), observed (predicted)^a	Dynamic C, Observed^b
Composite outcome^c (1115 events)		
Standard predictors (SP) only	0.711 (0.707)	0.640
The 10 newer markers & SP	0.732 (0.732)	0.657
Log(hsTnT/ng/L) + log(proBNP/ng/L) + SP	0.730 (0.730)	0.656
All-cause death (644 deaths)		
SP only	0.792 (0.793)	0.737
The 10 newer markers & SP	0.824 (0.816)	0.765
Log(hsTnT/ng/L) + log(proBNP/ng/L) + SP	0.821 (0.813)	0.762

a) The 'observed' AUCs summarize a ROC plot of cumulative events against cumulative non-events, with cumulation from large to small estimated risks. The corresponding 'predicted' AUC cumulates the predicted risks instead. Discrepancies between the two curves would suggest a model failure (calibration problems). The curves (not shown) were practically identical.

b) Analogous concordance rate between time to event and predicted risk.

c) Composite outcome: first occurrence of acute myocardial infarction, unstable angina pectoris, cerebrovascular disease or death. SP 'standard predictors', see table 1.

15

1
2
3
4 Table 3 summarizes the ROC analyses. For prediction of the composite outcome (yes / no),
5
6 the area under the ROC increases from 0.711 to 0.732 when the 10 novel biomarkers are
7
8 added to the 'standard predictors,' but almost all the marker information is contained in
9
10 log(hsTNT/ng/L), and log(proBNP/ng/L) (AUC = 0.730). The 'dynamic' C-index values are
11
12 smaller as prediction of event times is more difficult, but the gains are similar. All-cause
13
14 death shows the same general pattern.
15
16

17 18 **DISCUSSION**

19
20
21 In this study we assessed the combined value of 12 newer biomarkers not routinely used in
22
23 clinical work to predict all-cause death and a composite outcome (AMI, UAP, CeVD, or all-
24
25 cause death). We used a cut value of predicted risk = 0.5 to separate correct predictions of
26
27 the observed patient status from incorrect ones. When we combined the biomarkers with
28
29 the 'standard predictors' routinely available for a general practitioner when he/she meets a
30
31 patient with stable coronary heart disease, 84.7 % of the survival status were correctly
32
33 predicted. In case of the composite outcome the number was 68.4%. In both cases, the
34
35 combined contribution of the newer biomarkers amounted to less than 1.5%.
36
37
38
39
40
41

42 Our patients resemble those of The Prospective Observational Longitudinal Registry of
43
44 Patients with Stable Coronary Heart Disease (CLARIFY) study³² which enrolled 20,291
45
46 patients. The CLARIFY patients had been observed with a median of 24.1 months. However,
47
48 enrollment took place 10 years later than in the CLARICOR trial and the incidence of
49
50 cardiovascular deaths or myocardial infarctions in these patients was considerably lower,³²
51
52 probably reflecting improved quality of treatment and more frequent statin treatment in the
53
54 CLARIFY patients (84% compared to only 41% in the CLARICOR material). So, the age of
55
56 our material is a weakness.
57
58
59
60

16

1
2
3
4
5
6
7
8 In our present study, we are using our data to develop a prediction model. Then we evaluate
9
10 the performance using the same data that we used to develop the model. Clearly this is
11
12 bound to produce overly optimistic results compared to testing our model using independent
13
14 data. But we argue that the aim of this study was not to present a prediction model but to
15
16 assess the newer biomarkers' contribution to model performance when added on top of
17
18 routinely available clinical and laboratory data. Therefore, if tested on independent data, the
19
20 contribution of the newer biomarkers to prognosis of patients with stable coronary heart
21
22 disease are likely going to be worse than observed here.
23
24
25
26
27
28
29

30 **Methodology**

31
32
33 Regarding our methodology, the performance statistics reported here are minimal, but they
34
35 suffice to show that the results are meagre. Prediction at 3, 6, and 9 years covers the follow-
36
37 up as well as would a sophisticated integral over continuous time.
38
39
40
41
42
43

44 **Strengths**

45
46
47 The strengths of the CLARICOR trial are the size of the patient population, the long duration
48
49 of follow-up, few losses to follow-up (1%), the ethnic homogeneity of the patient population
50
51 (most being Caucasians), rarity of missing values, with focus on an operationally defined,
52
53 homogeneous and relevant patient category. The design implies that the patients are
54
55 sampled at random, presumably uneventful, time points during their stable state (as defined
56
57 by the CLARICOR trial).
58
59
60

Limitations

Among those 7586 patients who declined our invitation to visit a cardiology centre, many must have been eligible for the CLARICOR trial, and we do not know how they looked and fared. With a response rate about 50%, the cohort could represent a prognostic elite if responders were mostly mobile and health-conscious patients. So, selection bias cannot be excluded.

Furthermore, users of these data should remain aware of one feature: patients if any who became eligible for the CLARICOR trial during the period 1993 to 1999 and then died before August 1999 are absent. Thus, our data do not represent patients as they enter a stable disease state (as delimited by CLARICOR exclusion criteria); instead, they may be regarded as community patients (subject to some self-selection) seen by their physician or at an outpatient clinic on a random date during their stable state.

The patients recruited for the CLARICOR trial were diagnosed with coronary heart disease about 20 years ago. Because of the developments in treatment and rehabilitation, there has been a very significant and gradual improvement in the prognosis of such patients as shown in national data.³³ Given these uncertainties, prognostic findings in the CLARICOR cohort may not be directly applied to present-day patients. However, the overall, somewhat disappointing, picture presented by the predictive performance of standard¹ and newer biochemical predictors studied 10-20 years ago would hardly be much different if studied today.

Potential weaknesses of the present cohort within the context of prognostication of stable coronary heart disease patients as here defined include the fact that only questionnaire data

1
2
3
4 were collected at randomisation. No data are available concerning left ventricle function,
5
6 body mass index, blood pressure, and general health. These shortcomings are mitigated by
7
8 the fact that, by design, the present study sees the patient in a situation where (s)he visits a
9
10 physician for reasons unrelated to the coronary disease, as already stressed. In such
11
12 situations, counselling and decisions must typically be made without access to
13
14 echocardiography or other special investigations. Furthermore, if this information had been
15
16 available, the prognostic gain we study would probably have been still poorer. Moreover, we
17
18 included age, sex, hypertension, prior myocardial infarction, information about current
19
20 medication which has previously been shown to be a fair replacement for prognostication
21
22 instead of left ventricular ejection fraction.³⁴
23
24
25
26
27

28 It is noted that the patients studied by us were all in a stable state of their disease, without
29
30 cardiac complaints. Therefore, one should not conclude from this study that the biomarkers
31
32 studied here may not be useful in many other clinical contexts, although biomarkers have
33
34 been shown to of modest help in evaluating cardiovascular risk assessment in asymptomatic
35
36 people not suffering from CAD.³⁵
37
38
39
40
41
42

43 **Conclusions** In the present clinical context the contribution of the 12 biomarkers not yet
44
45 used in clinical routine work proved to be minimal. Furthermore, of the 10 statistically
46
47 promising novel biomarkers all could be replaced by hs-cTnT and proBNP, possibly
48
49 supplemented by osteoprotegerin.
50
51
52
53
54
55

56 **Author affiliations**

57
58
59
60

19

1
2
3
4 1 Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet.

5
6 Copenhagen University hospital, Blegdamsvej 9, Copenhagen, Denmark.

7
8
9 2 Department of Cardiology, Holbæk Hospital, Holbæk, Denmark.

10
11
12 3 Department of Regional Health Research, The Faculty of Health Sciences, University of
13
14 Southern Denmark

15
16
17 4 Section of Biostatistics, Department of Public

18
19
20 Health Research, University of Copenhagen, Copenhagen, Denmark.

21
22
23 5 Department of Cardiology, Hvidovre Hospital, Copenhagen University Hospital,
24
25 Copenhagen, Denmark.

26
27
28 6 Department of Cardiology S, Herlev Hospital,

29
30
31 Copenhagen University Hospital, Copenhagen, Denmark.

32
33
34 7 Department of Cardiology,

35
36
37 Bispebjerg Hospital, University Hospital, Copenhagen, Denmark.

38
39
40 8 Department of Cardiology B, The Heart Centre, Rigshospitalet, Copenhagen

41
42
43 University Hospital, Copenhagen, Denmark.

44
45
46 9 Department of Clinical

47
48
49 Microbiology, Odense University Hospital, Odense, Denmark.

50
51
52 10 The Medical Research Laboratory, Department of Clinical Medicine, Aarhus University,
53
54
55 Denmark.

20

1
2
3
4 11 Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
5
6

7 12 Division of Family Medicine and Primary Care, Department of Neurobiology, Care
8 Sciences and Society, Karolinska Institutet, Huddinge, Sweden
9

10
11
12 13 Division of Family Medicine and Primary Care, Department of Neurobiology, Care
13 Science and Society, Karolinska Institutet, Huddinge, Sweden.
14
15
16

21 **Abbreviations**

22
23 AMI: acute myocardial infarct; Apo A1: apoprotein A1; Apo B: apoprotein B; CeVD: cerebro-
24 vascular disease; Chol-HDL: cholesterol high density lipoprotein; Chol-LDL: cholesterol low
25 density lipoprotein; CLARICOR: Clarithromycin for patients with stable coronary heart
26 disease; CRP: c-reactive protein; GFR: Glomerular filtration rate; hs-cTnT: High-sensitive
27 assay cardiac troponin T; NGAL: neutrophil gelatinase-associated lipocalin; NYHA: New
28 York Heart Association; OPG: osteoprotegerin; PREMAC: Predictors for major
29 cardiovascular outcomes in stable ischaemic heart disease; proBNP: N-terminal pro-B-type
30 natriuretic peptide;
31
32 TNFR1: tumor necrosis factor receptor 1; TNFR2: tumor necrosis factor receptor 2; UAP:
33 unstable angina pectoris.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48

49 **Acknowledgements**

50
51 We thank the CLARICOR trial participants. We thank the investigators and
52 other staff involved during the first phases of the CLARICOR trial (for full list of
53 names, please see references 6, 11, and 13). We also thank our original funders of the
54
55
56
57
58
59
60

21

1
2
3
4 CLARICOR trial (see references 6, 11, and 13). The Copenhagen Trial Unit, Centre for
5
6 Clinical Intervention Research, is thanked for providing monetary support for part of the
7
8 biochemical analyses for the PREMAC study as well as wages for Per Winkel, Janus C.
9
10 Jacobsen, and Christian Gluud.
11
12

13 14 **Funding**

15
16 This study was funded by the Copenhagen Trial Unit, Centre for Clinical
17
18 Intervention Research; original funders of the CLARICOR trial; and The
19
20 Swedish Research Council, Swedish Heart-Lung foundation; Thuréus
21
22 Foundation; Marianne and Marcus Wallenberg Foundation, Dalarna
23
24 University; and Uppsala University.
25
26
27
28
29

30 31 **Availability of data and materials**

32
33 All pertinent anonymised data will be uploaded at ZENODO (<http://zenodo.org/>)
34
35 when the individual manuscripts have been published.
36
37
38
39

40 41 **Authors' contributions**

42
43 PW, JH, JCJ, and CG contributed substantially to the concept and design and
44
45 drafted the manuscript, PW and JH contributed equally to this paper, and conducted the
46
47 statistical analyses. AL and JÄ conducted the analysis of lipids and creatinine. PW, JCJ, JH,
48
49 GBJ, EK, AS, JK, HJK, KKI, MB, AL, JÄ, CG revised the manuscript critically for important
50
51 intellectual content, gave final approval of version to be published, and
52
53 agreed to be accountable for all aspects of the work in assuring that questions related to
54
55 the accuracy or integrity of any part of the work are appropriately investigated and
56
57
58
59
60

22

resolved. PW, JCJ, JH, GBJ, EK, AS, JK, HJK, KKI, MB, AL, JÄ, CG contributed substantially to the interpretation of the data.

Competing interests

The authors declare that they have no competing interests.

REFERENCES

1. Winkel P, Jakobsen JC, Hilden J, et al. Prognostic value of routinely available data in patients with stable coronary heart disease. A 10-year follow-up of patients sampled at random times during their disease course. *Open Heart* 2018:e000808. Doi:10.1136/openhrt-2018-000808
2. Winkel P, Jakobsen JC, Hilden J, Lange T, Jensen GB, Kjøller E, et al: Predictors for major cardiovascular outcomes in stable ischaemic heart disease (PREMAC): statistical analysis plan for data originating from the CLARICOR (clarithromycin for patients with stable coronary heart disease) trial: *Diagnostic and Prognostic Research* (2017) 1:10 DOI 10.1186/s41512-017-0009-y.
3. Jespersen CM, Als-Nielsen B, Damgaard M, Hansen JF, Hansen S, Helø OH, et al: Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial. *BMJ*. 2006; 332:22–7.
4. Hansen S, Als-Nielsen B, Damgaard M, Helø OH, Petersen L, Jespersen CM, et al: Intervention with clarithromycin in patients with stable coronary heart disease: the CLARICOR trial design. *Heart Drug*. 2001; 1:14–9.
5. Carlsson AC, Ruge T, Kjøller E, Hilden J, Kolmos HJ, Sajadieh A o. a. 10-year associations between tumor necrosis factor receptors 1 and 2 and cardiovascular events in patients with stable coronary heart disease: a CLARICOR (effect of clarithromycin on

mortality and morbidity in patients with coronary heart disease) trial substudy. Journal of the American Heart Association 2018 apr 23;7(9): e 008299 Doi:10. 116/JAHA 127.008299

6. Wuopio J, Hilden J, Bring C, Kastrup J, Sajadieh A, Jensen GB o.a. Cathepsin B and S as markers for cardiovascular risk and all-cause mortality in patients with stable coronary heart disease during 10 years: a CLARICOR trial substudy. *Atherosclerosis*. 2018 nov 1;278: 97 to 102. Tilgængelig fra, DOI: 10. 1016/j atherosclerosis. 2018.09.006

7. Harutyunyan MJ, Mathiasen AB, Winkel P, Gøtze JP, Hansen JF, Hildebrandt P, et al: High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary heart disease: a prognostic study within the CLARICOR trial. *Scand J Clin Lab Invest*. 2011; 71:52–62.

8. Schroder J, Jakobsen CJ, Winkel P, Hilden J, Jensen GB, Sajadieh A, et al. Prognosis and Reclassification by YKL-40 in Stable Coronary Artery Disease. *J Am Heart Assoc*. 2020;9: e014634. DOI: 10.1161/JAHA.119.014634.

9. Lyngbaek S, Winkel P, Gotze JP, Kastrup J, Gluud C, Kolmos HJ, et al. Risk stratification in stable coronary artery disease is possible at cardiac troponin levels below conventional detection and is improved by use of N-terminal pro-B-type natriuretic peptide. *European Journal of Preventive Cardiology* 2014; 21:1275-1284.

10. Iversen KK, Teisner B, Winkel P, Gluud C, Kjoller E, Kolmos HJ, et al. Pregnancy associated plasma protein-A as a marker for myocardial infarction and death in patients with stable coronary artery disease: a prognostic study within the CLARICOR Trial. *Atherosclerosis* 2011; 214:203-208.

24

- 1
2
3
4 11. Larsen SB, Grove EL, Pareek M, Kristensen SD, Hvas AM. Calprotectin and
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
10(5):e0125992.
12. Bjerre M, Hilden J, Kastrup J, Skoog M, Hansen JF, Kolmos HJ, et al.
Osteoprotegerin independently predicts mortality in patients with stable coronary artery
disease: the CLARICOR trial. *Scandinavian Journal of Clinical and Laboratory Investigation*
2014; 74:657-664.
13. Winkel P, Hilden J, Hansen JF, Kastrup J, Kolmos HJ, Kjoller E, et al.
Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular
mortality and cerebrovascular morbidity over 10years in the CLARICOR randomised,
blinded clinical trial. *International Journal of Cardiology* 2015, 182:459-465.
14. Winkel P, Hilden J, Fischer Hansen J, Hildebrandt P, Kastrup J, Kolmos HJ, et
al: Excess sudden cardiac deaths after short-term clarithromycin administration in the
CLARICOR trial: why is this so, and why are statins protective? *Cardiology*. 2011; 118:63–
67.
15. Gluud C, Als-Nielsen B, Damgaard M, Fischer Hansen J, Hansen S, Helø OH,
et al: Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the
CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart
disease. *Cardiology*. 2008; 111:280

25

- 1
2
3
4 16. Helmersson-Karlqvist J, Ridefelt P, Lind L, Larsson A. Reference values for 34
5 frequently used laboratory tests in 80-year-old men and women. *Maturitas*. 2016; 92: 97-
6
7 101.
8
9
10
11
12 17. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al:
13 Estimating glomerular filtration rate from serum creatinine and cystatin C. *N Engl J Med*.
14 2012;367:20–9.
15
16
17
18
19 18. Wang N, Bai X, Jin B, Han W, Sun X, Chen X. The association of serum
20 cathepsin-B concentration with age-related cardiovascular-renal subclinical state in a
21 healthy Chinese population. *Arch Gerontol Geriatr*. 2016; 65:146-55.
22
23
24
25
26
27 19. Arnlov J, Ruge T, Ingelsson E, Sundstrom J, Lind L. Serum endostatin and risk
28 of mortality in the elderly: findings from 2 community-based cohorts. *Arterioscler Thromb*
29 *Vasc Biol*.2013, 33: 2689-95.
30
31
32
33
34
35 20. Jobs E, Ingelsson E, Risérus U, Nerpin E, Jobs M, Sundström J, et al.
36 Association between serum cathepsin S and mortality in older adults. *JAMA*. 2011;
37 306:1113-21.
38
39
40
41
42
43 21. Carlsson AC, Larsson TE, Helmersson-Karlqvist J, Larsson A, Lind L, Ärnlöv J.
44 Soluble TNF receptors and kidney dysfunction in the elderly. *J Am Soc Nephrol*.
45 2014;25:1313-20.
46
47
48
49
50
51 22. Helmersson-Karlqvist J, Larsson A, Carlsson AC, Venge P, Sundstrom J,
52 Ingelsson E, et al. Urinary neutrophil gelatinase-associated lipocalin (NGAL) is associated
53 with mortality in a community-based cohort of older Swedish men. *Atherosclerosis* 2013;
54 227:408-13.
55
56
57
58
59
60

26

1
2
3
4 23. Kjølner E, Hilden J, Winkel P, Frandsen NJ, Galatius S, Jensen G, et al: Good
5 interobserver agreement was attainable on outcome adjudication in patients with stable
6 coronary heart disease. *J Clin Epidemiol.* 2012; 65:444–53.
7
8

9
10
11
12 24. Kjølner E, Hilden J, Winkel P, Galatius S, Frandsen NJ, Jensen GB, et al:
13 Agreement between public register and adjudication committee outcome in a cardiovascular
14 randomized clinical trial. *Am Heart J.* 2014; 168:197–204.ok
15
16

17
18
19
20 25. Helweg-Larsen K: The Danish register of causes of death. *Scand J Public*
21 *Health.* 2011;39(7 30. Suppl):26-9.
22
23

24
25 26. Lynge E, Sandegaard JL, Rebolj M: The Danish National Patient Register.
26
27 *Scand J Public Health.* 2011;39(7 suppl):30–3.
28
29

30
31 27. Lin DY, Wei LJ, Ying Z: Checking the Cox model with cumulative sums of
32 martingale-based residuals. *Biometrika.* 1993; 80:557–72.
33
34

35
36
37
38
39 28. Allison PD: *Survival Analysis Using SAS: A Practical Guide*, second edition
40 2010 SAS institute Inc. Cary, NC, USA.
41
42

43
44 29. Harrell FE Jr, Lee KL, Mark DB. *Multivariable prognostic models: issues in*
45 *developing models, evaluating assumptions and adequacy, and measuring and reducing*
46 *errors.* *Stat Med.* 1996;15: 361-87.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

27

1
2
3
4 30. Pencina MJ, d'Agostino RB. Overall C as a measure of discrimination in
5 survival analysis: model specific population value and confidence interval estimation. *Stat*
6
7
8
9 *Med.* 2004; 23: 2109 -23.

10
11
12
13
14
15 31. Little R: A test of missing completely at random for multivariate data with missing
16 values. *J Am Stat Assoc.* 1988; 83:1198–1202.

17
18
19
20 32. Steg PG, Greenlaw N, Tendera M, et al. Prevalence of anginal symptoms and
21 myocardial ischemia and their effect on clinical outcomes in outpatients with stable coronary
22 artery disease. Data from the International Observational CLARIFY Registry. *JAMA Intern*
23
24
25
26
27 *Med.* 2014;174(10):1651-1659. doi:10.1001/jamainternmed.2014.3773

28
29
30 33. Schmidt M, Jacobsen JB, Lash TL, Bøtker HE, Sørensen HT: 25-year trends in
31 first time hospitalisation for acute myocardial infarction, subsequent short and long-term
32 mortality, and the prognostic impact of sex and comorbidity: a Danish nationwide cohort
33 study. *BMJ.* 2012;344: e356.

34
35
36
37 34. Solomon SD, Claggett B, Desai AS, et al. Influence of ejection fraction on
38 outcomes and efficacy of sacubitril/valsartan (Ic2696) in heart failure with reduced ejection
39 fraction. *Circulation* 2016;9:e00274.

40
41
42
43 35. Scott IA. Evaluating cardiovascular risk assessment in asymptomatic
44 people. *BMJ* 2009;a2844doi:10.1136/bmj.a2844

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

<Winkel P. & al. * Supplementary file S1>

Supplementary file S1

Table 1S All-cause mortality hazard ratios (HR) of newer biochemical predictors not routinely used in clinical work when each of these predictors is used alone (columns 2 to 4), and when it is used in combination with the 'standard predictors'^a (column 5 to 7). Two of them were then discarded and each of the remaining 10 was assessed when used in combination with the standard predictors and the remaining 9 of the 10 newer biochemical predictors selected among the 12 candidates (columns 8 to 10).

Newer biochemical candidate predictor	When candidate predictor is the only predictor included in the model (stratified by centre)			When 'standard predictors' is added to the model (stratified by centre)			When in addition the 10 selected predictors are added to the model (stratified by centre)		
	HR ^b	95% CI	P	HR	95% CI	P	HR	95% CI	P
log (endostatin/ng/mL)	3.49	2.81 to 4.33	<0.0001	1.75	1.34 to 2.27	<0.0001	1.23	0.92 to 1.63	0.16
log (OPG/ng/L)	3.37	2.88 to 3.94	<0.0001	1.68	1.35 to 2.09	<0.0001	1.21	0.97 to 1.63	0.092
log (sTNFR1/pg/mL)	3.80	3.19 to 4.54	<0.0001	1.84	1.46 to 2.33	<0.0001	1.10	0.81 to 1.48	0.55
og (sTNFR2/pg/mL)	5.45	4.40 to 6.76	<0.0001	2.39	1.80 to 3.18	<0.0001	1.43	0.99 to 2.07	0.056
log(proBNP/ng/L)	1.76	1.66 to 1.87	<0.0001	1.44	1.34 to 1.55	<0.0001	1.28	1.19 to 1.39	<0.0001
log(hs-cTnT/ng/L)	2.31	2.16 to 2.47	<0.0001	1.73	1.56 to 1.92	<0.0001	1.46	1.30 to 1.65	<0.0001
PAPP-A_binary ^c	1.84	1.53 to 2.21	<0.0001	1.39	1.15 to 1.68	0.0007	0.85	0.69 to 1.03	0.10
log (YKL40/μg/L)	1.76	1.59 to 1.95	<0.0001	1.32	1.17 to 1.49	<0.0001	1.10	0.97 to 1.25	0.15
log (NGAL/ng/L)	1.33	1.12 to 1.57	0.0011	1.03	0.85 to 1.24	0.78	0.90	0.74 to 1.10	0.30
log(Calprotectin/)	1.08	0.95 to 1.23	0.25	1.02	0.89 to 1.18	0.74	Not included in analysis		
log (Cathepsin-B/μg/L)	2.81	2.40 to 3.28	<0.0001	1.43	1.19 to 1.73	0.0002	1.09	0.89 to 1.33	0.42
log (Cathepsin-S/μg/L)	1.12	0.86 to 1.47	0.40	1.10	0.83 to 1.45	0.53	Not included in analysis		

a) The standard predictors are shown in Table 1.

b) Hazard ratio associated with unit increase on log scale, except for PAPP-A (binary).

<Winkel P. & al. * Supplementary file S1>

c) Binary quantity. 1: PAPP-A was ≥ 4 mIU/L, 0: PAPP-A was < 4 mIU/L.

1. Inferential impact of the newer biomarkers

As the proportional hazard's assumption was violated for age²⁹ and age interacted significantly with time since randomisation, we included an interaction between age at entry and time (since randomisation) in the inference analyses.

Table 1S shows the results of a Cox regression of all-cause death on each of the 12 biomarkers when the biomarker was used alone as a covariate (columns 2 through 4), and when it was used in combination with the 'standard predictors' (columns 5 through 7).

Columns 8 through 10 in Table 1S shows the result of a regression of the outcome on the 'standard predictors' and the 10 best biochemical predictors. Now only log (proBNP /ng/L) and log(hs-cTnT/ng/L) have a HR significantly ($P < 0.01$) different from 1. Log(calprotectin/mg/L) and log(cathepsin-S/ μ g/L) did not have an inferential impact ($P < 0.01$ not attained), not even when used alone.

<Winkel P. & al. * Supplementary file S1>

Table 2S the composite outcome (comprising first occurrence of acute myocardial infarction, unstable angina pectoris, cerebro-vascular disease, and death). Hazard ratios of each of 13 biochemical predictors not routinely used in clinical work when each of these predictors is used alone (columns 2 to 4), and when it is used in combination with the 'standard predictors' (column 5 to 7). Two of them were then discarded and each of the remaining 11 was assessed when used in combination with the standard predictors and the remaining 10 of the 11 newer biochemical predictors selected among the 13 candidates (columns 8 to 10)

Newer biochemical candidate predictor	When candidate predictor is the only predictor included in the model (stratified by centre)			When 'standard predictors' is added to the model (stratified by centre)			When in addition the 11 ^a selected predictors are added to the model (stratified by centre)		
	HR	95% CI of HR	P	HR	95% CI of HR	P	HR	95% CI of HR	P
log (Endostatin/ng/mL)	2.18	1.84 to 2.58	<0.0001	1.44	1.17 to 1.72	0.0006	1.23	0.99 to 1.54	0.062
log (OPG/ng/L)	1.34	1.05 to 1.71	0.019	0.94	0.70 to 1.26	0.67	0.78	0.58 to 1.04	0.094
log (OPG/ng/L) ·time/year ^b	1.11	1.06 to 1.16	<0.0001	1.09	1.03 to 1.16	0.0022	1.104	1.044 to 1.168	0.0005
log (sTNFR1/pg/mL)	2.14	1.86 to 2.46	<0.0001	1.33	1.11 to 1.60	0.0021	1.05	0.84 to 1.32	0.67
log (sTNFR2/pg/mL)	2.56	2.15 to 3.03	<0.0001	1.49	1.19 to 1.85	0.0004	1.13	0.85 to 1.50	0.40
log (proBNP/ng/L)	1.37	1.31 to 1.44	<0.0001	1.26	1.19 to 1.33	<0.0001	1.18	1.11 to 1.25	<0.0001
log (hs-cTnT/ng/L)	1.83	1.70 to 1.97	<0.0001	1.49	1.35 to 1.64	<0.0001	1.31	1.17 to 1.46	<0.0001
PaPP-A (binary) ^c	1.45	1.24 to 1.70	<0.0001	1.24	1.06 to 1.46	0.0077	0.89	0.75 to 1.05	0.15
log (YKL40/μg/L)	1.35	1.24 to 1.47	<0.0001	1.13	1.03 to 1.24	0.013	1.01	0.91 to 1.11	0.93
log (NGAL/ng/L)	1.23	1.08 to 1.40	0.0023	1.03	0.89 to 1.19	0.73	0.97	0.84 to 1.13	0.74
log (Calprotectin/)	1.06	0.95 to 1.17	0.32	1.00	0.90 to 1.12	0.95	Not included in analysis		
log (cathepsin-B/μg/L)	1.70	1.50 to 1.93	<0.0001	1.17	1.01 to 1.35	0.040	0.99	0.85 to 1.16	0.92
log (cathepsin-S/μg/L)	1.06	0.86 to 1.31	0.59	0.98	0.79 to 1.22	0.88	Not included in analysis		

<Winkel P. & al. * Supplementary file S1>

- a) Note that now a time dependent covariate has been added [$\log(\text{OPG}/\text{ng/L}) \cdot \text{time}/\text{year}$] to the 10 original predictors.
- b) $\log(\text{OPG}/\text{ng/L})$ significantly violated the proportional hazard assumption. We found a significant linear relationship between $\log(\text{OPG}/\text{ng/L})$ and time since randomisation which may explain the violation. The product of $\log(\text{OPG}/\text{ng/L})$ and time/year was therefore included in the inference analysis. However, when the Cox model is used for prediction, time dependent covariates are not allowed (SAS 9.4). Therefore, in the latter context we only include $\log(\text{OPG}/\text{ng/L})$.
- c) Binary quantity. 1: PAPP-A was ≥ 4 mIU/L, 0: PAPP-A was < 4 mIU/L.

Table 2S corresponds to Table 1S except that the outcome is the composite outcome. It is noted that a time-dependent covariate is now included because $\log(\text{OPG}/\text{ng/L})$ violated the proportional hazard assumption. This was remedied by including the covariate $\log(\text{OPG}/\text{ng/L}) \cdot \text{time}/\text{year}$. It is seen that when all the biomarkers were included in the Cox analysis $\log(\text{OPG}/\text{ng/L}) \cdot \text{time}/\text{year}$, $\log(\text{proBNP}/\text{ng/L})$, and $\log(\text{hs-cTnT}/\text{ng/L})$ were the only ones which had a P value below the threshold of 0.01. Again $\log(\text{calprotectin}/\text{ng/L})$ and $\log(\text{cathepsin-S}/\mu\text{g/L})$ could be excluded from the final analysis, the result of which is shown in columns 8 through 10.

2. Practical impact of the novel biomarkers

Table 3S All-cause death. Correct predictions of favorable (alive) and unfavorable (not alive) status made at 3 years, at 6 years, and at 9 years following randomisation in the 1998 placebo patients from the CLARICOR trial. Four covariate scenarios were examined with Cox regression (see text of columns 4, 5, 6, and 8). For comparison with the results of column 6, column 7 shows the corresponding results when the accelerated failures model was used.

<Winkel P. & al. * Supplementary file S1>

(1) Number of predictions made	(2) Time at which prediction was made	(3) Correctly predicted patient status	(4) Data without covariates included Both models N (%)	(5) Data including Standard predictors as covariates Cox model N (%)	(6) Data including Standard predictors + advanced biochemical predictors as covariates Cox model N (%)	(7) Data including Standard predictors + advanced biochemical predictors as covariates Parametric model N (%)	(8) Data including Standard predictors log(OPG/ng/L) log (hs-cTnT/ng/L) and log(proBNP/ng/L) as covariates Cox Model N (%)
1996	Three years	Favorable status	1825 (91.4)	1821 (91.2)	1816 (91.0)	1814 (90.9)	1816 (91.0)
		Unfavorable status	0 (0.00)	10 (0.50)	19 (0.95)	14 (0.70)	19 (0.95)
1989	Six years	Favorable status	1601 (80.5)	1555 (78.2)	1551 (78.0)	1538 (77.3)	1553 (78.1)
		Unfavorable status	0 (0.00)	85 (4.27)	120 (6.03)	118 (5.93)	113 (5.68)
1987	Nine years	Favorable status	1342 (67.5)	1192 (60.0)	1219 (61.3)	1217 (61.2)	1212 (61.0)
		Unfavorable status	0 (0.00)	297 (14.9)	331 (16.7)	323 (16.3)	339 (17.1)
5972	All three times combined	Favorable status	4768 (79.8)	4585 (76.8)	4586 (76.8)	4569 (76.5)	4581 (76.7)
		Unfavorable status	0 (0.00)	392 (6.56)	470 (7.87)	364 (6.10)	471 (7.89)
		Total	4768 (79.8)	4977 (83.3)	5056 (84.7)	4933 (82.6)	5052 (84.6)

bmjopen-2019-033820
 on 21 August 2019
 Protected by copyright.

<Winkel P. & al. * Supplementary file S1>

The results of the predictions of survival status made at 3 years, at 6 years, and at 9 years following randomisation in the 1998 placebo patients are summarized in Table 3S.

When the 'standard predictors' were included as covariates (column 5) for all-cause mortality, 83.3% of the predictions were correct.


Adding the 10 newer biochemical predictors (column 6) the percentage was increased by 1.4% to 84.7%.

For peer review only

bmjopen-2019-033720 on 20 August 2020. Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.

<Winkel P. & al. * Supplementary file S1>

Figure 1S A



bmjopen-2019-033720 on 20 August 2020. Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.

<Winkel P. & al. * Supplementary file S1>


Figure 1S B

For peer review only

bmjopen-2019-033720 on 20 August 2020. Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

<Winkel P. & al. * Supplementary file S1>



bmjopen-2019-033720 on 20 August 2020. Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.

<Winkel P. & al. * Supplementary file S1>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15 The parametric model fitted the data reasonably well (see figure 1S A and B). The distribution of years to outcome using the accelerated
16 failure model where the error term is modelled using the general gamma distribution showed that for both outcomes all values were within
17 the 95% confidence limits. However, in case of all-cause death (see figure 1S A) the distribution was upwards biased but still within the 95%
18 confidence limits.
19
20
21
22
23
24
25
26
27

28 It is noted that the results obtained with the parametric model (column 7 Tables S3 and S4) are not dramatically different from the
29 corresponding results in column 6, when this theoretically equally valid model is used. When only the three significant predictors
30 $\log(\text{OPG}/\text{ng/L})$, $\log(\text{proBNP}/\text{ng/L})$, and $\log(\text{hs-cTnT}/\text{ng/L})$ were used in the Cox model in place of all 10 (column 8), the results were
31 practically unaffected (compare columns 8 and 6).
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

<Winkel P. & al. * Supplementary file S1>

Table 4S the composite outcome of AMI, UAP, CeVD, and all-cause death. Correct predictions of favorable (no outcome so far) and unfavorable status made at 3, 6 and 9 years. Cox model: four covariate scenarios as in Table 4; and parametric model (column 7) for comparison with column 6. Note that log (OPG) qualified for inclusion in column 8.

(1) Number of predictions made	(2) Time at which prediction was made	(3) Correctly predicted patient status	(4) Data without covariates included	(5) Data including Standard predictors as covariates	(6) Data including Standard predictors + advanced biochemical predictors as covariates	(7) Data including Standard predictors + advanced biochemical predictors as covariates Parametric model	(8) Data including Standard predictors + Log(OPG/ng/L), Log(hcTnT/ng/L), and log(pBNP/ng/L) as covariates Cox model
			Both models N (%)	Cox model N (%)	Cox model N (%)	N (%)	N (%)
1996	Three years	Favorable status	1514 (75.9)	1471 (73.7)	1464 (73.3)	1479 (74.1)	1463 (73.3)
		Unfavorable status	0 (0)	51 (2.56)	77 (3.86)	57 (2.86)	77 (3.81)
1989	Six years	Favorable status	1144 (57.5)	935 (47.0)	920 (46.3)	916 (46.1)	925 (46.5)
		Unfavorable status	0 (0)	349 (17.5)	370 (18.6)	368 (18.5)	367 (18.5))
1987	Nine years	Favorable status	0 (0)	504 (25.4)	542 (27.3)	550 (27.7)	529 (27.6)
		Unfavorable status	1115 (56.1)	774 (39.0)	792 (39.9)	803 (40.4)	799 (39.2)
5972	All three times combined	Favorable status	2658 (44.5)	2910 (48.7)	2926 (49.0)	2945 (49.3)	2927 (49.2)
		Unfavorable status	1115 (18.7)	1174 (19.7)	1239 (20.7)	1228 (20.6)	1222 (20.5)
		Total	3773 (63.2)	4084 (68.4)	4165 (69.7))	4173 (69.9)	4159 (69.6)

<Winkel P. & al. * Supplementary file S1>

1
2 Table 4S shows the results corresponding to Table 3S obtained when the composite outcome was used. Including the 'standard
3
4 predictors' in the model increases the percent correct predictions from 63.2 (see column 4, Table 4S) to 68.4 (see column 5, Table 4S), i.e.
5
6 an increase of 5.2%. Adding the 10 newer biomarkers to the model increases the number of correct predictions by 1.3%. Using the
7
8 parametric model does not change the results appreciably and neither does a reduction of the biomarkers to include only the three
9
10 significant ones.
11
12
13
14
15
16
17
18

19 **Legend to figure 1S**

20
21 Figure 1S A Distribution of years to death using the accelerated failure model where the error term is modelled using the general gamma distribution.

22
23 Figure 1S B Distribution of years to composite outcome (AMI, UAP, CeVD, death) using the accelerated failure model where the error term is modelled
24
25 using the general gamma distribution.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

STROBE Statement items 1 to 12

Title and abstract	Item no	Recommendation	
	1	(a) Design in title	See page 1 the term 'placebo receiving' implies that controls from a trial were used
		(b) Abstract: informative and balanced summary of what was done and found	See abstract methods and results sections p 2 and p 3
Introduction			
Background/rationale	2	Scientific background and rationale	See introduction first section on page 5
Objectives	3	objectives	See introduction last section page 5
Methods			
Study design	4	Key elements of study design	See first section on the patients in material page 5
Setting	5	Setting, location, relevant dates, period of recruitment, follow-up, and data collection	See first section on the patients in material page 5 and the two sections on predictors and on the outcomes pages 6 and 7
Participants	6	(a) Cohort study eligibility, selection, follow-up	See first section on page 6 and introduction page 4 second section
Variables	7	Outcomes, predictors	See section 'the outcomes' on page 7 and the section on predictors on page 6 and 7, and table 1
Data sources/measurement	8	Sources of data, methods of assessment	See section on the outcomes on page 7 and the section on predictors on page 6 and 7, and table 1 plus references to methods.
Bias	9	Addressing potential sources of bias	See page 9 second section from above. Assessment of the potential bias due to missing values.
Study size	10	How study size was arrived at	See Hansen S et al: the CLARICOR trial design. HeartDrug 2001; 1:14-9
Quantitative variables	11	How quantitative variables were handled	They were all handled as continuous variables except for PAP-A which was dichotomized into normal vs elevated values (see table 1 and page 7 line 3)
Statistical methods	12	Statistical methods	See 'statistical analysis'

STROBE Statement items 1 to 12

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

			page 8
		Missing data	See item 9
		Loss to follow-up	See page 6 last line of first section

For peer review only

STROBE Statement items 13 to 22

Results			
	Item no	Recommendation	
Participants	13	Flow diagram during enrolment, randomisation, and follow-up in original trial of 2006.	See BMJ 2006;332;22-27 (paper is enclosed)
Descriptive data	14	(a) Characteristics of study participants (b) Number of participants with missing data for each variable (c) Summary of follow-up time	(a) See table 1 (b) See table 1 (c) See page 9 line 3 to5
Outcome data	15	Number of outcome events	See page 9 line 11 to 14
Main results	16	(a) Hazard rates (b) Results of predictions	(a) See tables 2, 3 (b) See tables 4 and 5
Other analyses	17	interaction	See inferential impact of the newer biomarkers page 9 first 3 lines
Discussion			
Key results	18	Summary of key results	See discussion page 11 first section
limitations	19	(a) Positive bias due to development of model and test of model using same data (b) Methodology (c) Selection bias (d) Prognosis may be worse than at present time (e) Only questionnaire data were collected at randomisation	(a) See page 12 last two lines 6 to 13 (b) See section on methodology page 12 (c) See limitations page 13 first two sections (d) See last 6 lines on page 13 and first two at page 14 (e) See page 14 line 3 to 14
Interpretations	20		See last section of discussion page 14
Generalisability	21		See (a), (b), (c), and (d) item 19
Other information			
Funding	22		See the section on acknowledgements and section on funding, both on page 19